α7 nicotinic acetylcholine receptors at the glutamatergic synapse

Victoria J. Hammond

Thesis submitted for the degree of Doctor of Philosophy

University of Bath
Department of Biology and Biochemistry

August 2014

COPYRIGHT
Attention is drawn to the fact that copyright of this thesis rests with the author. A copy of this thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with the author and that they must not copy it or use material from it except as permitted by law or with the consent of the author.

Signed on behalf of the Faculty of Science: .........................

Dated: .........................
Abstract

Nicotinic acetylcholine receptor (nAChR) activation is neuroprotective and nicotine is a cognitive enhancer. Loss of nAChRs, deposition of tau neurofibrillary tangles, cleavage of amyloid precursor protein (APP) and inflammation are well documented in the pathogenesis of Alzheimer’s disease (AD). Sequential cleavage of APP by β- and γ-secretase enzymes generates soluble Aβ peptides, with oligomeric forms of Aβ implicated in both the control of synaptic excitability and dysregulation of synaptic transmission and induction of neuronal death in AD. Aβ production is inhibited by calcium-dependent recruitment of α-secretase, as exemplified by activation of N-methyl-D-aspartate receptors (NMDAR). All neurodegenerative diseases are associated with inflammation, arising from altered homeostasis of the innate immune system, resulting in heightened activation of immune cells and induction of a pro-inflammatory environment. Stimulation of the α7 subtype of nAChR is anti-inflammatory and also enhances cognition and promotes neuronal survival. This work addressed the hypotheses that stimulation of highly calcium-permeable α7nAChR inhibits Aβ production by promoting α-secretase-mediated processing of APP and also modulates inflammatory cellular behaviour of microglia. Thus, this study assessed the role of α7nAChR at glutamatergic synapses, through probing effects on APP processing and phagocytosis in primary cortical neurons and microglia, respectively. Primary cortical neurons expressed functional α7nAChR and glutamate receptors, and through a number of experimental approaches, including immunoblotting and a cleavage reporter assay, results indicated α7nAChR activation with the α7nAChR-selective agonist PNU-282987 and positive allosteric modulator PNU-120596 had no effect on APP and Tau, in contrast to NMDAR activation that significantly modulated these proteins. Data suggest low expression of α7nAChR, coupled with distinct localisation of presynaptic α7nAChR and postsynaptic APP could explain the lack of effect. In addition, primary microglia were highly responsive to lipopolysaccharide and possessed functional α7nAChR that coupled to ERK phosphorylation. Microglial α7nAChR activation promoted neuroprotective phagocytic behaviour, in agreement with the ‘cholinergic anti-inflammatory pathway’. This study supports the hypothesis that α7nAChR are modulators of anti-inflammatory behaviour, thus α7nAChR-selective ligands are viable candidates for the treatment of AD and promoting cognitive enhancement.
# Table of Contents

Abstract ................................................................................................................................................. 2

List of Figures .......................................................................................................................................... 7

List of Tables ........................................................................................................................................... 8

List of Abbreviations ............................................................................................................................... 9

Acknowledgements ................................................................................................................................. 12

1. Introduction ......................................................................................................................................... 14

1.1 Cholinergic signalling within the central nervous system .............................................................. 14

1.2 Nicotinic acetylcholine receptors ..................................................................................................... 14

1.3 nAChR function .................................................................................................................................. 16

1.4 nAChR diversity ................................................................................................................................. 18

1.4.1 Neuronal nAChR subtypes .......................................................................................................... 19

1.4.2 The α7 subtype of nAChR ............................................................................................................ 21

1.4.2.1 α7nAChR expression and distribution .................................................................................... 22

1.4.2.2 Expression of α7nAChR within CNS cell types ...................................................................... 23

1.4.2.3 α7nAChR physiological functions .......................................................................................... 23

1.5 nAChR pharmacology ....................................................................................................................... 29

1.5.1 Modulators of nAChR and effects on cognitive function .............................................................. 33

1.5.1.1 α7nAChR-selective agonists ................................................................................................. 35

1.5.1.2 α7nAChR-selective PAMs ..................................................................................................... 35

1.6 The cholinergic hypothesis of Alzheimer’s disease .......................................................................... 35

1.6.1 Alzheimer’s disease and age-related cognitive decline ............................................................... 36

1.7 Amyloid cascade hypothesis ............................................................................................................ 37

1.8 Amyloid precursor protein ................................................................................................................. 40

1.8.1 Physiological functions of APP ................................................................................................... 40

1.8.2 APP processing ............................................................................................................................. 41

1.8.2.1 Regulation of APP processing by secretases .......................................................................... 42

1.8.2.2 Activity-dependent regulation of APP processing ................................................................. 46

1.9 Targeting α7nAChR in Alzheimer’s disease ..................................................................................... 54

1.9.1 AChE inhibitors ............................................................................................................................ 55

1.10 Hypotheses and aims ....................................................................................................................... 56
2.1 Materials .................................................................................................................. 58

2.2 Methods .................................................................................................................. 63
  2.2.1 Primary cortical neuron cell culture ................................................................. 63
  2.2.2 Primary cortical glial cell culture ................................................................. 63
  2.2.3 Primary microglia purification ..................................................................... 64
  2.2.4 Immunocytochemistry ............................................................................... 64
    2.2.4.1 Immunocytochemistry staining ............................................................. 64
    2.2.4.2 Image acquisition ................................................................................. 65
  2.2.5 Fluorescent labelling of α7nAChR ............................................................... 65
  2.2.6 Intracellular calcium microfluorimetry imaging ............................................. 65
  2.2.7 SDS-PAGE and Western blotting ................................................................. 66
    2.2.7.1 Sample preparation for SDS-PAGE ....................................................... 66
    2.2.7.2 Tris-Glycine SDS-PAGE .................................................................... 66
    2.2.7.3 Western blotting ................................................................................... 67
    2.2.7.4 Protein detection .................................................................................. 67
    2.2.7.5 Analysis of protein densitometry .......................................................... 67
  2.2.8 APP C-terminal fragment Western blotting ..................................................... 68
    2.2.8.1 APP-CTF sample preparation .............................................................. 68
    2.2.8.2 Tris-Tricine SDS-PAGE .................................................................... 68
    2.2.8.3 Western blotting for APP-CTFs .......................................................... 68
  2.2.9 Synaptosome preparation and treatment ...................................................... 69
    2.2.9.1 Tissue preparation .............................................................................. 69
    2.2.9.2 Percoll gradient preparation ................................................................. 69
    2.2.9.3 Synaptosome preparation and purification ........................................ 70
    2.2.9.4 Synaptosome drug treatments ............................................................ 70
  2.2.10 APP-Gal4 cleavage luciferase reporter assay ............................................... 71
  2.2.11 Egr-1 transcription luciferase reporter assay ............................................. 71
  2.2.12 Microglial bead uptake assay ..................................................................... 72
  2.2.13 Statistical analyses ..................................................................................... 72

3.1 Introduction ............................................................................................................. 74

3.2 Results .................................................................................................................... 76
  3.2.1 Primary cortical cultures display a neuronal phenotype and express
    neuron-specific proteins ....................................................................................... 76
3.2.2 Primary cortical neurons express postsynaptic AMPAR that couple to calcium influx

3.2.3 Neuronal AMPAR are functional and couple to ERK phosphorylation

3.2.4 Neuronal NMDAR couple to cellular activation and ERK phosphorylation

3.2.5 Primary cortical neurons express calcium-permeable α7 nicotinic acetylcholine receptors

3.2.6 Neuronal nAChR couple to ERK phosphorylation

3.2.7 α7nAChR-activation has no effect on Egr-1 promoter-driven luciferase expression

3.3 Discussion

3.3.1 Primary cortical neurons express functional glutamate receptors

3.3.2 Primary cortical neurons express functional calcium-permeable α7nAChR

3.3.3 Primary cortical neuronal α7nAChR couple to ERK phosphorylation without effecting ERK-dependent transcription

3.3.3 Summary

4.1 Introduction

4.2 Results

4.2.1 APP is predominantly expressed at postsynaptic sites in primary cortical neurons

4.2.2 Primary cortical neurons express putative α-secretase enzymes, ADAM-10 and ADAM-17

4.2.3 NMDAR activation reduces levels of full-length APP

4.2.4 α7nAChR activation has no effect on full-length APP levels

4.2.5 Isolation and activation of presynaptic α7nAChR has no effect on full-length APP levels

4.2.6 α7nAChR activation has no effect on APP-CTF production

4.2.7 α7nAChR activation has no effect on β-γ-secretase activity

4.2.8 α7AChR stimulation does not modulate full length Tau

4.3 Discussion

4.3.1 α7nAChR activation does not modulate APP processing
# List of Figures

## Chapter 1

**Figure 1.1**: Cholinergic signalling pathways in the rodent brain. ..........................15
**Figure 1.2**: nAChR physiology and structural components. .................................17
**Figure 1.3**: Putative vertebrate nAChR subunit combinations. .........................20
**Figure 1.4**: Schematic of the MAPK signalling cascade .................................26
**Figure 1.5**: The electrophysiological distinction between type I/II positive allosteric modulators (PAMs) of α7nAChR. .................................................................34
**Figure 1.6**: The amyloid cascade hypothesis. .........................................................39
**Figure 1.7**: Amyloid precursor protein (APP) processing. .................................43
**Figure 1.8**: Schematic highlighting APP processing, Aβ production and secretion are closely related to neuronal activity and modulate neuronal survival. ...............50

## Chapter 3

**Figure 3.1**: Cortical neurons display a classical neuronal phenotype and express neuron-specific proteins. .................................................................77
**Figure 3.2**: Cortical neurons express postsynaptic and functional AMPAR. ........78
**Figure 3.3**: AMPA-induced ERK phosphorylation is time-dependent. ...............80
**Figure 3.4**: AMPAR-induced ERK phosphorylation is MEK-dependent. ..........82
**Figure 3.5**: NMDA-induced cellular activation is time-dependent. .................83
**Figure 3.6**: NMDA-induced ERK phosphorylation is NMDAR- and MEK-dependent. .................................................................84
**Figure 3.7**: Primary cortical neurons express functional calcium-permeable α7nAChR. ..................................................................................87
**Figure 3.8**: nAChR couple to cellular activation and ERK phosphorylation. ....90
**Figure 3.9**: Activation of α7nAChR does not stimulate ERK-dependent transcription of Egr-1 in primary cortical neurons. ...........................................92

## Chapter 4

**Figure 4.1**: APP is mainly trafficked to postsynaptic neuronal compartments. ....101
**Figure 4.2**: Primary cortical neurons express putative α-secretase proteins ADAM-10 and ADAM-17. ........................................................................102
Figure 4.3: NMDAR activation induces cleavage of APP. ..........................104
Figure 4.4: α7nAChR activation does not affect APP levels. ....................105
Figure 4.5: Density gradient centrifugation produces viable synaptosomes with functional presynaptic α7nAChR. .................................................................107
Figure 4.6: NMDAR-stimulation increases time-dependent APP processing, whilst α7nAChR-stimulation has no effect over basal CTF production. ..................111
Figure 4.7: α7nAChR activation does not affect APP-Gal4 cleavage in a luciferase reporter assay measuring γ-secretase-mediated APP processing. .................114
Figure 4.8: NMDAR-stimulation induces concentration-dependent Tau cleavage and/or dephosphorylation, whilst α7nAChR-stimulation has no effect on Tau. ......117

Chapter 5

Figure 5.1: Morphological assessment of primary cortical mixed glia over time in vitro. ........................................................................................................................................127
Figure 5.2: Purification of microglia from a mixed glial population. ..............128
Figure 5.3: Purified primary microglia are free of astrocytic contaminants and express microglia-specific markers. .................................................................130
Figure 5.4: LPS exposure of primary microglia induces a reactive phenotype. ...131
Figure 5.5: Cellular activation and stimulation of α7nAChR couples to ERK phosphorylation in 28-50 DIV primary microglia. ....................................................133
Figure 5.6: LPS-activated and α7nAChR-stimulated microglia display increased phagocytic behaviour. ......................................................................................136

Chapter 6

Figure 6.1: Schematic of α7nAChR at the glutamatergic synapse. ...............147

List of Tables

Table 1.1: nAChR-interacting ligands, nAChR-subtype selectivity and pharmacological effects. .................................................................30
Table 2.1: Pharmacological compounds used to assess α7nAChR at the glutamatergic synapse in vitro. ....................................................59
Table 2.2: Antibodies used for Western blotting and immunocytochemistry. ....61
### List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-HT</td>
<td>5-Hydroxytryptamine</td>
</tr>
<tr>
<td>ACh</td>
<td>Acetylcholine</td>
</tr>
<tr>
<td>AChE</td>
<td>Acetylcholinesterase</td>
</tr>
<tr>
<td>AD</td>
<td>Alzheimer’s disease</td>
</tr>
<tr>
<td>ADAM</td>
<td>A disintegrin and metalloproteinase</td>
</tr>
<tr>
<td>AICD</td>
<td>Amyloid intracellular domain</td>
</tr>
<tr>
<td>Akt</td>
<td>Protein kinase B</td>
</tr>
<tr>
<td>AM</td>
<td>Acetoxymethyl ester</td>
</tr>
<tr>
<td>AMPA</td>
<td>α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid</td>
</tr>
<tr>
<td>AMPAR</td>
<td>α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor</td>
</tr>
<tr>
<td>ANOVA</td>
<td>Analysis of variance</td>
</tr>
<tr>
<td>APH-1</td>
<td>Anterior pharynx defective-1</td>
</tr>
<tr>
<td>APLP</td>
<td>Amyloid precursor like protein</td>
</tr>
<tr>
<td>ApoE</td>
<td>Apolipoprotein E</td>
</tr>
<tr>
<td>APP</td>
<td>Amyloid precursor protein</td>
</tr>
<tr>
<td>Aβ</td>
<td>Amyloid-β peptide</td>
</tr>
<tr>
<td>BACE</td>
<td>β-site APP cleaving enzyme</td>
</tr>
<tr>
<td>BDNF</td>
<td>Brain-derived neurotrophic factor</td>
</tr>
<tr>
<td>BFC</td>
<td>Basal forebrain complex</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>CA1</td>
<td>Cornu Ammonis area 1</td>
</tr>
<tr>
<td>Ca²⁺</td>
<td>Calcium ions</td>
</tr>
<tr>
<td>CaMK</td>
<td>Calmodulin kinase</td>
</tr>
<tr>
<td>CD11b</td>
<td>Cluster of differentiation molecule 11B</td>
</tr>
<tr>
<td>ChT</td>
<td>Choline reuptake transporters</td>
</tr>
<tr>
<td>CICR</td>
<td>Calcium-induced calcium release</td>
</tr>
<tr>
<td>CO₂</td>
<td>Carbon dioxide</td>
</tr>
<tr>
<td>CREB</td>
<td>CRE-binding protein</td>
</tr>
<tr>
<td>CSF</td>
<td>Cerebrospinal fluid</td>
</tr>
<tr>
<td>CTF</td>
<td>C-terminal fragment</td>
</tr>
<tr>
<td>DAPI</td>
<td>4′,6-Diamidino-2-phenylindole</td>
</tr>
<tr>
<td>DHβE</td>
<td>Dihydro-β-erythroidine</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>DIV</td>
<td>Days in vitro</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco's modified Eagle's medium</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulphoxide</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>DUSPs</td>
<td>Dual-specificity phosphatases</td>
</tr>
<tr>
<td>ECL</td>
<td>Enhanced chemiluminescence</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>Egr-1</td>
<td>Early growth response gene-1</td>
</tr>
<tr>
<td>EGTA</td>
<td>Ethylene glycol tetraacetic acid</td>
</tr>
<tr>
<td>ERK</td>
<td>Extracellular signal-regulated kinase</td>
</tr>
<tr>
<td>GABA</td>
<td>γ-Amino butyric acid</td>
</tr>
<tr>
<td>GABAR</td>
<td>γ-Amino butyric acid receptor</td>
</tr>
<tr>
<td>GFAP</td>
<td>Glial fibrillary acidic protein</td>
</tr>
<tr>
<td>GSK-3β</td>
<td>Glycogen synthase kinase 3β</td>
</tr>
<tr>
<td>GTP</td>
<td>Guanosine-5′-triphosphate</td>
</tr>
<tr>
<td>HEPES</td>
<td>N-2-Hydroxyethylpiperazine-N-2-ethane sulfonic acid</td>
</tr>
<tr>
<td>HRP</td>
<td>Horseradish peroxidase</td>
</tr>
<tr>
<td>IL</td>
<td>Interleukin</td>
</tr>
<tr>
<td>IP₃</td>
<td>Inositol (1,4,5)-trisphosphate</td>
</tr>
<tr>
<td>JAK2</td>
<td>Janus kinase 2</td>
</tr>
<tr>
<td>JNK</td>
<td>C-Jun N-terminal kinase</td>
</tr>
<tr>
<td>KCl</td>
<td>Potassium chloride</td>
</tr>
<tr>
<td>LDT</td>
<td>Laterodorsal tegmental areas</td>
</tr>
<tr>
<td>LPS</td>
<td>Lipopolysaccharide</td>
</tr>
<tr>
<td>LTD</td>
<td>Long-term depression</td>
</tr>
<tr>
<td>LTP</td>
<td>Long-term potentiation</td>
</tr>
<tr>
<td>mAChR</td>
<td>Muscarinic acetylcholine receptor</td>
</tr>
<tr>
<td>MAP</td>
<td>Microtubule associated protein</td>
</tr>
<tr>
<td>MAPK</td>
<td>Mitogen activated protein kinase</td>
</tr>
<tr>
<td>MEK</td>
<td>Mitogen activated ERK kinase</td>
</tr>
<tr>
<td>Mg²⁺</td>
<td>Magnesium ions</td>
</tr>
<tr>
<td>mGluR</td>
<td>Metabotropic glutamate receptor</td>
</tr>
<tr>
<td>MLA</td>
<td>Methyllycaconitine</td>
</tr>
<tr>
<td>nAChR</td>
<td>Nicotinic acetylcholine receptor</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>NaCl</td>
<td>Sodium chloride</td>
</tr>
<tr>
<td>NFT</td>
<td>Neurofibrillary tangle</td>
</tr>
<tr>
<td>NMDA</td>
<td>N-Methyl-D-aspartic acid</td>
</tr>
<tr>
<td>NMDAR</td>
<td>N-Methyl-D-aspartic acid receptor</td>
</tr>
<tr>
<td>NMJ</td>
<td>Neuromuscular junction</td>
</tr>
<tr>
<td>PAM</td>
<td>Positive allosteric modulator</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate-buffered saline</td>
</tr>
<tr>
<td>PEN-2</td>
<td>Presenilin enhancer-2</td>
</tr>
<tr>
<td>pERK</td>
<td>Phosphorylated ERK</td>
</tr>
<tr>
<td>pfu</td>
<td>Plaque forming units</td>
</tr>
<tr>
<td>PI3K</td>
<td>Phosphatidylinositol 3-kinase</td>
</tr>
<tr>
<td>PKC</td>
<td>Protein kinase C</td>
</tr>
<tr>
<td>PPT</td>
<td>Pedunculopontine</td>
</tr>
<tr>
<td>PS</td>
<td>Presenilin</td>
</tr>
<tr>
<td>PSD</td>
<td>Postsynaptic density</td>
</tr>
<tr>
<td>PVDF</td>
<td>Polyvinylidene difluoride</td>
</tr>
<tr>
<td>RIPA</td>
<td>Radioimmunoprecipitation assay</td>
</tr>
<tr>
<td>sAPPα</td>
<td>Soluble APPα ectodomain</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>SDS</td>
<td>Sodium dodecyl sulphate</td>
</tr>
<tr>
<td>SDS-PAGE</td>
<td>Sodium dodecyl sulphate polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>SEM</td>
<td>Standard error of the mean</td>
</tr>
<tr>
<td>TBS</td>
<td>Tris-buffered saline</td>
</tr>
<tr>
<td>TBS-T</td>
<td>Tris-buffered saline with Tween-20</td>
</tr>
<tr>
<td>TEMED</td>
<td>Tetramethylethylenediamine</td>
</tr>
<tr>
<td>TIMP</td>
<td>Tissue inhibitors of metalloproteases</td>
</tr>
<tr>
<td>TM</td>
<td>Transmembrane</td>
</tr>
<tr>
<td>TNFα</td>
<td>Tumour necrosis factor-α</td>
</tr>
<tr>
<td>TTX</td>
<td>Tetrodotoxin</td>
</tr>
<tr>
<td>UAS</td>
<td>Upstream activating sequence</td>
</tr>
<tr>
<td>VACHT</td>
<td>Vesicular acetylcholine transporter</td>
</tr>
<tr>
<td>α7nAChR</td>
<td>α7-subtype of nicotinic acetylcholine receptor</td>
</tr>
<tr>
<td>αBTX</td>
<td>α-bungarotoxin</td>
</tr>
<tr>
<td>αBTX-488</td>
<td>α-bungarotoxin conjugated to Alexa Fluor-488</td>
</tr>
</tbody>
</table>
Acknowledgements

This is a major milestone: my sincerest gratitude to all who made this possible.

The greatest of thanks go to my two fantastic supervisors, Dr Rob Williams and Prof Sue Wonnacott. Without being exposed to your immense knowledge and passion, I would never have fallen in love with APP and nicotinic receptors. Rob, your honesty and support have provided a fantastic, fun and friendly environment in which to spend my Ph.D.; and of course the Halloween pink monkey tale shall forever be legendary. Sue, your unfathomable knowledge is awe-inspiring and I feel truly blessed to have been involved in your work. Both of you have challenged and pushed me to ensure I have got the most out of this experience.

Bath has been more than my home over the last 8 years; many of the relationships I have formed will last forever. Most notably, to Matt, I owe my journey deeper into science to you. I should have known you were the one when you patiently taught me basic mathematics over weekends in the physics laser lab. Thanks to you, Geoff, Fred and Jim et al., I have known for some time what I was getting myself into; except I’ve not come out of academia with an unrelenting love of ABBA... Secondly, to my lab mate Carla- your happy outlook and endless energy made every weekday genuinely brilliant fun, even if you are so very messy in the lab.

To past and present members of the office (including Gail, Tülay, Chris, Joe and my undergraduate minions, to name but a few), thank you for the baklava, cuppas and in-jokes. To those of you I leave behind, I am insisting the office traditions carry on. Full commitment to office parties is a prerequisite: fancy dress is not optional. Ever.

Outside of the lab, I blame Roxy for weekday cocktail-induced hangovers, which impaired my Western blotting capabilities on more than a few occasions. To Alison, my oldest and dearest friend, you have provided me with hilarious distractions from science; I can’t wait to re-read the last 15 years of your diaries when we’re old and wrinkly. Nonetheless both your friendships have helped me through the whirlwind of the last 4 years, thanks for being there for me: I'll get the next round of drinks.

Finally I’d like to thank my parents, Jayne and Shaun, for having unwavering faith in me. Your support and advice has always been faultless. Yow bin bostin’ ay ya!
Chapter 1

1. General Introduction
1. Introduction

1.1 Cholinergic signalling within the central nervous system

Acetylcholine (ACh) modulates a wide array of physiological processes within both the peripheral nervous system and the central nervous system (CNS). CNS roles of ACh include modulation of reward, pain, memory and cognition (reviewed by Miwa et al., 2011). An early pharmacological approach enabled identification of distinct acetylcholine receptor subtypes, namely muscarinic and nicotinic receptors, after observing the plant alkaloids muscarine and nicotine mimicked some of the actions of ACh. The identification of these pharmacologically distinct receptors resulted in the classification of two functionally unrelated receptor groups, muscarinic acetylcholine receptors (mAChR) and nicotinic acetylcholine receptors (nAChR), with nAChR being the focus of this thesis. ACh is generated by the enzyme choline acetyltransferase, which catalyses the formation of ACh from acetyl-CoA and choline. Conversely, ACh is rapidly broken down by acetylcholinesterase (AChE), which enables choline reuptake into neurons for conversion back to ACh, allowing precise temporal and spatial regulation of signalling (Brady et al., 2012). Regions of dense cholinergic activity within the brain and peripheral nervous system have been mapped through biochemical detection of choline acetyltransferase, AChE, choline reuptake transporters (ChT) and vesicular acetylcholine transporters (VAcT). The major cholinergic projection pathways (in the rodent CNS) are indicated in figure 1.1. Of particular importance, with respect to this thesis, are the neurons projecting from the basal forebrain complex (BFC), which send axons to the hippocampus, limbic cortex, olfactory bulb, amygdala and neocortex. The cholinergic projections from the BFC to the neocortex, hippocampus and limbic cortex degenerate in Alzheimer's disease (AD) (Whitehouse et al., 1982), as discussed below (section 1.6), which gives rise to the clinical symptoms of memory loss, personality alterations and declined cognitive performance.

1.2 Nicotinic acetylcholine receptors

nAChR were the first identified from the muscle endplate of electric ray, eel and Torpedo from the Electrophorus family. The presence of nAChR was also observed within mammalian skeletal muscle, where they are found highly concentrated at the neuromuscular junction (NMJ). Muscle nAChR have been extensively studied and
Figure 1.1: Cholinergic signalling pathways in the rodent brain. The basal forebrain (BFC) provides the major cholinergic output projections to the cortex and hippocampus. Acetylcholine signalling (red arrows) into the hippocampus and cortex enhances plasticity and learning. The pedunculopontine (PPT) and laterodorsal tegmental areas (LDT) innervate the brain stem and midbrain, whilst cholinergic interneurons are found within the striatum (taken from Brady et al., 2012).
well characterised, and more recently the structurally analogous neuronal nAChR have been the focus of significant research efforts. Muscle nAChR were the first neurotransmitter receptors identified (Nachmansohn, 1966) and are the prototypical receptor within the Cys loop family of pentameric ligand-gated ion channels. The Cys loop family comprises nAChR, GABA$_A$, GABA$_C$, glycine, 5-HT$_3$ receptors and invertebrate glutamate-, histamine- and 5-HT-gated chloride channels (Changeux, 2013a). The extracellular N-terminus of each receptor subunit contains a 15-residue disulphide bonded 'Cys loop', providing the defining feature of this ligand-gated ion channel family of receptors, purported to be involved in channel opening, following agonist binding, figure 1.2A.

In the ~50 years since their identification (Changeux, 2012), nAChR have been extensively studied by pharmacology, electrophysiology, biochemistry, molecular biology, structural biology and cellular biology techniques. As discussed below (section 1.4) using a pharmacological approach, identification of distinct nAChR subtypes was possible, thanks to subtype-selective ligands. Such, subtype-selective ligands have been developed to target nAChR, in order to investigate a number of human diseases. Biochemistry and molecular biology enabled identification of endogenous neurotransmitter interaction sites within nAChR, through mutagenesis screens, figure 1.2B. Electrophysiology has enabled a detailed understanding of nAChR responses to exogenous ligands and endogenous neurotransmitters. nAChR were the first receptors to have channel currents and kinetics studied and the era of structural biology has begun to elucidate the detailed molecular composition and functional regions of nAChR, and specifically how nAChR-ligand interactions modulate receptor behaviour (Unwin, 2005). Finally, cellular biology has begun to investigate downstream cellular signalling events, following nAChR activation (Dajas-Bailador and Wonnacott, 2004).

1.3 nAChR function

Thanks to a number of structural studies (Brejc et al., 2001; Karlin, 2002; Samson et al., 2002; Miyazawa et al., 2003; Unwin, 2005; Sine and Engel, 2006; Li et al., 2011), we now have a greater understanding of Cys loop receptor functionality, from the stages of neurotransmitter binding, communication between binding site and the channel barrier, and opening and closing of the channel modulating ion passage, in turn affecting membrane potential. For all Cys loop family members, at least two agonist molecules are required for channel opening and receptor activation.
Figure 1.2: nAChR physiology and structural components. A: Orientation of a single nAChR subunit within the plasma membrane. B: Schematic of an assembled homomeric nAChR composed of five $\alpha_7$-subunits arranged around a central pore, lined by M2. Each principle agonist binding site is derived from three loops of the entire extracellular N-terminal domain of an $\alpha$-subunit and three loops from an adjacent complementary subunit. Notional sites of nAChR-interacting drugs are indicated, either on extracellular or luminal domains of the receptor.
Upon agonist binding, the channel opens following an allosteric transition and agonist remains bound, due to its high affinity for an open-state receptor. In the open state, an influx of Na\(^+\) and Ca\(^{2+}\) ions is permitted, alongside efflux of K\(^+\) ions. The kinetics of channel opening are rapid, with the time between agonist binding and channel opening measured as tens of microseconds (Sine and Engel, 2006). In the transition from closed to open state, the second transmembrane segment (M2 domain) of each subunit acts as a barrier to ion passage, which following agonist binding undergoes a rotation to widen the channel pore by 3\(\text{Å}\), enabling transient ion passage. In the open state, the residues flanking M2 act as an ion selectivity filter. Coupled with this, the presence of a ring of negatively charged residues within the internal channel vestibule contributes to cation selectivity (Li et al., 2011). Naturally occurring mutations within nAChR subunits and other Cys loop receptor family members can lead to reduced function receptors and result in a number of disease-causing conditions, termed channelopathies. The presence of bound agonist does not guarantee channel opening and receptor activation, as nAChR are subject to rapid desensitisation, a period in which the receptor is non-conducting following agonist-induced activation. Primary hippocampal neurons exhibit desensitisation periods of ~1 second (Dani et al., 2000) and desensitisation is entirely overcome by 15-30 seconds (Frazier et al., 1998a, 1998b). Alternatively, blockade of nAChR activation can arise from antagonist binding. Structural studies have enabled mechanistic insight into competitive nAChR antagonists, which bind within the agonist binding pocket (Samson et al., 2002), blocking the entrance of agonist and thus preventing channel opening and receptor activation.

1.4 nAChR diversity

The (limited) diversity of muscle nAChR subtypes, has been appreciated for over 60 years but extensive diversity amongst neuronal nAChR was only accepted ~20 years ago, following sequencing, cloning, exogenous oocyte expression and examining nAChR pharmacology using subtype-selective antagonists (Marks et al., 1986; Chen and Patrick, 1997; Wu and Lukas, 2011). Partially cross-linking nAChR from electric eel revealed a pentameric structure. Each of the five subunits combine to form a functional ion channel, spanning the plasma membrane, enabling the inward passage of Ca\(^{2+}\) and Na\(^+\) ions and efflux of K\(^+\) ions. The five subunits comprising muscle nAChR are known to be composed of up to five different proteins, termed \(\alpha 1\), \(\beta 1\), \(\gamma\), \(\delta\) and \(\varepsilon\). Through gel separation, the relative subunit stoichiometry for muscle nAChR
was determined as $\alpha_1\beta_1\delta_1(\gamma/\varepsilon)_1$, where $\gamma$ and $\varepsilon$ are foetal and adult expressed muscle nAChR subunits, respectively (Changeux, 2013a). In contrast, 9 neuronal nAChR subunits have been identified to date, designated $\alpha_2$-$\alpha_7$ and $\beta_2$-$\beta_4$, figure 1.3. In addition, an $\alpha_8$ subunit has been identified in avian species and $\alpha_9$-$\alpha_{10}$ in mammalian non-CNS tissues. In both muscle and neuronal nAChR, ligand binding occurs at the interface between an $\alpha$- and an adjacent complementary (either $\alpha$- or $\beta$-) subunit (Sauguet et al., 2013). Mutagenesis of single residues within the N-terminus of the $\alpha$-subunit has revealed four crucial aromatic residues that constitute the agonist binding site. These residues (Tyr$^{93}$, Trp$^{149}$, Tyr$^{190}$ and Tyr$^{198}$), coupled with two adjacent cysteine residues (Cys$^{192}$ and Cys$^{193}$) constitute the principle binding site of a nAChR, with the adjacent subunit ($\beta$-strand rich, containing Trp$^{55/57}$) termed the complementary site (Sine and Engel, 2006; Li et al., 2011). The presence of differing nAChR subunits at the complementary site alters the affinity of nAChR ligands, giving rise to the agonist affinity variations between nAChR subtypes (Andersen et al., 2011).

1.4.1 Neuronal nAChR subtypes

Each of the above listed $\alpha$-subunits (except $\alpha_5$, which lacks Tyr$^{190}$) is capable of acting as the principle agonist binding site. Conversely, $\beta$-subunits lack the agonist binding site, but instead contain the complementary site (with the exception of the $\beta_3$ subunit). Thus, $\alpha$- and $\beta$-subunit conformations can form complementary pairs and constitute functional heteropentameric nAChR. In addition, $\alpha_7$-$\alpha_9$ subunits can form functional homomeric receptors that lack $\beta$-subunits. Homomeric $\alpha$-subunit expression results in the formation of both the principle and complementary binding sites, which are capable of binding up to five agonist molecules per receptor (Rayes et al., 2009), with enhanced agonist sensitivity and Ca$^{2+}$ permeability over heteromeric nAChR (Andersen et al., 2011, 2013). As a result, the potential number of receptor subunit combinations is huge, and there exists a large diversity of naturally expressed nAChR subtypes (Wu and Lukas, 2011), named according to their subunit composition, figure 1.3. Following successful efforts to sequence, clone and express neuronal nAChR subunits (Boulter et al., 1987; Heinemann et al., 1990; Séguela et al., 1993), the distinction between muscle, neuronal and ganglionic nAChR pharmacology began to be appreciated, along with the breadth of receptor subtypes. The differential affinity of nicotine for populations of nAChR was further
Figure 1.3: Putative vertebrate nAChR subunit combinations. Reported subunit combinations reveals vast heterogeneity of nAChR subunit stoichiometry. Black circles indicate putative agonist binding sites between principle and complementary binding sites. Vertebrate neuronal (α2-α8 and β2-β4) and mammalian non-CNS (α9-α10) nAChR subunits are coloured, whilst muscle nAChR subunits (α1, β1, δ, ε and γ) are white. The α7nAChR subtype (circled) is the focus of this thesis.
evidence for expression of a host of neuronal nAChR subtypes, as determined by subunit combinations. Accordingly, the α4β2 nAChR subtype possesses a high affinity for nicotine, and accounts for >90% of [3H]-nicotine binding within brain material, with α7nACHr making up the remainder, with a minimal contribution from other nAChR subtypes. Native α4β2 receptors exhibit an (α4)2(β2)3 stoichiometry, containing the minimum required two agonist binding sites. In contrast, exogenous expression of an (α4)3(β2)2 nAChR conformation reduced ACh affinity but enhanced Ca²⁺ permeability, reminiscent of homomeric α-subunit expression properties (Andersen et al., 2011, 2013). The most phylogenetically ancient α7nACHr forms a homopentamer ligand-gated ion channel, with α4β2* and α7nACHr exhibiting complementary distributions across the mammalian CNS.

1.4.2 The α7 subtype of nAChR

Initial work comparing the nAChR within the muscle and brain highlighted a striking difference between muscle and neuronal nAChR. All muscle nAChR (which bind nicotine) bind the 74 amino acid 8kDa α-neurotoxin, α-bungarotoxin (αBTX), which renders the nAChR silent. In contrast, within the brain, only the low affinity nicotine-binding nAChR bind αBTX. αBTX is now known to be an α7nACHr-selective antagonist (Chen and Patrick, 1997), binding to the α-subunit agonist binding pocket (Samson et al., 2002) to stop access of the agonist molecule.

α7nACHr are distinguished from other nAChR subtypes due to their unique pharmacological properties, most notably their high permeability to calcium (Séguéla et al., 1993; Dajas-Bailador and Wonnacott, 2004; Fucile, 2004), rapid desensitisation kinetics (Williams et al., 2012) and low open state probability (Pesti et al., 2014). The α7nACHr has the highest fractional Ca²⁺ current (Fucile, 2004), being the highest reported for ligand-gated ion channels and is equal to NMDA-type glutamate receptors (Dajas-Bailador and Wonnacott, 2004). Desensitisation of α7nACHr is more likely to occur following saturating agonist binding to the principle binding sites, with maximal receptor activation occurring with 1-2 bound agonist molecules (Williams et al., 2011a, 2012) or with 3 agonist molecules bound at non-consecutive binding sites (Rayes et al., 2009).

Following α7nACHr activation increased intracellular Ca²⁺ concentration can be produced through a number of means. Firstly, Ca²⁺ influx can occur directly through the Ca²⁺-permeable nAChR ion channel. Secondly, nAChR-mediated cellular
depolarization, as a result of Na\(^+\) influx, also activates voltage-operated calcium channels (Barrantes et al., 1995a), significantly increasing the influx of Ca\(^{2+}\) ions. Thirdly, α7nAChR activation induces calcium-induced calcium release (CICR) from endoplasmic reticulum calcium stores, via ryanodine receptors (Dajas-Bailador and Wonnacott, 2004). Finally, α7nAChR-mediated Ca\(^{2+}\)-induced activation of the inositol (1,4,5)-(trisphosphate (IP\(_3\)) receptor within the endoplasmic reticulum results in further release of Ca\(^{2+}\) from intracellular stores, which is purported to be ryanodine receptor-dependent. Thanks to the strong increase in intracellular calcium following α7nAChR activation, a range of signalling cascades and cellular processes are facilitated (Dajas-Bailador and Wonnacott, 2004). As populations of α7nAChR have differential spatial distribution across the CNS and are capable of increasing intracellular Ca\(^{2+}\) by a number of means, the diversity of nAChR-induced calcium-dependent cellular processes is vast (Berg and Conroy, 2002) and is subject to intense research efforts.

1.4.2.1 α7nAChR expression and distribution

\textit{In situ} hybridization, radio-ligand binding and immunolabelling studies have enabled extensive analyses of nAChR expression throughout the CNS (Marks et al., 1986; Breese et al., 1997; Lewis and Picciotto, 2013) and across human brain aging (Perry et al., 2000). The α7nAChR subtype is of particular interest due to its relatively high expression within discrete brain regions associated with cognition, learning and memory. α7nAChR are highly expressed within the hippocampus (Fabian-Fine et al., 2001; Ji et al., 2001; Kawai et al., 2002), cortex (Lubin et al., 1999; Metherate, 2004; Poorthuis et al., 2013) and ventral tegmental area (Mansvelder and Mcgehee, 2000; Mansvelder et al., 2009). The α7nAChR expressed within these brain regions are well documented as being involved in attention, learning and memory and reward processes, respectively. Thus, targeting α7nAChR within these brain regions has been the focus of intense research efforts to treat cognitive disorders, ranging from schizophrenia to mild cognitive impairment and Alzheimer’s disease (AD) (Wallace and Porter, 2011), as discussed below (section 1.9).
1.4.2.2 Expression of $\alpha 7nAChR$ within CNS cell types

Within native CNS tissue, $\alpha 7nAChR$ are expressed across a number of brain regions by neurons (Ji et al., 2001; Charpantier et al., 2005; Wu and Lukas, 2011; Poorthuis et al., 2013), astrocytes (Teaktong et al., 2003; Poisik et al., 2008; Duffy et al., 2011; Wang et al., 2013) and microglia (Shytle et al., 2004; Thomsen and Mikkelsen, 2012; Parada et al., 2013; Morioka et al., 2014). $\alpha 7nAChR$ have also been extensively studied in mammalian CNS cell lines (Nakayama et al., 2002; El Kouhen et al., 2009), primary neurons (Dajas-Bailador et al., 2002; Brown and Wonnacott, 2014) and through exogenous expression of $\alpha 7nAChR$ (and non-$\alpha 7$ nAChR subtypes) in *Xenopus* oocytes (Charpantier et al., 2005; Williams et al., 2011a). $\alpha 7nAChR$ have also been documented within non-CNS cell types (Sharma and Vijayaraghavan, 2002; Wessler and Kirkpatrick, 2008). The most intensively studied non-CNS cell type is macrophages (Lu et al., 2014), due to $\alpha 7nAChR$'s reported role as an inhibitor of inflammation (Wang et al., 2003; Cui and Li, 2010; Bencherif et al., 2011), in line with their purported function of reducing pro-inflammatory cytokine release from microglia (Giunta et al., 2004; Lu et al., 2014; section 1.4.2.3.2).

1.4.2.3 $\alpha 7nAChR$ physiological functions

Neuronal $\alpha 7nAChR$ are expressed at presynaptic, perisynaptic, somatodendritic and extrasynaptic sites. Their function within the CNS is broadly to modulate synaptic function and plasticity (Gray et al., 1996; Lozada et al., 2012; Pesti et al., 2014), underlying their role in cognition (Hurst et al., 2013). The majority of studies have focused on the presynaptic population of $\alpha 7nAChR$ and their role in modulating calcium-dependent release of neurotransmitters (Wonnacott, 1997; Wonnacott et al., 2006), such as aspartate (Rousseau et al., 2005) dopamine (Grilli et al., 2012), GABA (Alkondon et al., 1997) and glutamate (Gray et al., 1996; Dickinson et al., 2008; Gomez-Varela and Berg, 2013). For example, in the hippocampus, where some of the highest levels of $\alpha 7nAChR$ are expressed presynaptically on mossy fibres, the $\alpha 7nAChR$ modulate release of the major excitatory neurotransmitter glutamate. As a result of enhanced glutamate release, increased numbers of $\alpha$-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)- and N-methyl-D-aspartate (NMDA)-type glutamate receptors are trafficked to the postsynaptic membrane; increasing the potential to enhance synapse strength and long-term potentiation (LTP, Lin et al.,
2010; Halff et al., 2014), and thus α7nAChR can modulate synaptic plasticity, learning and memory. Conversely, the postsynaptic population of α7nAChR (mostly found at extrasynaptic sites) are best known for their role in generating excitatory responses. As α7nAChR are capable of being (weakly) activated by choline, the ubiquitously present precursor to Ach, it has also been suggested α7nAChR evolved to undertake slower signalling and alternative physiological roles, as well as rapid neurotransmission (Papke, 2014). The physiological levels of choline at pyramidal neurons of the CA1 region of the hippocampus (estimated to be ~10μM, Kalappa et al., 2010) were used to assess α7nAChR activation, revealing persistent activation of α7nAChR (Kalappa et al., 2010) and thus emphasizing the potential of α7nAChR modulators as cognitive enhancers.

1.4.2.3.1 α7nAChR in cognition, learning and memory

α7nAChR activation selectively promotes glutamatergic synapse formation in development, as determined by examination of glutamatergic synapse number in α7nAChR knock-out mice (Lozada et al., 2012). Furthermore, α7nAChR maintain and modulate glutamate release probability. A pool of presynaptic α7nAChR, within primary hippocampal neurons, was shown to transition from mobile and freely diffusible to synaptically constrained (via PSD-95 and CAST/ELKS association), which in turn increased the capacity for neurotransmitter release by enhancing the size of the readily releasable pool of vesicles (Gomez-Varela and Berg, 2013). Following enhanced glutamate release, α7nAChR activation also indirectly modulates glutamate receptor trafficking (Lin et al., 2010) to the postsynaptic membrane, promoting synapse maintenance and synaptic plasticity (Gomez-Varela and Berg, 2013). α7nAChR activity-dependent regulation of glutamate release results in long-term consequences, such as changes in gene expression, regulation of gene transcription, namely immediate-early genes, which in turn activate the MAPK pathway and subsequent activation of CREB (Berg and Conroy, 2002) and section 1.4.2.3.1.1. As α7nAChR are highly expressed in brain regions associated with cognition, such as the hippocampus and cortex, they are capable of inducing long-lasting synaptic changes that act as the cellular basis for learning and memory (Newhouse et al., 2004; Lendvai et al., 2013; Yang et al., 2013). Depletion of ACh signalling to the prefrontal cortex significantly impairs working memory (Croxson et
al., 2011), whilst chronic \( \alpha 7 \text{nAChR} \)-selective agonist treatment of aged AD model mice restored cognition (Medeiros et al., 2014).

1.4.2.3.1.1 \( \alpha 7 \text{nAChR} \) signalling in cognition, learning and memory

The specific downstream cellular events following nAChR activation have not been fully defined, owing to a lack of subtype-selective antagonists. In recent years the effects of nicotine and selective \( \alpha 7 \text{nAChR} \) activation and cellular transduction have been mapped to phosphatidylinositol 3-kinase (PI3K, Kihara et al., 2004) and protein kinase B (Akt) via Janus Kinase 2 (JAK2, Shaw et al., 2002) and extracellular signal-related kinase (ERK, Steiner et al., 2007; Dickinson et al., 2008; El Kouhen et al., 2009) phosphorylation as part of the mitogen-activated protein kinase (MAPK) pathway. The central signalling cascade implicated in learning and memory processes is the MAPK pathway, physiologically targeted by neurotrophins binding a cell surface receptor-linked tyrosine kinase (such as TrkB) and a number of ionotrophic and metabotropic receptors. Upon ligand binding, receptor activation, dimerization and autophosphorylation results, and a downstream phosphorylation signalling cascade initiates. Receptor-docking proteins (SOS and GRB2) activate GTP-bound Ras, which activates a central three-tiered core signalling module beginning with Raf, which in turn activates and phosphorylates MEK, figure 1.4. Activation of the serine/threonine-selective protein kinase MEK results in rapid but reversible ERK1/2 isoform phosphorylation at both a serine and threonine residue (Ferrell and Bhatt, 1997). ERK1/2 activation results in a number of signalling events, which can broadly be attributed to cytoplasm-specific and nucleus-specific ERK targets. Within the cytoplasm, phospho-ERK1/2 act on components of the MAPK pathway (such as destabilization of the receptor docking SOS-GRB2 complex and ERK dephosphorylation enzyme activation) to serve as a negative feedback regulator of further ERK phosphorylation and hyperactivation. Within the nucleus, phospho-ERK activates numerous pro-survival transcription factors and subsequent transcription and translation of pro-survival and cell cycle genes and proteins, such as CREB (Bitner et al., 2007) and Akt (Nakayama et al., 2002). \( \alpha 7 \text{nAChR} \)-mediated ERK activation (Cui and Li, 2010) has also been observed in microglia, with subsequent PI3K-, Akt- and JAK-mediated cell survival (Bencherif et al., 2011). There exists a balance between ERK phosphorylation by kinase enzymes and dephosphorylation by phosphatase enzymes. Dual-specificity phosphatases (DUSPs) serve to dephosphorylate ERK1/2 at both serine and threonine residues.
Physiological activation of a receptor-linked tyrosine kinase (RTK) by growth factors results in receptor dimerization and autophosphorylation. Receptor-docking proteins (SOS and GRB2) activate GTP-bound Ras, which activates Raf, which in turn activates and phosphorylates MEK. Activation of MEK results in rapid but reversible ERK1/2 phosphorylation and activation, resulting in a number of signalling events, including activation of pro-survival transcription factors and cell cycle genes. As a negative feedback loop, phospho-ERK1/2 acts to destabilise the SOS-GRB2 complex and activate dual-specificity phosphatases (DUSPs), which dephosphorylate and inactivate ERK1/2.
and regulate MAPK signal transduction cascades (Caunt and Keyse, 2013). Activation of α7nAChR stimulates MEK-dependent ERK phosphorylation in neurons (Dajas-Bailador et al., 2002; Bitner et al., 2007; Steiner et al., 2007; Dickinson et al., 2008; El Kouhen et al., 2009), astrocytes (Koyama et al., 2004) and microglia (Giunta et al., 2004), in response to a number of ligands. The resultant MAPK signalling results in cell survival, cell division, and in a neuronal context: axon growth (Nordman et al., 2014), LTP (Schafe et al., 2008) and memory consolidation (Schafe et al., 2000). Phosphorylated ERK is increased in the hippocampus following memory consolidation and pharmacological antagonism of MEK prevents ERK phosphorylation and concomitant blockade in long-term memory formation (Bitner et al., 2007). The emerging role of phospho-ERK in cognition, learning and memory is only now becoming more apparent, with the development of more sensitive molecular, biochemical and imaging tools (Sweatt, 2004).

1.4.2.3.2 α7nAChR and CNS inflammation

All CNS degenerative diseases are associated with inflammation (Shytle et al., 2004). The cholinergic anti-inflammatory pathway modifies the immune system, through immune cells, such as macrophages (in the peripheral nervous system) and microglia (in the CNS). α7nAChR are essential regulators of cholinergic anti-inflammatory pathway (Wang et al., 2003), controlling the innate immune response to prevent excessive inflammation. Macrophage pro-inflammatory TNFα cytokine release is negatively regulated by ACh signalling to the vagus nerve, with enhanced TNFα release in α7nAChR knock-out mice (Wang et al., 2003).

Microglia are intrinsic immune cells of the brain, derived from erythromyeloid precursor lineage (Kierdorf et al., 2013; Prinz and Priller, 2014). Microglia are highly ramified cells, with motile processes, termed ‘resting’ microglia. Resting microglia constantly survey their environment and are the first cells to respond to any changes, by transforming into an amoeboid morphology and becoming ‘activated’. Activated microglia can proliferate, secrete cytokines, reactive oxygen species and phagocytose damaged cells and debris (Pocock and Kettenmann, 2007). Macrophages and microglia are activated by lipopolysaccharide (LPS), found on the outer membrane of Gram-negative bacteria. LPS exposure triggers synthesis of inflammatory mediators, such as TNFα and interleukin-1β (IL-1β), along with regulatory cytokines, such as IL-12. Diffusible inflammatory mediators activate large numbers of immune cells, amplifying the immune response, which produce large
quantities of pro-inflammatory cytokines, such as TNFα, IL-1, IL-6, IL-12 and IL-18 (Bencherif et al., 2011) resulting in neurodegeneration (Bodea et al., 2014). Microglia not only express chemokine and cytokine receptors, but have more recently been shown to respond to neurotransmitters via expression of neurotransmitter receptors (reviewed by Pocock and Kettenmann, 2007). Activation of microglial neurotransmitter receptors can be protective or inflammatory, depending on the receptor class. For example, activation of ionotrophic AMPA-type glutamate receptors is pro-inflammatory, enhancing TNFα release, whereas metabotropic glutamate receptors can be either protective or inflammatory (via activation of type III or type II, respectively). Activation of G-protein coupled purinergic P2Y receptors is neuroprotective, enhancing microglial motility, migration and phagocytosis. α7nAChR expression on glial cells has not been well studied, as the focus on α7nAChR’s cognitive enhancing effects have historically remained on the neuronal population within the CNS. However, as α7nAChR flux calcium, which is the basis for glial cell excitability (Parri et al., 2011), the question of whether α7nAChR can modulate glial cell behaviour remains largely unanswered. However, the few studies of nAChR in microglia show sole expression of the α7-subtype; and its activation is anti-inflammatory and neuroprotective. Activation of microglial α7nAChR enhanced neuroprotective gene expression (Parada et al., 2013), reduced LPS-induced TNFα release (Shytle et al., 2004), reduced IFN-γ mediated pro-inflammatory cell activation (Giunta et al., 2004), enhanced GLAST/EAAT1 expression (Morioka et al., 2014), reducing glutamate-mediated neuronal excitotoxicity and enhanced macrophage phagocytosis of bacteria in infected mice (Sitapara et al., 2014). Furthermore, the anti-inflammatory effects of macrophages can be attenuated by αBTX application (Ulloa, 2005). The anti-inflammatory nature of α7nAChR activation can also be attributed to reduced inflammasome activation. The inflammasome is a multicomponent complex that orchestrates the activation of pro-inflammatory caspase-1 and IL-1β and IL-18 release. Bacteria-mediated macrophage activation prime microglia to activate the NLRP3 inflammasome (Lee et al., 2013). The activated NLRP3 inflammasome is released as an extracellular particle to signal and amplify an immune response (Baroja-Mazo et al., 2014). Knock-out of the NLRP-3 inflammasome reduced caspase-1 activation and IL release, whilst enhancing microglial phagocytosis (Heneka et al., 2013). Recent data has shown α7nAChR activation inhibits NLRP3 inflammasome activation by preventing mitochondrial DNA
release (Lu et al., 2014). Thus activation of microglial neurotransmitter receptors (especially α7nAChR) and their subsequent downstream signalling cascades may be a key strategy in controlling inflammatory cell behaviour, with the potential to regulate inflammation within the CNS for the treatment of inflammatory neurodegenerative diseases (Bencherif et al., 2011).

1.5 nAChR pharmacology

As nAChR (particularly the α7 subtype) are involved in a vast range of cellular processes and are implicated in cognitive function; compounds that modulate nAChR have been the focus of significant research efforts in a bid to improve cognition and also combat neurological decline. Table 1.1 lists neuronal nAChR-selective ligands, grouped into agonists, antagonists and modulators. Agonists activate nAChR to bring about a biological response, whereas antagonists block agonist-mediated responses, by binding to orthosteric or allosteric sites on the receptors. Modulators encompass all nAChR-binding ligands that exert alternative effects to agonism and antagonism of nAChR. Allosteric modulators of nAChR have been developed to modulate native nAChR in cognitive disease states, such as schizophrenia and Alzheimer’s disease, where nAChR-mediated processes are reduced (Timmermann et al., 2007; Taly et al., 2009; Williams et al., 2011b). Positive allosteric modulators (PAMs) have been grouped into two classes, type I and type II PAMs (Grønlien et al., 2007), as determined by their apparent peak current profile and type II PAMs can reactivate nAChR following receptor desensitisation (Bertrand and Gopalakrishnan, 2007; Changeux, 2013b; Uteshev, 2014), figure 1.5. PAMs bind to nAChR at sites distinct from the agonist binding (orthosteric) site (Barron et al., 2009) and enhance receptor gating in the presence of agonists. PNU-120596 dramatically enhances the channel open time (daCosta et al., 2011; Williams et al., 2012) and also enables α7nAChR to overcome desensitisation and receptor silencing (Papke et al., 2009; Szabo et al., 2014). Non-desensitising α7nAChR-selective agonists have also recently been reported in the literature (Gill et al., 2011) and exhibit potential in neurological conditions where endogenous neurotransmitter levels are reduced.

Throughout this thesis, the α7nAChR-selective type II PAM PNU-120596 (Table 1.1; Hurst et al., 2005; Grønlien et al., 2007) was used in combination with the α7nAChR-selective agonist PNU-282987
<table>
<thead>
<tr>
<th>Drug</th>
<th>nAChR-isoform selectivity</th>
<th>Comment(s)</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A-85380</td>
<td>α4β2*-selective</td>
<td>Analog of (±)-Epibatidine, with lower binding to non-α4β2 nAChR.</td>
<td>Sullivan et al, 1996</td>
</tr>
<tr>
<td>Acetylcholine</td>
<td>All mAChR and nAChR subtypes</td>
<td>Susceptible to hydrolysis and requires the presence of AChE inhibitor.</td>
<td>Williams et al, 2011</td>
</tr>
<tr>
<td>AR-R17779</td>
<td>α7-selective</td>
<td>100-fold greater potency for binding to α7nAChR than α4β2nAChR. Binding potency Ki: 0.2μM, EC50: 10-20μM.</td>
<td>Mullen at al, 2000</td>
</tr>
<tr>
<td>Choline</td>
<td>Weak agonist at α7</td>
<td>Weak agonist, 10-fold lower potency than ACh. Binding potency Ki: 2mM, EC50: 0.4-1.6mM.</td>
<td>Alkondon et al, 1997; Kalappa et al, 2010</td>
</tr>
<tr>
<td>Compound A</td>
<td>α7-selective agonist</td>
<td>Potent and selective agonist. Binding potency Ki: 40nM, EC50: 14nM-0.95μM.</td>
<td>Ondrejcak et al, 2012</td>
</tr>
<tr>
<td>(-)-Cotinine</td>
<td>α4β2*-selective agonist</td>
<td>Metabolite of nicotine, with lower potency.</td>
<td>Vainio et al, 2001</td>
</tr>
<tr>
<td>(-)-Cytisine</td>
<td>α4β2*-selective partial agonist</td>
<td>Isolated from leguminosae plant family. Full efficacy for the β4 subunit. Binding potency Ki: 1nM.</td>
<td>Marotta et al, 2014</td>
</tr>
<tr>
<td>(±)-Epibatidine</td>
<td>Highly potent agonist at heteromeric nAChR</td>
<td>Isolated from Amazonian frog skin.</td>
<td>Rousseau et al, 2005</td>
</tr>
<tr>
<td>EVP-6124</td>
<td>Partial agonist at α7</td>
<td>Acts as an agonist as well as potentiating ACh-evoked responses.</td>
<td>Prickaerts et al, 2012</td>
</tr>
<tr>
<td>GTS-21</td>
<td>Partial agonist at α7</td>
<td>Elicits only 30% of an ACh-evoked α7nAChR maximum response. Binding potency Ki: 0.2-0.5μM, EC50: 6-26μM.</td>
<td>Sitapara et al, 2014</td>
</tr>
<tr>
<td>(-)-Nicotine</td>
<td>All nAChR subtypes</td>
<td>Higher affinity for α4β2* over α7. Prolonged nicotine-binding induces a reversible desensitisation state.</td>
<td>Wonnacott et al, 2005</td>
</tr>
<tr>
<td>Compound</td>
<td>Subunit Composition</td>
<td>Description</td>
<td>Binding Potency Kᵢ</td>
</tr>
<tr>
<td>-------------------</td>
<td>------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>RJR 2403</td>
<td>α4β2* selective agonist</td>
<td>EC₅₀: 26nM.</td>
<td></td>
</tr>
<tr>
<td>Sazetidine-A</td>
<td>α4β2* desensitising agent α7 agonist and desensitising agent</td>
<td>Originally thought to have no effect on nAChR activation. EC₅₀: 4.2μM.</td>
<td></td>
</tr>
<tr>
<td>SSR180711</td>
<td>α7-selective partial agonist</td>
<td>Elicits 30-50% of an ACh-evoked α7nAChR maximum response. Binding potency Kᵢ: 20nM, EC₅₀: 1-4μM.</td>
<td></td>
</tr>
<tr>
<td>TC 2559</td>
<td>α4β2-selective partial agonist</td>
<td>Selective for (α4)₂(β2)₃ stoichiometry. Low efficacy. EC₅₀: 200nM.</td>
<td></td>
</tr>
</tbody>
</table>

**Antagonists**

<table>
<thead>
<tr>
<th>Compound</th>
<th>Subunit Composition</th>
<th>Description</th>
<th>Binding Potency Kᵢ</th>
<th>IC₅₀</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-bungarotoxin (αBTX)</td>
<td>Homomeric α7-, α8-, α9-selective competitive antagonist</td>
<td>Polypeptide toxin from snake venom. Interacts with α-subunit. Binding potency Kᵢ: 0.5-1nM, IC₅₀: 1-100nM.</td>
<td></td>
<td></td>
<td>Samson et al, 2002</td>
</tr>
<tr>
<td>Dihydro-β-erythroidine (DHβE)</td>
<td>Competitive neuronal non-α7 antagonist</td>
<td>Isolated from <em>Erythrina</em> seeds. More potent at α4β2 and α3β2 and 50-fold less potent at α3β4 and α7 in oocytes. In neurons, DHβE only blocked α4β2*.</td>
<td></td>
<td></td>
<td>Harvey et al, 1996; Alkondon and Albuquerque, 1993</td>
</tr>
<tr>
<td>Mecamylamine</td>
<td>Non-competitive non-selective antagonist Weak NMDAR antagonist</td>
<td>α7 less sensitive then heteromeric nAChR (mecamylamine only blocks ~70% of a αBTX block). Saturating concentrations inhibit NMDAR. IC₅₀: 0.1-1μM.</td>
<td></td>
<td></td>
<td>Chavez-Noriega et al, 1997; Ridley et al, 2002; Sharma and Vijayaraghavan, 2003</td>
</tr>
<tr>
<td>Methylycaconitine (MLA)</td>
<td>Potent α7 competitive antagonist Relatively potent at α9, α9/10 and α6β2*</td>
<td>Isolated from <em>Delphinium sp</em>. Discriminates between muscle and α7nAChR. Binding potency Kᵢ: 1nM, IC₅₀: 10-200nM.</td>
<td></td>
<td></td>
<td>Ward et al, 1990; Drasdo et al, 1992; Mogg et al, 2002</td>
</tr>
<tr>
<td>Modulators</td>
<td>nAChR Interacting Ligands</td>
<td>nAChR Subtype Selectivity and Pharmacological Effects</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------</td>
<td>-----------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MK-801</td>
<td>Potent NMDAR antagonist</td>
<td>IC&lt;sub&gt;50&lt;/sub&gt; at nAChR: 15µM.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Weak open nAChR channel</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>blocker</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Modulators**

| Galantamine | AChE inhibitor            | Isolated from the common snowdrop. Modest         |
|            |                           | potentiating of Ach-evoked currents (30%) and     |
|            |                           | increases intracellular calcium at low            |
|            |                           | concentrations, above which reverts to a nAChR    |
|            |                           | antagonist. Approved for use in treatment of mild |
|            |                           | to moderate AD.                                   |
|            | Potentiates nAChR responses |                                                     |
| Galantamine |                           |                                                     |

| 5-hydroxyindole | Potentiates α7 | 5-HT metabolite, Type I PAM: increases Ach       |
|                 |                | potency and efficacy without effect on            |
|                 |                | desensitisation. EC<sub>50</sub>: 2.5mM.        |

| JNJ-1930942 | α7-selective positive allosteric modulator | No agonist properties at α7. Type I PAM:         |
|            | No effect at α4β2, α3β4 or 5-HT<sub>3</sub>R | enhances recovery but does not prevent           |
|            |                                               | desensitisation. EC<sub>50</sub>: 1.9µM         |

| LY2087101 | Potent potentiator of α7 and α4β2 | Avoids potentiating of α3β4 nAChR hence          |
|          |                                  | removes undesirable in vivo side effects. EC<sub>50</sub>: 4.2µM. |

| PNU-120596 | α7-selective positive allosteric modulator | Type II PAM. No agonist properties at α7.        |
|            | No effect on α4β2, α3β4 or α9α10 | Prolongs and increases agonist-evoked             |
|            |                                   | currents. No effect on ion-selectivity or unitary |
|            |                                   | conductance. Reactivates desensitized            |
|            |                                   | α7nAChRs. Binds to α7nAChR within α-helical       |
|            |                                   | transmembrane regions. Capable of cognitive       |
|            |                                   | enhancement in vivo. EC<sub>50</sub>: 200nM       |

**Table 1.1: nAChR-interacting ligands, nAChR-subtype selectivity and pharmacological effects.** Selected notable neuronal nAChR ligands grouped into agonists, antagonists and positive allosteric modulators (PAMs), with key references of characterisation included.
(Bodnar et al., 2005; Hajos et al., 2005; del Barrio et al., 2011) to reveal the activity of native $\alpha 7nAChR$, in order to examine the biological role of $\alpha 7nAChR$ at the glutamatergic synapse.

1.5.1 Modulators of nAChR and effects on cognitive function

Presynaptic $\alpha 7nAChR$-mediated glutamate release at hippocampal synapses is known to contribute to development of synaptic plasticity (Mansvelder and Mcgehee, 2000; Huang et al., 2010), and is modulated by inhibitory GABA signalling inputs (Alkondon et al., 1997). Due to the high expression level of $\alpha 7nAChR$ within the hippocampus (Dani and Bertrand, 2007) and the nicotinic deficits observed in pathological conditions (section 1.6.1), $\alpha 7nAChR$ are implicated in various neurological and cognitive disorders. In support of this, $\alpha 7nAChR$ gene knockout studies showed impaired learning and memory (Marubio and Changeux, 2000; Dineley et al., 2002b; Young et al., 2007). The depolarisation contributed by $\alpha 7nAChRs$ helps to relieve the magnesium block of postsynaptic NMDA-type glutamate receptors (NMDAR) (Kenney and Gould, 2008; Yang et al., 2013; Cheng and Yakel, 2014) and enhance probability of LTP induction. Hence, a loss of hippocampal and cortical ACh signalling through $\alpha 7nAChRs$ in aging or pathological acceleration of aging is of significant detriment, and is thought to be a major contributing factor underlying age-related memory decline (Bierer et al., 1995) and loss of working memory (Croxson et al., 2011). Many years of research (Mansvelder and Mcgehee, 2000; Miwa et al., 2011) has shown in both animals and humans, that nicotine can paradoxically, both improve and impair cognitive performance (Newhouse et al., 2004). Nicotine-induced cognitive enhancement is generally observed in subjects exhibiting sub-optimal cognitive performance, such as those with age-related cognitive decline or Alzheimer’s disease (AD). Contrastingly, nicotinic stimulation impairs cognitive performance in those performing at a near-optimal level (Newhouse et al., 2004). However, the mechanism of nicotine-induced improvements in cognition is unknown. To this end, an array of pharmacological compounds (namely agonists, positive allosteric modulators (PAMs) and AChE inhibitors) have been developed to selectively enhance physiological $\alpha 7nAChR$ activity, in favour of $\alpha 7nAChR$ activation-induced cognitive enhancement (Table 1.1, reviewed by Wallace and Porter, 2011), without the undesirable side effects of ACh and nicotine-mediated pan-mAChR and nAChR activation, respectively.
Figure 1.5: The electrophysiological distinction between type I/II positive allosteric modulators (PAMs) of α7nAChR. Type I and type II PAM-potentiated signals (grey traces) produce different peak current profiles following agonist-mediated (black traces) receptor activation (adapted from Lendvai et al., 2013). Type II PAMs prevent receptor desensitisation and allow increased mean channel open time.
1.5.1.1 \( \alpha 7 \text{nAChR}-\text{selective agonists} \)

Agonists acting at nAChR exhibit inverted U-shaped dose response curves, attributed to the rapid desensitisation of nAChR (particularly the \( \alpha 7 \) subtype), thus resulting in a dose-limiting loss of effect (Picciotto, 2003; Wallace and Porter, 2011), when applied in the absence of type II PAMs. Development of orthosteric agonists has been intense, however, the homology of nAChR with other members of the Cys-loop ligand-gated ion channel family has resulted in few wholly \( \alpha 7 \text{nAChR}-\text{selective} \) compounds. The few \( \alpha 7 \text{nAChR}-\text{selective} \) agonists have been shown to improve deficits in sensory gating in schizophrenia (Toyohara and Hashimoto, 2010), enhance cognition in humans and animals (Levin and Rezvani, 2000), mild cognitive impairment and AD mouse models (Medeiros et al., 2014), enhance attention (Levin, 2013), episodic memory (Wallace and Porter, 2011) and working memory (Lendvai et al., 2013). Conversely, \( \alpha 7 \text{nAChR}-\text{selective} \) antagonists, such as MLA (Table 1.1) impair cognition in animal behavioural models (Wallace and Porter, 2011). Thus enhanced activation of native \( \alpha 7 \text{nAChR} \) is widely regarded as an attractive strategy in cognitively impaired disease states.

1.5.1.2 \( \alpha 7 \text{nAChR}-\text{selective PAMs} \)

Type II PAMs are more favourable clinical molecules, over type I PAMs, as they prevent or overcome nAChR desensitisation (Grønlie et al., 2007), but may introduce the risk of excitotoxicity (Ng et al., 2007; Hu et al., 2009a). PAMs serve to enhance small \( \alpha 7 \text{nAChR} \) stimuli and thus heighten them above the receptor activation threshold, leading to cellular activation and concomitant cell survival. PAMs allow enhancement of endogenous agonist effect and have shown promise in models of sensory gating deficits and paradigms of altered cholinergic tone (Wallace and Porter, 2011). Many of the AChE inhibitors also act as \( \alpha 7 \text{nAChR}-\text{selective} \) PAMs (Dajas-Bailador et al., 2003) to further boost cholinergic signalling.

1.6 The cholinergic hypothesis of Alzheimer’s disease

The cholinergic hypothesis (Perry, 1986) postulates that cholinergic neurodegeneration within the basal forebrain induces the cognitive decline observed in AD (Coyle et al., 1983). This neurodegeneration within the basal forebrain leads to reduced cholinergic neurotransmission and resultant losses of presynaptic terminals.
in the cortex and hippocampus (Pettit et al., 2001). Studies showed a marked reduction in acetylcholine synthesis and breakdown within post-mortem AD patient cortex and hippocampal tissue, by measuring choline acetyltransferase and acetylcholinesterase activity, respectively (Bartus et al., 1982; Whitehouse et al., 1982). Furthermore, reduced uptake of the acetylcholine precursor, choline (Apelt et al., 2002), reduced acetylcholine release (Francis et al., 1999) and reduced levels of nAChR in AD brains (Martin-Ruiz et al., 2002) further reinforced this hypothesis. Hence following this theory, acetylcholinesterase inhibitors (section 1.9.1) were adopted as therapeutic treatments for AD. These findings, when coupled with the central role of acetylcholine in memory and cognition implicate dysregulation of acetylcholine release and nAChR signalling in the pathogenesis of AD, and reinforce the central role of cholinergic function in healthy cognitive aging.

1.6.1 Alzheimer’s disease and age-related cognitive decline

Dementia affects approximately 30-40 million people worldwide with numbers projected to rise to 115 million by 2050 (Alzheimer’s Society, 2014), due to the world’s aging population. The most common cause of dementia is AD. AD is characterised by progressive memory loss with age, due to specific vulnerability of the neurons within the hippocampus and cortex associated with memory formation and storage, with pathology beginning in and spreading from the entorhinal cortex (Khan et al., 2013). It is these brain regions that show the pathological signs of AD, including extracellular plaques, composed of Aβ peptide and intracellular neurofibrillary tangles (NFT), composed of hyperphosphorylated Tau (Walsh and Selkoe, 2007). Subsequently, the hippocampus and cortex exhibit synapse loss and neuronal cell death (Wei et al., 2010), leading to the impaired cognition and behavioural changes observed in AD (Näslund et al., 2000). Throughout physiological aging, the brain accrues extracellular plaques of Aβ peptides (Walsh et al., 2002; Walsh and Selkoe, 2007). These plaques are observed to a greater degree in AD patient brains (La Joie et al., 2012), but whether they play a primary role in initiating, or secondary role in mediating cholinergic dysfunction in both aging and AD is controversial (Kenney and Gould, 2008; Knowles et al., 2014). Cholinergic axon loss has been shown to be more pronounced in the vicinity of Aβ plaques in aged humans, primates and AD patients (Shah et al., 2010). Soluble and oligomeric Aβ peptide species have been shown to modulate synaptic plasticity and LTP (Walsh et al., 2002; Wang et al., 2002; Cleary et al., 2005; Abramov et al., 2009), as well as cholinergic synapse dysfunction
A\(\beta\) dimerisation, oligomerisation and differential species formation may precede deposition of insoluble A\(\beta\) plaques (Schliebs and Arendt, 2011; Larson and Lesnê, 2012). A\(\beta\) may exert its cholinergic neurotoxic effects through interactions with \(\alpha7nAChR\) (Wang et al., 2000a, 2000b; Parri and Dineley, 2010; Tong et al., 2011; Liu et al., 2013) but conversely, cholinergic signalling has also been shown to be neuroprotective against A\(\beta\) toxicity (Liu et al., 2001; Lahiri et al., 2002; Mousavi and Hellström-Lindahl, 2009; Nie et al., 2010). Thus, understanding the mechanism leading to A\(\beta\)-induced neurodegeneration of the neurons within the hippocampus and cortex is central to aging-induced cognitive decline and AD, and the fundamental process underlying this is the cleavage of amyloid precursor protein (APP) to yield A\(\beta\) peptides. The amyloid cascade hypothesis posits that the A\(\beta\) peptides, derived from APP holoprotein, are the root cause of AD.

### 1.7 Amyloid cascade hypothesis

The essence of the amyloid cascade hypothesis is that increased A\(\beta\) production (especially the A\(\beta_{42}\) species, over A\(\beta_{40}\)) or reduced A\(\beta\) clearance causes AD. Accumulation of A\(\beta\) results in aggregation and plaque formation, which initiates a cascade of cellular events ultimately resulting in cell death. The amyloid cascade hypothesis was suggested ~20 years ago (Hardy and Allsop, 1991; Hardy and Selkoe, 2010), with genetic and biochemical data supporting the hypothesis although some researchers believe that A\(\beta\) is one factor and not the sole cause of AD (Pimplikar et al., 2010).

Of the millions of AD sufferers worldwide, less than 1% exists as ‘familial’ cases, caused by autosomal dominant mutation(s) in either APP or presenilin (PS-1/PS-2) genes (Price and Sisodia, 1998; Hardy and Selkoe, 2002). Presenilin 1 and 2 make up the catalytic core of \(\gamma\)-secretase (De Strooper, 2003; Selkoe and Wolfe, 2007), which cleaves APP to yield A\(\beta\) species; with familial presenilin mutations favouring the secretase-mediated production of the longer 42-residue A\(\beta\) form. APP mutations occur near the site of secretase cleavage and serve to enhance total A\(\beta\) levels and the A\(\beta_{42}\):A\(\beta_{40}\) ratio. A\(\beta_{42}\) is more prone to aggregation and plaque formation (Meisl et al., 2014). Familial AD typically affects patients at 40-50 years of age, whereas symptoms of sporadic AD occur after 65 years of age. These two forms of AD present with similar neurological and pathological hallmarks and are thus thought to be...
identical or at least highly analogous diseases. Whilst mutations in APP or presenilin potentially cause AD, Tau NFT load more closely correlates with disease severity and cognitive decline correlates with hippocampal volume (Ong et al., 2014). Whilst the presence of amyloid plaques (composed of Aβ) and NFT (composed of Tau) are considered to be the defining hallmarks of AD, these aggregates are increasingly recognised as not being the neurotoxic species underlying cell death in AD. As more research has been undertaken into the amyloid cascade hypothesis, the central toxic species has been revised, from Aβ plaques to a multi-faceted neurotoxic insult (Oddo et al., 2006), including NFT, environmental factors and soluble Aβ species, which have been isolated from cell culture medium (Walsh and Selkoe, 2007), AD brain extracts (Shankar et al., 2007) and AD mouse models (Lesné et al., 2006); but this remains controversial as the exact toxic nature of the Aβ species is yet to be resolved, figure 1.6. Aβ plaques are no longer purported to be the toxic species, after they were shown to be present in cognitively normal people (Nordberg, 2008), lacking in AD patients (Terry et al., 1991), the non-correlative relationship between plaque load and disease progression (Ong et al., 2014) and a number of animal models showing cognitive impairment prior to plaque deposition (Lesné et al., 2006). Nonetheless, the majority of modern pharmacological intervention strategies for AD have focussed on amyloid-based therapeutic approaches, aiming to lower Aβ production, in accordance with mechanisms postulated through the amyloid cascade hypothesis. A number of pharmacological compounds have been developed to target toxic Aβ species, namely β- and γ-secretase inhibition (Zhou et al., 2011), inhibition of Aβ aggregation (McKoy et al., 2012), Aβ immunisation (Schenk et al., 1999) and enhancing amyloid degradation (Walker et al., 2013); each of which has had minimal success in the clinic (Karran et al., 2011). However, given the emerging evidence highlighting Aβ-mediated NFT formation and the strong correlation between NFT deposition and cognitive decline, this suggests amyloid-targeting mechanisms may have some future scope, inhibiting Aβ as an upstream modulator of Tau modification (namely hyperphosphorylation), further validating the amyloid cascade hypothesis and placing it at the crux of on-going research into the basic mechanistic biology of AD.
According to the amyloid cascade hypothesis, the causative event in AD pathogenesis is an imbalance between Aβ production and clearance. Various Aβ species can directly inhibit hippocampal LTP and impair synaptic function, in addition to the inflammatory and oxidative stress caused by Aβ plaques. As a result, Tau hyperphosphorylation and subsequent NFT formation impairs neuronal and synaptic function, resulting in neuronal death, neurotransmitter deficits and cognitive decline before the symptomatic onset of dementia.
1.8 Amyloid precursor protein

APP is found in the plasma membrane as a type I transmembrane glycoprotein (Hardy and Selkoe, 2002). There are three major isoforms, APP<sub>770</sub>, APP<sub>751</sub> and APP<sub>695</sub>. APP<sub>695</sub> is the major isoform localised to the brain, where it is found in a mature O- and N-glycosylated state. APP<sub>695</sub> is the major isoform in mouse primary cortical neurons (Hoey <i>et al</i>., 2009), whilst primary astrocytes and microglia express all three isoforms of APP (Haass <i>et al</i>., 1991), where APP is found densely localised to the Golgi and endoplasmic reticulum (Palacios <i>et al</i>., 1992).

APP interacts with a number of cell-surface localised proteins but its role in both development and the mature brain is yet to be elucidated. Analysis of APP's <i>in vivo</i> physiological function is made difficult by its proteolytic cleavage, to yield various peptides with their own functions. Furthermore, APP is part of a highly conserved family with overlapping and redundant functions (Müller and Zheng, 2012). APP is a member of a gene family including APL-1 in <i>Caenorhabditis elegans</i>, APPL in <i>Drosophila</i>, appa and appb in zebrafish and APLP1 and APLP2 (along with APP) in mammals. APP family proteins are composed of highly conserved regions, and interestingly, the extracellular and juxtamembrane regions are divergent across the family, with Aβ being specific to APP (Müller and Zheng, 2012). The family is subject to posttranslational modifications, such as N- and O-glycosylation, sialylation, and phosphorylation at many intracellular C-terminal sites by GSK-3β (Rockenstein <i>et al</i>., 2007). The exact role of APP phosphorylation is unknown, but is the subject of intense study. Hypothesised functions include regulation of APP secretion (Caporaso <i>et al</i>., 1992), neuronal sensitivity to trophic signalling (Matrone <i>et al</i>., 2011), regulation of APP's interaction with adaptor and signalling proteins (Schettini <i>et al</i>., 2010) and as an iron-export ferroxidase (Duce <i>et al</i>., 2011). The phosphorylation state-mediated regulation of APP processing remains a topic of considerable debate (Sano <i>et al</i>., 2006; Barbagallo <i>et al</i>., 2010; Matrone <i>et al</i>., 2011) and its <i>in vivo</i> relevance is only beginning to be revealed. APP is particularly highly expressed in neurons, where it is localised to the cell body, axons and dendrites (Back <i>et al</i>., 2007; Hoe <i>et al</i>., 2009; Hoey <i>et al</i>., 2009, 2013).

1.8.1 Physiological functions of APP

Despite a wealth of data on Aβ and its production, the physiological role of APP remains an enigma (Hoe <i>et al</i>., 2009). Much of the data on APP comes from knock-
out studies, complemented by cellular *in vitro* studies (Müller and Zheng, 2012). Complete knock-out of APP produced viable and fertile mice, but with 20% reduced body mass and 10% reduced brain weight (Zheng et al., 1995), consistent with *in vitro* data showing APP mediates neurogenesis, synaptic adhesion and axonal pathfinding (Sosa et al., 2013; Wang et al., 2014). The mice also showed increased levels of metal deposition, consistent with recent data highlighting APP and its cleavage product sAPPα as being involved in iron efflux (Duce et al., 2011; McCarthy et al., 2014). Furthermore, knock-out mice were hypersensitive to kainate-induced seizures, and impaired performance in learning and spatial memory tasks, associated with a defect in LTP, consistent with a role for APP in mediating the balance of neuronal excitation (Zhang et al., 2013). Finally, knock-out mice displayed reduced grip strength, consistent with APP’s hypothesised role in directing the formation of the neuromuscular junction early in development (Zheng et al., 1995). Combinatorial knock-out of APP family members (APP/APLP) is postnatal lethal, revealing defects in glutamatergic synaptic transmission (Schrenk-Siemens et al., 2008) and reinforcing the role of APP in mature synapse formation and synaptic transmission.

In contrast, APP cleavage products have been extensively studied, and extracellular soluble forms of APP (particularly sAPPα) have been shown to act as neurotrophins, regulating axon pruning and degeneration (Copanaki et al., 2010) through binding to the death receptor DR6 under stress (Nikolaev et al., 2009; Kallop et al., 2014). sAPPα is able to rescue the APP knock-out phenotypes of anatomical, behavioural and electrophysiological defects (Ring et al., 2007), reinforcing the important physiological function of APP and its cleavage products. The AICD produced from γ-secretase cleavage of APP-CTFs regulates gene expression (Pardossi-Piquard and Checler, 2012), following its stabilisation by Fe65 (Kimberly et al., 2001) and translocation to the nucleus; where AICD forms a transcriptionally active complex with Fe65 and Tip60 (Cao and Südhof, 2001). Understanding the physiological processing of APP may provide a more in depth insight into the fundamental role of APP and its cleavage products.

1.8.2 APP processing

Processing of APP produces the Aβ peptide which appears to be central to the pathogenesis of AD. Only a small quantity of mature APP is cleaved, however its half-life is predicted to be ~10 min (De Strooper and Annaert, 2000), indicating a highly dynamic regulation. There are two principal APP processing pathways, the pro-
amyloidogenic pathway, leading to Aβ formation and the non-amyloidogenic pathway, preventing Aβ formation, figure 1.7. The principle proteolytic cleavage of APP, under basal homeostatic conditions is via the non-amyloidogenic pathway, with initial APP cleavage performed by an α-secretase (Buxbaum et al., 1998). α-secretase cleaves APP between Lys16 and Leu17 residues, cutting APP within the Aβ peptide sequence (Sisodia et al., 1999), preventing the formation of the amyloid plaque-forming peptide. α-secretase action yields extracellular sAPPα and an 83-residue CTF-α (also known as C83). Intracellular CTF-α is subsequently cleaved by intra-membrane γ-secretase, to give rise to intracellular p3 and AICD, figure 1.7.

Conversely, pro-amyloidogenic APP processing produces the Aβ peptide by the consecutive action of β- and γ-secretase (Lichtenthaler and Haass, 2004). β-secretase cleaves APP at the N-terminus of the Aβ sequence, producing a large ectodomain peptide, CTF-β or C99, which is cleaved by γ-secretase to give rise to intracellular AICD and Aβ, which has been found to be secreted into plasma and CSF (Cirrito et al., 2003). Distinct sites of γ-secretase action on CTF-β yield a number of potentially neurotoxic Aβ species (Hartmann et al., 1997; Lesné et al., 2006). There is conflicting evidence to show α-/β-secretase activity act in competition or reciprocally with one another. Some studies indicate BACE-1 inhibition does not enhance α-secretase activity and sAPPα release (Kim et al., 2008; Dobrowolska et al., 2014) and others reporting the converse (Postina et al., 2004; Fukumoto et al., 2010; Zhang et al., 2010; May et al., 2011) with enhanced sAPPα production following reduced BACE-1 expression. Similarly, a number of studies report increased α-secretase activity results in reduced β-secretase activity and Aβ formation (Lichtenthaler and Haass, 2004; Hiraoka et al., 2007). However, this relationship may depend on cell type and subcellular localisation of both secretase enzymes and APP substrate.

1.8.2.1 Regulation of APP processing by secretases

1.8.2.1.1 α-secretase

Putative α-secretases (ADAM-9, ADAM-10 and ADAM-17) are members of the ADAM (a disintegrin and metalloproteinase) family and are each type I transmembrane proteins. Of the three putative α-secretase enzymes, ADAM-10 and
43

**Figure 1.7: Amyloid precursor protein (APP) processing.** Initial cleavage of APP occurs in the extracellular region of the peptide by either α- or β-secretase to release soluble APP fragments (sAPP) and intracellular C-terminal fragments (CTF). Membrane embedded γ-secretase subsequently carries out a second cleavage of APP within the transmembrane (TM) region of the CTF peptide. Cleavage of CTF-α by γ-secretase within the non-amyloidogenic pathway (right hand side), gives rise to APP intracellular cytoplasmic domain (AICD) and p3 fragments. Pro-amyloidogenic cleavage (left hand side) of APP gives rise to CTF-β that is cleaved by γ-secretase to yield AICD and various putative Aβ species, dependent on the residue of γ-secretase action. Aβ peptides can subsequently be degraded by neprilysin or dimerise, oligomerise and form fibrils, which are deposited as extracellular plaques.
ADAM-17 are the best characterised, whilst knock-out of ADAM-9 had no effect on APP processing and sAPPα generation, suggesting it is not a constitutive α-secretase and can be compensated for by other ADAMs (Kuhn et al., 2010). Under normal conditions, constitutive α-secretase processing is carried out by the zinc metalloproteinase ADAM-10 (Kuhn et al., 2010), which is localised to the cell surface and Golgi apparatus. Overexpression of ADAM-10 enhances non-amyloidogenic APP cleavage and knock-down completely suppressed α-cleavage (Kuhn et al., 2010) and results in enhanced Aβ plaque deposition (Postina et al., 2004). Rare ADAM-10 mutations exist in the population, but have been shown to have no role in sporadic AD onset (Cai et al., 2012) but in transgenic mice can enhance Aβ production through chaperone dysfunction (Suh et al., 2013; Vassar, 2013). ADAM-17 cleaves APP (as well as TNFα, amongst other notable cytokine and growth factor substrates) in a PKC-dependent process (Nitsch et al., 1992) and knock-out of ADAM-17 produced defective PKC-mediated sAPPα secretion, suggesting ADAM-17 is a regulated and stimulatory α-secretase (Buxbaum et al., 1998) in both primary neurons and cell lines (Zhang et al., 2011). The pharmacological broad-spectrum matrix metalloproteinase inhibitor TAPI-1 blocks the in vitro shedding of α-secretase cleaved cell surface proteins by both constitutive and stimulated ADAMs (Slack et al., 2001). In vivo, ADAM-10 is regulated by endogenous secreted TIMP-1 and TIMP-3 matrix metalloproteinase inhibitors (Postina, 2012; Vingtdeux and Marambaud, 2012).

1.8.2.1.2 β-secretase

Only one β-secretase has been identified in neurons and is known to be the sole enzyme responsible for pro-amyloidogenic APP processing, known as BACE-1. β-site APP cleaving enzyme (BACE-1) is a type I integral transmembrane protein and is an aspartyl protease (Cole and Vassar, 2007). BACE-1 functions optimally at low pH, hence is found in endosomes and the Golgi apparatus (Vassar, 1999), and whose activity is required for Drosophila glial cell survival (Bolkan et al., 2012). The BACE-1 homolog BACE-2 is expressed as the APP cleaving β-secretase in astrocytes (Bettegazzi et al., 2011), which cleaves APP within the Aβ peptide, analogous to α-secretase (Farzan et al., 2000). Under physiological conditions APP and BACE-1 are spatially segregated (Das et al., 2013) in neurons, with APP and BACE-1 localised to the trans-Golgi and recycling endosomes, respectively. BACE-1 overexpression shifts the subcellular localisation of APP, suggesting cleavage of the APP substrate and Aβ
formation are tightly controlled and depend on secretase availability (Lee et al., 2005). BACE-1 cleavage is the rate-limiting step in Aβ production (Vassar, 2004) and is an important therapeutic target, as BACE-1 knock-out removes both Aβ production and CTF-β generation, which has also been reported as a toxic species (Lahiri et al., 2006; Lauritzen et al., 2012) and reduces Aβ plaque pathology (Cai et al., 2001). BACE-1 knock-out mice display severe defects in hippocampal CA1 mossy fibre synapses, due to defective ryanodine receptor-mediated intracellular calcium release, which can be rescued by nicotine-mediated activation of α7nAChR that restores LTP (Wang et al., 2010a). BACE-1 knock-out mice are viable and fertile, but exhibit behavioural, pain sensitivity and muscle defects (Cheret et al., 2013) as a result of an accumulation of other BACE-1 substrates, such as Notch (Brou et al., 2000), neuregulin-1 and the β2 subunit of voltage-gated sodium channels.

1.8.2.1.3 γ-secretase

The intra-membrane cleavage of both α- and β-CTFs by γ-secretase gives rise to p3 and Aβ peptides, respectively. CTFs generated by α-/β-secretase cleavage of APP are difficult to detect due to a very short half-life (Kuhn et al., 2010) as a result of their high affinity to γ-secretase and subsequent rapid hydrolysis. The hydrophobic nature of the plasma membrane makes γ-secretase cleavage controversial, as peptide bond hydrolysis typically requires a water molecule (Haass et al., 2012). γ-secretase exists as a high molecular weight complex, composed of a number of components: presenilin-1/2, nicastrin, anterior pharynx-defective-1 (APH-1) and presenilin enhancer-2 (PEN-2). Each component is necessary for γ-secretase activity. Either of the presenilin (PS) isoforms (PS-1 and PS-2) can make up the transmembrane catalytic core of γ-secretase (Xia et al., 1998). PEN-2 regulates presenilin maturation, whilst nicastrin is a scaffold protein within the complex, acting as the size-selective substrate receptor (Xie et al., 2014) and implicated in intracellular calcium homeostasis and synaptic plasticity (Lee et al., 2014). APH-1 acts to stabilise nicastrin during formation of the γ-secretase complex (Zhang et al., 2011; Haass et al., 2012).

There exist a number of intra-membrane γ-secretase substrates, with 91 known to date (Haapasalo and Kovacs, 2011), with the most notable being APP and Notch. The huge variety of cellular processes regulated by PS-substrates makes targeting γ-secretase for therapeutic intervention in AD an enormous challenge (Wolfe, 2012).
Designing inhibitors capable of selectively targeting γ-secretase-mediated Aβ production remains a challenge in intelligent drug design (Haapasalo and Kovacs, 2011). The spatial separation of specific substrates across various subcellular membranous organelles may make targeting specific populations of presenilin-containing γ-secretase complexes easier (Jeon et al., 2013; Mizutari et al., 2013). γ-secretase can cleave CTF-β within the plasma membrane to give rise to Aβ peptides ranging from 38-43 amino acids in length (Zhang et al., 2012). The predominant γ-secretase cleavage gives rise to the Aβ40 isoform, but (as discussed above) mutations within PS-1 and PS-2 are a major cause of familial AD (Sisodia et al., 1999), with the majority of PS mutations altering γ-secretase action to favour formation of the aggregation-prone Aβ42 isoform (Page et al., 2008). Selective loss of presenilins at presynaptic sites within neurons of the hippocampus impairs activity-dependent neurotransmitter release (Pratt et al., 2011), due to depleted endoplasmic reticulum calcium stores (Zhang et al., 2009) in a ryanodine receptor-mediated fashion (Oulès et al., 2012; Wu et al., 2013), resulting in impaired LTP induction. Thus, γ-secretase and its components play a vital role in a number of cellular processes and which probably accounts for the adverse effects observed both in vivo and in vitro following γ-secretase inhibition or knock-out (Wang et al., 2004; Selkoe and Wolfe, 2007).

1.8.2.2 Activity-dependent regulation of APP processing

APP processing and thus generation of Aβ is closely related to excitatory neuronal activity (Kamenetz et al., 2003; Cirrito et al., 2005, 2008; Tampellini et al., 2009; Tampellini and Gouras, 2010; Bero et al., 2011; Walker and Jucker, 2011). However, determining the precise relationship of APP, its proteolytic by-products and functional neuronal excitation is yet to be completely elucidated. Neuronal activity has been shown to modulate formation and secretion of Aβ in a number of cellular models, such as CNS cell lines, primary neurons, organotypic brain slices and in vivo using plasma and CSF microdialysis. Electrical depolarisation of synapses has been shown to both enhance pro-amyloidogenic APP cleavage and Aβ production (Kamenetz et al., 2003; Cirrito et al., 2005; Schroeder and Koo, 2005; Bero et al., 2011; Walker and Jucker, 2011) and conversely also promote non-amyloidogenic cleavage and reduce Aβ (Buxbaum et al., 1992; Nitsch et al., 1992; Hoey et al., 2009, 2013; Tampellini et al., 2009; Tampellini and Gouras, 2010; Cisse et al., 2011).
Recent data has attempted to clarify the opposing synaptic regulation of Aβ production by neuronal activity (Verges et al., 2011). Thus, it appears that neuronal electrical hyperexcitability is detrimental to synapses as a result of excessive neuronal activity, which enhances Aβ production and its progressive accumulation. For example, Aβ-mediated synaptic depression was observed in hippocampal slices, and the enhanced CTF-β production was reversed by blocking sustained neuronal activity with TTX or by blocking NMDAR with high Mg²⁺ application, and Aβ/CTF-β production was enhanced by (GABA_A channel blocker) picrotoxin application. Reciprocally, hippocampal slices over expressing APP showed Aβ-mediated reductions in excitatory synaptic transmission in an NMDAR activity-dependent fashion (Kamenetz et al., 2003), suggesting a negative feedback loop to keep neuronal hyperactivity under control. The synaptic depression observed from hyperactivity-dependent Aβ production could contribute to the cognitive decline observed in AD. Furthermore, epileptiform electrical stimulation of afferent axons leading into the hippocampus and concomitant real-time in vivo microdialysis sampling of ISF showed a 30% increase in Aβ over a 1 h time period, which was reversed by TTX perfusion (Cirrito et al., 2005). Similarly, neuronal hyperexcitability is observed in transgenic models of AD (Palop et al., 2007; Busche et al., 2008), and increased Aβ deposition is observed in human epilepsy (Mackenzie and Miller, 1994), suggesting neuronal hyperexcitation could promote enhanced Aβ release and deposition. Excessive electrical depolarisation of cortical and hippocampal neurons increases presynaptic glutamate release, resulting in activation of both the synaptic and extrasynaptic population of ionotropic glutamate receptors. More subtle activation of neurons will induce release of physiological concentrations of glutamate, solely acting at the synaptic ionotrophic glutamate receptor population (section 1.8.2.2.1). Activation of these distinct ionotrophic glutamate receptor populations may give rise to the differential APP processing effects, further discussed below, and figure 1.8. Following more ‘subtle’ neuronal signalling, under more physiological conditions, synaptic activation reduced intraneuronal Aβ and protected synapses from Aβ-mediated synaptic changes and PSD-95 loss. Physiological synaptic activity has been shown to promote Aβ degradation by neprilysin and also enhanced APP trafficking to synapses (Tampellini et al., 2009), away from sites of BACE-1 activity. Under normal conditions, the physiological concentration of Aβ species in the CSF is very low, within the picomolar range (1,500pM and 200pM for Aβ40 and Aβ42,
respectively (Puzzo and Arancio, 2013)), even after activity-dependent release of Aβ (Cirrito et al., 2003), and is not neurotoxic at these low concentrations. However, the rising concentration of Aβ in the extracellular space will no doubt play a role in the aggregation state of Aβ and thus its eventual toxicity (Schroeder and Koo, 2005). Nonetheless, exogenous application of picomolar concentrations of Aβ monomers and oligomers has been shown to enhance LTP and synaptic plasticity in hippocampal brain slices and boost both reference and contextual fear memory in vivo (Puzzo et al., 2008). In humans, the protective nature of cognitive activity has been shown by the correlation between higher educational level and reduced incidence of AD (Stern, 2006). This is further reinforced by environmental enrichment of transgenic AD model mice displaying reduced Aβ plaque load (Lazarov et al., 2005) and the fact that cognitively normal humans also secrete Aβ into the CSF. Thus, the notion that cognitive activity may or may not be protective is still somewhat controversial; due to conflicting data indicating neuronal depolarisation can paradoxically both increase and decrease Aβ level (Verges et al., 2011). Many of these contradictory findings will vary depending on the model system and especially the experimental conditions of promoting neuronal activity, through either electrical, synaptic or ion channel-mediated activation (Bordji et al., 2011).

A number of receptor and ion channel populations have been shown to selectively mediate activity-dependent non-amyloidogenic APP processing, including ionotropic glutamate receptors, metabotropic glutamate receptors, muscarinic and nicotinic acetylcholine receptors and other ligand-gated ion channels, and their associated literature shall be reviewed below.

1.8.2.2.1 Ionotropic glutamate receptors and APP processing

Ionotropic glutamate receptors are important in learning and memory, due to their role in mediating a large part of the postsynaptic calcium influx into neurons (Grienberger and Konnerth, 2012). NMDAR activation exhibits contrasting effects in vivo, with over activation being implicated in excitotoxicity, whilst physiological signalling through NMDAR is neuroprotective and plays a role in synaptic plasticity and neurotrophic processes (Hardingham, 2006). In recent years, uncovering the molecular mechanisms behind the reciprocal effects of NMDAR activation have identified two distinct pools of NMDAR, synaptic and extrasynaptic, which may explain the contradictory relationship between NMDAR activation and both cell survival and death. Synaptic NMDAR activation is neuroprotective (Léveillé et al., 2008; Hoey et
al., 2009; Bordji et al., 2010), whereas extrasynaptic NMDAR initiate neuronal death and neurodegeneration (Léveillé et al., 2008; Bordji et al., 2010; Talantova et al., 2013; Parsons and Raymond, 2014; Rush and Buisson, 2014). Selective NR2A-containing synaptic NMDAR activation reduced Aβ production whilst NR2B-containing extrasynaptic NMDAR activation increased Aβ release (Bordji et al., 2010), and hence is a promising therapeutic target. Accordingly, the NMDAR antagonist memantine (an approved therapeutic agent for the treatment of AD) has been shown to selectively block extrasynaptic NMDAR (Léveillé et al., 2008; Xia et al., 2010), with no effect on the remaining synaptic activity (Lipton, 2007) and confers a beneficial effect in AD patients. Memantine is a non-competitive open channel NMDAR blocker that only comes into effect in pathological conditions, to prevent prolonged channel opening of the extrasynaptic population of NMDAR (Lipton, 2007; Bordji et al., 2011) resulting in excitotoxicity and cell death. Aβ-induced down-regulation of synaptic NMDAR expression acts to further disrupt the balance between pro-survival and apoptotic cell signalling (Snyder et al., 2005). Thus, the relationship between prolonged extrasynaptic NMDAR activation and Aβ production is clear, whilst the mechanism behind synaptic NMDAR signalling and reduced Aβ production is yet to be fully elucidated, figure 1.8. The high calcium permeability of NMDAR (and also AMPAR) contributes to their ability to participate in induction of LTP and modulate synaptic plasticity. The calcium influx is also required for glutamate receptor-mediated APP processing (Hoey et al., 2009, 2013). In primary hippocampal neurons, activation of synaptic NMDAR promoted upregulation of transcription (Wan et al., 2012) and protein trafficking of the α-secretase ADAM-10 to the postsynaptic membrane (Marcello et al., 2007), where APP is predominantly localised (Hoey et al., 2009, 2013). Both synaptic NMDAR and AMPAR activation increases non-amyloidogenic APP processing, with reduced β-secretase cleavage of APP, reduced Aβ production and enhanced sAPPα and CTF-α production in primary cortical neurons (Hoey et al., 2009, 2013). Similarly,
Figure 1.8: Schematic highlighting APP processing, Aβ production and secretion are closely related to neuronal activity and modulate neuronal survival. A: Subtle signalling through α7nAChR (grey) induces physiological concentrations of glutamate release (blue dots) throughout the cortex (Gray et al., 1996), which acts at synaptic receptor populations (NMDAR (blue), AMPAR (purple), mGluR (green)). Activation of synaptic receptors enhances non-amyloidogenic APP processing, through ERK-dependent ADAM-10 (orange) activation (Hoey et al., 2009; Verges et al., 2011), ERK-dependent ADAM-10 trafficking (Marcello et al., 2007; Wan et al., 2012), enhanced Aβ degradation and spatial separation of APP from BACE-1, whilst also reducing pro-amyloidogenic APP processing by BACE-1 (Tampellini et al., 2009). Synaptic receptor activation enhances pro-survival signalling cascades, through PI3K Akt, and CREB phosphorylation resulting in increased BDNF transcription (Léveillé et al., 2008). B: Neuronal hyperexcitability is detrimental to synapses through activation of extrasynaptic receptor populations, which increases pro-amyloidogenic APP processing, Aβ release, CTF-β production (Bordji et al., 2010) and pro-apoptotic signalling cascades through p38 MAPK and p53 (Parsons and Raymond, 2014). Extrasynaptic receptor activation is targeted by the clinically approved drug memantine (Lipton, 2007) for the treatment of AD.
selective activation of NMDAR (not AMPAR or metabotropic glutamate receptors) induced activity-dependent ADAM-10-mediated cleavage of nectin-1 and ectodomain shedding (Kim et al., 2010a). Upregulation of α-secretase expression and activity is ERK-dependent (Marcello et al., 2007; Wan et al., 2012), suggesting an ERK-dependent mechanism for non-amyloidogetic APP processing. Thus, the high relative calcium permeability and MAPK/ERK signalling through α7nAChR makes them a logical candidate for being putative APP processing modulators.

1.8.2.2.2 Neuronal α7nAChR and APP processing

Initial studies focussed on the effect of muscarinic acetylcholine receptors (section 1.8.2.2.3), with subsequent research highlighting the effect of nAChR activation on APP processing, however this has mostly been restricted to cell lines and through nAChR activation with the non-selective agonist nicotine. Many in vitro studies have highlighted the protective effect of nAChR activation, especially the α7 subtype, against Aβ-induced neurotoxicity (Zamani et al., 1997; Kihara et al., 2001; Shimohama and Kihara, 2001; Picciotto and Zoli, 2008; Yu et al., 2011) and also nicotine-induced sAPPα release (Kim et al., 1997; Lahiri et al., 2002; Mousavi and Hellström-Lindahl, 2009; Nie et al., 2010). Chronic treatment with nicotine for 6 weeks in vivo, following Aβ infusion, reduced CSF Aβ levels and BACE-1 protein levels in the hippocampus, whilst preventing Aβ-induced synaptic transmission defects and Aβ-mediated reduction in nAChR subunit expression (Srivareerat et al., 2011). Accordingly, when APP overexpressing AD transgenic mice were crossed with α7nAChR knock-out mice, enhanced cognitive decline was observed, with a dramatic loss in hippocampal neuron number and reduced brain volume, versus APP transgenic mice alone (Hernandez and Dineley, 2012). Furthermore, nicotine treatment of α7nAChR-expressing cell lines reduced Aβ release (Nie et al., 2010) and lowered Aβ plaque deposition (Nordberg et al., 2002) and soluble Aβ species (Hellström-Lindahl et al., 2004; Hedberg et al., 2008) in AD transgenic mice. Aβ has also been shown to modulate nAChR signalling, through directly binding to the α7 subtype of nAChR (Wang et al., 2000a, 2000b, 2009; Dineley et al., 2002a; Parri and Dineley, 2010; Nery et al., 2013), with implications in enhanced tau phosphorylation (Wang et al., 2010b), aberrant cell signalling (Dineley et al., 2001) and synaptic dysfunction (Hu et al., 2007).
1.8.2.2.3 Other cell surface receptors and APP processing

Modulation of APP processing by cell surface receptors was first demonstrated for M1 and M3 muscarinic acetylcholine receptors (mAChR), with the M2 and M4 subtypes displaying no effect (Nitsch et al., 1992). mAChR activation increased sAPP release and numerous subsequent studies confirmed this to be robust and reproducible (Haring et al., 1998; Davis et al., 2010; Cisse et al., 2011; Fisher, 2012). Activation of mAChR in both neuronal and glial cell lines induced a dose-dependent release of sAPP that was blocked by TTX (Buxbaum et al., 1992; Nitsch et al., 1992), and was PKC-dependent (Nitsch et al., 1992; Caputi et al., 1997). Furthermore, knock-out of M1 mAChR increased amyloid pathology, with enhanced Aβ production and reduced sAPPα secretion, both in vivo and in primary neurons (Davis et al., 2010). AChE inhibitors serve to boost endogenous ACh levels in the CNS and along with mAChR-selective PAMs, enhance and prolong mAChR activation (Fisher, 2012), enhancing cognition, similar to nAChR activation. Thus, targeting cholinergic signalling is an attractive a therapeutic target in AD, as both nAChR and mAChR activation exerts beneficial effects both in vivo and in vitro.

The purinergic P2X7 receptor, a non-selective ATP-gated cation channel is expressed in hippocampal neurons and glial cells, has been shown to mediate non-amyloidogenic APP processing, with enhanced sAPPα release, in a calcium influx-, ERK- and JNK-dependent manner (Delarasse et al., 2011). Furthermore, the G-protein coupled nucleotide receptor P2Y2 has been shown to similarly enhance ADAM-10/-17-mediated sAPPα release in a PKC- and ERK-dependent manner (Camden et al., 2005).

Metabotropic glutamate receptors have been shown, similar to ionotropic glutamate receptors, to possess contradictory effects on Aβ production, through both reducing and enhancing pro-amyloidogenic APP processing, Aβ production and release from synapses. Non-amyloidogenic APP processing was upregulated following mGluR activation in primary hippocampal neurons and a non-CNS cell line (Lee et al., 1995), however a bi-phasic effect of mGluR activation has been observed, with up to 50μM glutamate application to cortical brain slices promoting non-amyloidogenic APP processing, whilst higher doses produced negligible effect on sAPP release (Kirazov et al., 1997). In contrast, KCl-induced depolarisation of cortical synaptosomes has also been shown to induce sustained Aβ release, as well as α-, β- and γ-secretase activation (Kim et al., 2010b).
The similarities existing between receptor- and ion channel-mediated non-amyloidogenic APP processing subtype indicate $\alpha 7nAChR$ are endowed with equally similar properties and are a viable target in the treatment of AD.

1.9 Targeting $\alpha 7nAChR$ in Alzheimer's disease

Neuronal $\alpha 7nAChR$ promote both direct and indirect activity-dependent neuroprotective mechanisms and are thus critical for maintenance of neuronal integrity within the CNS. Stimulation of $\alpha 7nAChR$ has been proposed to reduce pro-amyloidogenic APP processing, enhance non-amyloidogenic APP processing and to attenuate A$\beta$-mediated toxicity. Exploiting these putative properties of $\alpha 7nAChR$ to either delay AD onset or to treat the disease at later stages is the crux of a number of potential therapeutic avenues that are currently being explored by drug discovery. The $\alpha 7$-selective agonist A-582941 was used in the treatment of 3xTg-AD transgenic mice (expressing mutated PS-1 and double mutated APP), displaying robust AD pathology and cognitive deficits. Long-term $\alpha 7nAChR$ activation restored cognition in the mice, as judged by novel object recognition, Morris water maze task and contextual fear conditioning, but had no effect on AD pathology (Medeiros et al., 2014).

The reported interaction between A$\beta$ and $\alpha 7nAChR$ has been the subject of intense research (Parri and Dineley, 2010), with data showing A$\beta$ binding with high affinity (Wang et al., 2000a, 2000b; Dineley et al., 2001; Nagele et al., 2002) to the agonist binding site of $\alpha 7nAChR$ (Nery et al., 2013); which when dissociated can restore $\alpha 7nAChR$- and also NMDAR-evoked currents (Dineley et al., 2002a; Wang et al., 2009), likely via restoring $\alpha 7nAChR$-mediated glutamate release. This remains controversial as A$\beta$-mediated toxicity has also been reported to occur through A$\beta$ binding to receptor-dense lipid rafts (Rushworth and Hooper, 2011; Rushworth et al., 2013) and not to $\alpha 7nAChR$ directly (Small et al., 2007). A$\beta$-induced $\alpha 7nAChR$ inactivation results in LTD, excitotoxicity, neuron death and eventual cognitive decline. Thus, targeting both reduced A$\beta$-$\alpha 7nAChR$ interaction and prolonged physiological $\alpha 7nAChR$ activation, through A$\beta$-$\alpha 7nAChR$ dissociating compounds, $\alpha 7nAChR$-selective agonists, PAMs and AChE inhibitors is an on going pharmaceutical strategy to enhance cognition and delay the onset of AD (Maelicke, 2000; Parri and Dineley, 2010; Parri et al., 2011).
1.9.1 AChE inhibitors

A long-standing mechanism for enhancing cholinergic transmission has been to selectively target and inhibit the hydrolysis of ACh by the serine hydrolase enzyme acetylcholinesterase (AChE), which acts to breakdown ACh at a rate of one molecule per 100μsec (Miwa et al., 2011). AChE inhibitors affect both nicotinic and muscarinic receptor function, as they boost levels and prolong action of the endogenous neurotransmitter ACh throughout the CNS. A number of AChE inhibitors have been approved for human clinical use (donepezil, galantamine and rivastigmine), for the treatment of AD. These compounds are the major class of drugs showing clinical efficacy, capable of retarding AD progression by 6-12 months. In AD cholinergic signalling from the basal forebrain degenerates, resulting in a loss of projections to the higher functioning centres of the brain (namely, the hippocampus and cortex) and subsequent cognitive decline and memory deficits (section 1.6). The reversible and non-competitive AChE inhibitor donepezil has shown cognitive enhancement properties and delayed deposition of AD-hallmark amyloid (Aβ) plaques (Colović et al., 2013) and reduced tau hyperphosphorylation (Noh et al., 2013). Donepezil has been further reported to exert homeostatic neuroprotective effects, by reducing microglial inflammatory cytokine release (Giunta et al., 2004; Hwang et al., 2010). In clinical trials the competitive, rapidly reversible, AChE inhibitor galantamine improved attention (Galvin et al., 2008) and has further been shown to block Aβ-induced glutamate excitotoxicity (Kihara et al., 2004) and boost Aβ clearance by microglia (Takata et al., 2010), another central mechanism in AD pathogenesis. Galantamine is known to further boost cholinergic signalling by acting as an α7nAChR-selective PAM (Maelicke et al., 2001; Dajas-Bailador et al., 2003). Rivastigmine acts at both AChE and the pseudocholinesterase butrylcholinesterase to enhance the endogenous level and temporal effect of ACh, and has been reported to lower Aβ levels in degenerating primary neurons (Bailey et al., 2011). Rivastigmine is approved for the treatment of both AD and Parkinson’s disease (Colović et al., 2013). Boosting cholinergic signalling is a widely used treatment in a number of neurological disorders. This stems from attempts to recover a loss of ACh signalling, following a wealth of evidence indicating cholinergic dysfunction in the early stages of AD onset, termed the cholinergic hypothesis of AD.
1.10 Hypotheses and aims

The hypotheses of this thesis were that:

1. $\alpha_7$nAChR activation would enhance non-amyloidogenic APP processing in an ERK-dependent manner in primary cortical neurons and
2. $\alpha_7$nAChR activation would modulate inflammatory cellular behaviour of primary cortical microglia.

To investigate these hypotheses, specific aims were outlined:

1. To characterise the primary cortical neuronal and microglial model systems
2. To assess the $\alpha_7$nAChR-mediated contribution to APP processing, using an $\alpha_7$nAChR-selective agonist and PAM, in primary cortical neurons
3. To determine the $\alpha_7$nAChR contribution to inflammatory cell behaviour using $\alpha_7$nAChR-selective agonist and PAM, in primary cortical microglia.
Chapter 2

2. Materials and Methods
2.1 Materials

All bench chemicals were purchased from Sigma Aldrich, unless otherwise stated. All pharmacological compounds were purchased from Tocris, unless otherwise stated and were made up as 1000x concentrated stock solutions in either purified water or DMSO for long-term storage at -20°C. Compounds were added directly into culture medium to achieve a working concentration, unless otherwise stated, refer to Table 2.1 for all pharmacological compounds. All tissue culture reagents were purchased from Invitrogen, Paisley, UK. For primary and secondary antibody working concentrations and suppliers, as used in Western blotting and/or immunocytochemistry, refer to Table 2.2. A custom-made (Eurogentec) rabbit polyclonal antibody CT20 raised against the C-terminus of human APP (residues 676-695: NGYENPTYKFFEQMQN) was optimised and used for both Western blotting and immunocytochemistry.
<table>
<thead>
<tr>
<th>Compound</th>
<th>Supplier</th>
<th>Stock concentration</th>
<th>Working concentration</th>
<th>Solvent</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-bungarotoxin (αBTX)</td>
<td>Tocris</td>
<td>100μM</td>
<td>100nM</td>
<td>dH₂O</td>
<td>Irreversible α7nAChR antagonist</td>
</tr>
<tr>
<td>α-bungarotoxin Alexa Fluor-488 (αBTX-488)</td>
<td>Invitrogen</td>
<td>100μM</td>
<td>100nM</td>
<td>dH₂O</td>
<td>Irreversible α7nAChR antagonist conjugated to AlexaFluor-488</td>
</tr>
<tr>
<td>AMPA</td>
<td>Tocris</td>
<td>10mM</td>
<td>50μM</td>
<td>dH₂O</td>
<td>Selective agonist of AMPA-type glutamate receptors</td>
</tr>
<tr>
<td>β-secretase inhibitor (BSI)</td>
<td>Calbiochem</td>
<td>10mM</td>
<td>10μM</td>
<td>dH₂O</td>
<td>Peptide inhibitor sequence: H-Lys-Thr-Glu-Ile-Ser-Glu-Val-Asn-Stat-Val-Ala-Glu-Phe-OH</td>
</tr>
<tr>
<td>Choline bitartrate</td>
<td>Sigma Aldrich</td>
<td>30mM</td>
<td>3mM</td>
<td>Neurobasal medium</td>
<td>Weak α7nAChR-selective agonist</td>
</tr>
<tr>
<td>DAPT</td>
<td>Sigma Aldrich</td>
<td>10mM</td>
<td>10μM</td>
<td>DMSO</td>
<td>γ-secretase inhibitor</td>
</tr>
<tr>
<td>Dynasore</td>
<td>Gift from Dr Paul Whitley (Bath)</td>
<td>50mM</td>
<td>100μM</td>
<td>DMSO</td>
<td>Dynamin inhibitor, blocks endocytosis</td>
</tr>
<tr>
<td>Ethylene glycol tetraacetic acid (EGTA)</td>
<td>Sigma Aldrich</td>
<td>0.25M</td>
<td>2.5mM</td>
<td>dH₂O</td>
<td>Free calcium chelator</td>
</tr>
<tr>
<td>Lipopolysaccharide (LPS)</td>
<td>Sigma Aldrich</td>
<td>1mg/ml</td>
<td>100ng/ml</td>
<td>DMEM:F12 medium</td>
<td>Prototypical endotoxin purified from gram-negative bacteria</td>
</tr>
<tr>
<td>(-)-Nicotine hydrogen tartrate</td>
<td>Sigma Aldrich</td>
<td>10mM</td>
<td>10μM</td>
<td>Neurobasal medium</td>
<td>Broad nAChR agonist</td>
</tr>
<tr>
<td>MK-801</td>
<td>Tocris</td>
<td>2.5mM</td>
<td>2.5μM</td>
<td>dH₂O</td>
<td>Selective open channel NMDA receptor antagonist</td>
</tr>
<tr>
<td>NMDA</td>
<td>Tocris</td>
<td>10mM</td>
<td>50μM</td>
<td>dH₂O</td>
<td>Selective NMDA-type glutamate receptor agonist</td>
</tr>
<tr>
<td>PNU-120596</td>
<td>Tocris</td>
<td>10mM</td>
<td>10μM</td>
<td>DMSO</td>
<td>Selective type II positive allosteric modulator of α7nAChR</td>
</tr>
<tr>
<td>PNU-282987</td>
<td>Tocris</td>
<td>100mM</td>
<td>10μM</td>
<td>DMSO</td>
<td>Potent and selective agonist of α7nAChR</td>
</tr>
<tr>
<td>Compound</td>
<td>Supplier</td>
<td>Concentration</td>
<td>Dilution</td>
<td>Solvent</td>
<td>Description</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------------</td>
<td>---------------</td>
<td>----------</td>
<td>---------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>TAPI-1</td>
<td>Enzo Life Sciences</td>
<td>10mM</td>
<td>50μM</td>
<td>DMSO</td>
<td>Broad spectrum TACE and metalloprotease inhibitor</td>
</tr>
<tr>
<td>Tetrodotoxin (TTX)</td>
<td>Tocris</td>
<td>1mM</td>
<td>1μM</td>
<td>dH₂O</td>
<td>Potent neurotoxin, blocks voltage-gated sodium channels</td>
</tr>
<tr>
<td>U0126</td>
<td>Tocris</td>
<td>5mM</td>
<td>5μM</td>
<td>DMSO</td>
<td>MEK inhibitor</td>
</tr>
</tbody>
</table>

**Table 2.1:** Pharmacological compounds used to assess α7nAChR at the glutamatergic synapse *in vitro.*
<table>
<thead>
<tr>
<th>Target</th>
<th>Supplier</th>
<th>Species</th>
<th>Working concentration</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADAM10</td>
<td>Sigma Aldrich</td>
<td>Rabbit</td>
<td>Not used</td>
<td>1:1,000 N/A Raised against C-terminal residues 732-748 of human ADAM10</td>
</tr>
<tr>
<td>ADAM17</td>
<td>Chemicon</td>
<td>Rabbit</td>
<td>Not used</td>
<td>1:400 2.5μg/ml Raised against residues 807-823 of human ADAM17</td>
</tr>
<tr>
<td>AlexaFluor-488/546</td>
<td>Invitrogen</td>
<td>Goat</td>
<td>Not used</td>
<td>1:1,000 2.0μg/ml Goat anti-mouse/rabbit IgG secondary antibody used for immunofluorescence</td>
</tr>
<tr>
<td>APP</td>
<td>Eurogentec</td>
<td>Rabbit</td>
<td>1:2,000 1:5,000 (CTF blots)</td>
<td>1:1,500 N/A Custom made, raised against C-terminal residues 680-695 of human APP695</td>
</tr>
<tr>
<td>APP</td>
<td>Alpha Diagnostics</td>
<td>Mouse</td>
<td>Not used</td>
<td>1:100 10μg/ml Raised against the N-terminus of APP (clone 13-M)</td>
</tr>
<tr>
<td>β-tubulin</td>
<td>Chemicon</td>
<td>Mouse</td>
<td>1:5,000 N/A</td>
<td>Not used Used as a loading control for Western blotting</td>
</tr>
<tr>
<td>CD11b</td>
<td>Serotec</td>
<td>Mouse</td>
<td>Not used</td>
<td>1:1000 1.0μg/ml Recognises cluster of differentiation molecule 11B, used as a specific marker for microglia</td>
</tr>
<tr>
<td>ERK2</td>
<td>Santa Cruz</td>
<td>Rabbit</td>
<td>1:5,000 0.4ng/ml</td>
<td>Not used Recognises both phosphorylated and un-phosphorylated ERK2</td>
</tr>
<tr>
<td>ppERK1/2</td>
<td>Cell Signalling Technologies</td>
<td>Rabbit</td>
<td>1:1,000 N/A</td>
<td>Not used Recognises individually or dually phosphorylated ERK1 and ERK2 at Thr202 and Tyr204 (ERK1) or Thr185 and Tyr187 (ERK2)</td>
</tr>
<tr>
<td>GFAP</td>
<td>Dako</td>
<td>Rabbit</td>
<td>Not used</td>
<td>1:10,000 0.1μg/ml Recognises glial fibrillary acidic protein, used as a specific marker of astrocytes</td>
</tr>
<tr>
<td>GluA1</td>
<td>Millipore</td>
<td>Rabbit</td>
<td>Not used</td>
<td>1:500 N/A Recognises GluA1-containing AMPA receptors. Raised against the cytoplasmic domain of GluA1</td>
</tr>
<tr>
<td>GluA2</td>
<td>Millipore</td>
<td>Rabbit</td>
<td>Not used</td>
<td>1:300 N/A Recognises GluA2-containing AMPA receptors. No cross-reactivity with GluA1, GluA3 or GluA4</td>
</tr>
<tr>
<td>HRP-conjugated</td>
<td>Millipore</td>
<td>Goat</td>
<td>1:2,500 0.8μg/ml</td>
<td>Not used Goat anti-mouse/rabbit-HRP secondary antibody used for Western blotting chemiluminescence</td>
</tr>
<tr>
<td>MAP-2</td>
<td>Chemicon</td>
<td>Rabbit</td>
<td>Not used</td>
<td>1:1,000 N/A Recognises all MAP-2 isoforms (MAP2A, MAP2B, MAP2C and MAP2D)</td>
</tr>
<tr>
<td>PSD-95</td>
<td>Millipore</td>
<td>Mouse</td>
<td>1:500 N/A</td>
<td>1:500 N/A Anchoring protein located at the postsynaptic density (PSD)</td>
</tr>
</tbody>
</table>
Table 2.2: Antibodies used for Western blotting and immunocytochemistry (ICC).

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Manufacturer</th>
<th>Species</th>
<th>Dilution</th>
<th>Concentration</th>
<th>Dilution</th>
<th>Concentration</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synaptophysin</td>
<td>Sigma Aldrich</td>
<td>Mouse</td>
<td>1:500 N/A</td>
<td></td>
<td>1:200</td>
<td></td>
<td>Pre-synaptic marker. Clone SVP-38</td>
</tr>
<tr>
<td>Tau-1</td>
<td>Chemicon</td>
<td>Mouse</td>
<td>1:2,000 5.0µg/ml</td>
<td></td>
<td>1:500</td>
<td>2.0µg/ml</td>
<td>Recognises all species of Tau</td>
</tr>
</tbody>
</table>

Table 2.2: Antibodies used for Western blotting and immunocytochemistry (ICC).
2.2 Methods

2.2.1 Primary cortical neuron cell culture

All animal work was carried out in accordance with UK Home Office guidelines. Pregnant CD1 mice were sacrificed by cervical dislocation following a schedule 1 procedure. Primary cortical neurons were produced from mouse embryos at embryonic day 15-16. Embryonic brains were dissected and cortices dissociated in phosphate buffered saline (PBS) (Mg$^{2+}$ and Ca$^{2+}$-free, pH 7.4) supplemented with 33mM glucose, using a heat-inactivated foetal bovine serum-coated fire-polished pipette. Subsequently, cells were centrifuged at 1,800 x g for 5 min and resuspended in Neurobasal medium, without phenol red and supplemented with B-27, 2mM glutamine, 100μg/ml streptomycin and 60μg/ml penicillin. During cortical dissection, care was taken to remove the striatum and meninges; these cultures also contained hippocampus precursor cells and hence are not 100% pure cortical neurons. Cells were plated (at 600,000 cells/ml for Western blotting or 300,000 cells/ml for all other uses) onto plastic Nunc multiwell (6- or 12- well) dishes coated with 20μg/ml poly-D-lysine and maintained for up to 18 days in vitro (DIV) in an incubator kept at 37°C with 5% CO$_2$. Morphological assessment of cell viability was made by phase contrast microscopy. Cells were visualised with a Nikon Eclipse TS100 microscope and phase contrast images taken using a Nikon Coolpix 5000 camera.

2.2.2 Primary cortical glial cell culture

All animal work was carried out in accordance with UK Home Office guidelines. Newborn P0-P2 CD1 mouse pups were sacrificed by cervical dislocation following a schedule 1 procedure. Cortices were dissected from brains in cold Mg$^{2+}$ and Ca$^{2+}$-free PBS supplemented with 33mM glucose. During cortical dissection, care was taken to remove the striatum and meninges and resulting cortical sections were minced before centrifugation at 200 x g for 3 min. Cells were resuspended in warm 0.25% Trypsin-EDTA and incubated for 15 min in a 37°C 100rpm shaking water bath. Trypsinisation was halted with addition of 0.5ml DNase I (7,500 units in PBS) plus DMEM/F12 medium supplemented with HEPES, 10% heat-inactivated foetal bovine serum, 2mM glutamine, 100μg/ml streptomycin and 60μg/ml penicillin and mixed by inversion and pipetted to a single cell suspension (as per Saura et al., 2003), before
centrifugation at 200 x g for 7 min. Cells were resuspended in DMEM-F12 supplemented with HEPES, 10% heat-inactivated foetal bovine serum, 2mM glutamine, 100µg/ml streptomycin and 60µg/ml penicillin and were filtered with a 100µm mesh cell strainer (Fisher) and brought to a final density of 300,000 cells/ml. Full media changes were done to the primary mixed glial cultures (microglia and astrocytes) at 5 DIV and every subsequent 7 d until 4-6 weeks *in vitro* when confluency was reached.

### 2.2.3 Primary microglia purification

Removal of contaminating astrocytes from microglia was carried out 24 h prior to experimental use. Conditioned medium was removed and kept at 37°C whilst cells were incubated in 0.0625% Trypsin-EDTA in DMEM-F12 supplemented with HEPES, 2mM glutamine, 100µg/ml streptomycin and 60µg/ml penicillin for 15-25 min at 37°C. Multiwell plates were knocked every 5 min to aid complete astrocyte layer detachment and Trypsin activity halted with DMEM-F12 supplemented with 10% heat-inactivated foetal bovine serum, HEPES, 2mM glutamine, 100µg/ml streptomycin and 60µg/ml penicillin. Medium and astrocytes were aspirated and conditioned medium replaced onto microglia, maintained in an incubator kept at 37°C with 5% CO₂.

### 2.2.4 Immunocytochemistry

#### 2.2.4.1 Immunocytochemistry staining

Visualisation of specific proteins of interest was carried out by immunocytochemistry on primary cells grown on 20µg/ml poly-D-lysine coated 13mm round glass coverslips in Nunc 12-well plates and used following 5-10 DIV. Cells were washed in fresh culture medium before fixation with 4% paraformaldehyde in PBS for 20 min at room temperature, washed with PBS three times. Non-specific primary antibody blocking was performed using 10% bovine serum albumin (BSA) in PBS (supplemented with 0.1% Triton X-100 for intracellular epitopes) for 30 min at room temperature. Primary antibodies were incubated overnight at 4°C in antibody buffer (3% BSA (with 0.1% Triton X-100 for intracellular epitopes) in PBS) on a rocking platform. Cells were washed three times with PBS before 1 h incubation with Alexa-Fluor conjugated secondary antibodies (1:1,000, Molecular Probes) in antibody buffer at room temperature. Finally, cells were washed with PBS three times and incubated with
DAPI (600nM, Invitrogen) for 10-30 min before coverslips were mounted onto glass slides using Mowiol.

2.2.4.2 Image acquisition

Immunofluorescence labelled cells were visualised using a Zeiss 510 META confocal laser-scanning microscope at either 40x or 63x. Images were analysed using Zeiss Image Browser software and ImageJ (NIH). Scale bars were applied following calibration of microscope-captured image size to relative image resolution.

2.2.5 Fluorescent labelling of α7nAChR

For α7 nicotinic acetylcholine receptor (α7nAChR) visualisation, live cells were incubated at 37°C with 100nM Alexa Fluor-488 conjugated α-bungarotoxin (αBTX-488, Invitrogen) for 45 min and subsequently washed in warm PBS (Kawai et al., 2002). The most commonly used primary antibodies directed to α7nAChR are unsuitable as they have shown immunoreactivity in α7nAChR knock out transgenic mice (Herber et al., 2004). Non-specific αBTX-488 binding was assessed by 10 min pre-incubation with 1mM nicotine or 5 μM α-bungarotoxin. Cells were fixed with 4% paraformaldehyde in PBS for 20 min at room temperature and washed with PBS three times and incubated with DAPI (600nM, Invitrogen) for 10-30 min. For subsequent immunofluorescence antibody labelling, cells were subjected to the immunocytochemistry protocol listed above, following the fixation stage. Coverslips were mounted onto glass slides using Mowiol and visualised using a Zeiss 510 META confocal laser-scanning microscope at either 40x or 63x. Images were analysed using Zeiss Image Browser software and ImageJ (NIH).

2.2.6 Intracellular calcium microfluorimetry imaging

Measurement of calcium ion influx into primary cortical neurons was carried out using the ratiometric calcium chelator and fluorescent indicator Fura-2-acetoxyethyl ester (AM). Primary cortical neurons were grown on glass coverslips for 7 DIV and dye loaded for 45 min at 37°C. 5μM Fura-2 AM was incubated in combination with 0.02% Pluronic F-127 (Invitrogen) in assay buffer (140mM sodium chloride, 5mM potassium chloride, 1mM magnesium chloride, 1.8mM calcium chloride, 10mM glucose and 5mM HEPES in distilled water at pH 7.4). Following dye incubation, cells were washed in assay buffer and coverslips applied to the Concord microscope-based live imaging
platform (Perkin Elmer, UK) and maintained at 37°C with a constant supply of assay buffer (rate of 5ml/min) supplemented with 1µM TTX (Tocris) to limit background action potential spectral noise. Following baseline image recording, drugs were applied (in assay buffer) to the neurons by microperfusion, followed by a washout period with assay buffer. Fields of view with 30-40 cells were captured live every ~1 sec by dynamic video imaging and Fura-2 AM excited at 340 and 380nm wavelengths (SpectroMaster I), with emission detected at 510nm (Ultrapix PDCI low light CCD camera). Analyses of emission spectra were performed using Ultraview Concord software (Perkin Elmer, UK) and F340:380nm ratios plotted in Graphpad Prism 6. Values expressed are mean F340:380nm ± SD or SEM.

2.2.7 SDS-PAGE and Western blotting

2.2.7.1 Sample preparation for SDS-PAGE

After 5-18 DIV primary cells (neurons or microglia) were treated with drugs as indicated in figure legends. Cells were subsequently washed with ice-cold PBS (Mg²⁺ and Ca²⁺-free, pH 7.4), lysed in 200µl RIPA buffer (50mM Tris, 150mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, in dH₂O at pH 7.4) containing Complete Protease and Phosphatase Inhibitor Cocktails (Roche) and kept on ice for 45-60 min. Samples were scraped into Eppendorf tubes and centrifuged at 2,000 x g for 2 min before dilution of the supernatant in sample boiling buffer (62.5mM Tris, pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol and 0.0025% bromophenol blue) before boiling for 5 min. Samples were stored at -20°C until required for Tris-Glycine SDS-PAGE.

2.2.7.2 Tris-Glycine SDS-PAGE

Tris-Glycine polyacrylamide resolving gels (8-12%) were prepared (375mM Tris (pH 8.8), 0.1% SDS, 8-12% acrylamide, 0.5mg/ml ammonium persulphate and 0.06% TEMED) and overlaid with 4% Tris-Glycine stacking gels (125mM Tris (pH 6.8), 0.1% SDS, 4% acrylamide, 0.5mg/ml ammonium persulphate, 0.06% TEMED) and stored at 4°C in SDS-PAGE running buffer (25mM Tris, 0.192M glycine and 0.01% SDS, National Diagnostics) for 24-48 h before use. Cell lysates were resolved by SDS-PAGE at 140V for ~1 h, alongside a See Blue protein molecular weight ladder (Invitrogen) in SDS-PAGE running buffer.
2.2.7.3 Western blotting

Acrylamide gel proteins were transferred onto 0.45μm nitrocellulose membranes (GE Healthcare) using a semi-dry transfer immunoblotting apparatus (Hoefer SemiPhor) at 1.5mA/cm² for 1 h. Nitrocellulose membranes were pre-soaked in distilled water before equilibration in blotting buffer (20% methanol plus SDS-PAGE running buffer), with Whatman filter papers equilibrated in blotting buffer placed either side of the gel and membrane. Non-specific antibody binding to membranes was blocked using 5% milk powder in TBS (20mM Tris, 150mM NaCl, pH 7.4) for 60 min. Membranes were rinsed quickly in TBS-T (20mM Tris, 150mM NaCl, 0.5% Tween-20, pH 7.4) before incubation with primary antibody in TBS-T and 1% milk powder overnight at 4°C on a rocking platform. Subsequent removal of unbound primary antibody occurred through quickly rinsing membranes once and subsequently three times for 5 min in TBS-T before 1 h incubation with a HRP-conjugated secondary antibody (1:2,500, Millipore) in TBS-T and 1% milk powder. Membranes were again washed three times for 5 min in TBS-T and finally once with TBS before protein band detection.

2.2.7.4 Protein detection

Primary and secondary antibody-incubated membranes were exposed to standard ECL reagent (GE Healthcare) for 1 min according to manufacturer’s instructions. Blots were exposed to Hyperfilm ECL (GE Healthcare) in an autoradiography film cassette in the dark, and developed by X-ray film processor (OPTIMAX). Alternatively, ECL-exposed membranes were imaged by a Fusion SL (Vilber Lourmat) chemiluminescence camera and digital images captured directly for analysis.

2.2.7.5 Analysis of protein densitometry

Densitometry quantification of bands on Hyperfilm-exposed blots was carried out after scanning films (Epson V700 scanner) at a resolution of 1200 dots/inch (dpi) and mean background optical density (OD) of bands interpolated from an OD calibration curve, calculated from an OD step tablet using ImageJ software (NIH). Fusion SL acquired digital images were analysed with FUSION software (Vilber Lourmat). Mean OD data were expressed relative to a loading control ± SEM and were subjected to statistical analysis in GraphPad Prism 6 software.
2.2.8 APP C-terminal fragment Western blotting

To assess the modulation of APP processing, intermediate APP$_{695}$ cleavage products (C-terminal fragments (CTF)) analyses was carried out by Tris-Tricine SDS-PAGE.

2.2.8.1 APP-CTF sample preparation

After 10-18 DIV neurons were treated with drugs as described in figure legends. Neurons were subsequently washed with ice cold PBS (Mg$^{2+}$ and Ca$^{2+}$-free, pH 7.4), lysed in sample boiling buffer for 30-60 min (62.5mM Tris pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol and 0.0025% bromophenol blue) and scraped into Eppendorf tubes. Samples were centrifuged at 2,000 x g for 5 min before boiling for 5 min.

2.2.8.2 Tris-Tricine SDS-PAGE

Tris-Tricine polyacrylamide resolving gels (16.5%) were prepared (1M Tris (pH 8.45), 16.5% acrylamide, 0.5mg/ml ammonium persulphate and 0.06% TEMED) and overlaid with 4% Tris-Tricine stacking gels (1M Tris (pH 8.45), 4% acrylamide, 0.5mg/ml ammonium persulphate, 0.06% TEMED) and stored at 4°C in SDS-PAGE running buffer (25mM Tris, 0.192M glycine and 0.01% SDS, National Diagnostics) for 24 h before use. Lysates were resolved by gel electrophoresis at a constant 105V using a defined inner/cathode gel tank buffer (100mM Tris, 100mM Tricine, 0.1% SDS pH 8.2) and outer/anode tank buffer (0.2M Tris pH 8.9) and run for 3-4 h, alongside a See Blue protein molecular weight ladder, until adequate separation of the low molecular weight ladder bands was reached.

2.2.8.3 Western blotting for APP-CTFs

Tris-Tricine gel-resolved samples were transferred to 0.2μm PVDF membranes (Millipore) using semi-dry transfer at 1.5mA/cm$^2$ for 1 h. PVDF membrane was pre-soaked in methanol before equilibration in CTF blotting buffer (20% methanol plus SDS-free running buffer, 25mM Tris and 0.192M glycine, National Diagnostics) with Whatman filter papers equilibrated in CTF blotting buffer placed either side of the gel and membrane. Non-specific antibody binding was blocked using 4% ECL Advance (GE Healthcare) blocking powder in TBS (20mM Tris, 150mM NaCl, pH 7.4) for 1 h. Membranes were rinsed three times for 20 min in TBS-T (20mM Tris, 150mM NaCl, 0.5% Tween-20, pH 7.4) before incubation with primary antibody in TBS-T and 4%
ECL Advance blocking powder overnight at 4°C on a rocking platform. Removal of unbound primary antibody followed through quickly rinsing membranes once and subsequently 3 times for 20 min in TBS-T before 1 h incubation with a HRP-conjugated secondary antibody (1:150,000, Millipore) in TBS-T and 4% ECL Advance blocking powder. Membranes were again washed at least 4 times for 20 min in TBS-T and finally once with TBS before exposure to ECL Advance reagent (GE Healthcare) for 1 min according to manufacturer’s instructions. Blots were exposed to Hyperfilm ECL (GE Healthcare) and developed for densitometry quantification using ImageJ software (NIH), as detailed above.

2.2.9 Synaptosome preparation and treatment

Synaptosomes are a useful tool for studying nerve terminals, free of axons and postsynaptic connections. Synaptosomes are resealed nerve terminals, and closely resemble functional nerve terminals found in vivo.

2.2.9.1 Tissue preparation

All animal work was carried out in accordance with UK Home Office guidelines. Adult CD1 mice were sacrificed by cervical dislocation following a schedule 1 procedure. Cortices were rapidly dissected, washed in isotonic homogenisation buffer (0.32M sucrose, 1mM EDTA, 5mM Tris, 0.25mM DTT, pH 7.4), before being weighed and homogenised in 10% w/v homogenisation buffer. All brain material was carefully stored on ice for the duration of the preparation and centrifuges and rotors cooled to 4°C in advance. The crude homogenate was centrifuged at 1000 x g for 10 min in polycarbonate tubes and the S1 supernatant diluted 1.5x in homogenisation buffer before being flowed onto the top of a discontinuous Percoll gradient.

2.2.9.2 Percoll gradient preparation

Discontinuous Percoll gradients were used to separate and purify organelles, including synaptosomes, by their differential density (as per Dunkley et al., 2008). Percoll slurry was filtered through 0.45μm syringe filter units (Millipore) before diluting in gradient buffer (1.28M sucrose, 4mM EDTA, 20mM Tris, 0.1mM DTT, pH 7.4) to produce 3%, 10%, 15% and 23% (w/v) Percoll gradient buffers. 2ml of each gradient buffer was flowed, using a peristaltic pump (Gilson Minipuls 2), at a rate of 0.5ml/min, through a 12 gauge needle constantly placed at the top of the meniscus whilst
touching the wall of an angled polycarbonate tube, to minimise Percoll layer disruption. Percoll gradient buffers of 15%, 10% and 3% were sequentially layered onto the bottom 23% Percoll gradient buffer to create the discontinuous gradient required for density gradient centrifugation of mouse brain material. Gradients were made 15-20 h before use and carefully stored on ice at 4°C until S1 supernatants were prepared.

2.2.9.3 Synaptosome preparation and purification

S1-layered Percoll gradients were centrifuged at 31,000 x g for exactly 5 min (excluding acceleration and deceleration times) with rotor breaking disabled, thus ensuring optimal interface separation. Fractions 3 and 4 (synaptosomes plus membranes and pure synaptosomes, respectively) were pooled to increase yield. Synaptosomes were diluted at least 4-fold with ice-cold sucrose/EDTA buffer (0.32M sucrose, 1mM EDTA, 5mM Tris, pH 7.4) before centrifugation at 20,000 x g for 30 min at 4°C to remove Percoll. The synaptosomal pellet was carefully resuspended (using a fire-polished glass pipette) in 1-2ml physiological buffer (118mM sodium chloride, 2.4mM potassium chloride, 1.2mM magnesium chloride, 1.2mM sodium dihydrogen orthophosphate 1-hydrate, 2.4mM calcium chloride 2-hydrate, 20mM HEPES, 10mM glucose, pH 7.4) before a final spin at 18,000 x g for 10 min and the pellet of viable synaptosomes resuspended in a required volume (typically 0.5-1ml) of physiological buffer and subjected to Bradford protein assay.

2.2.9.4 Synaptosome drug treatments

Synaptosomes (at 2-3mg/ml protein concentration) were incubated in a water bath at 37°C for 10 min pre-treatment with vehicle or 10μM PNU-120596, before a 30 min vehicle or agonist (10μM PNU-282987 or 50μM NMDA) treatment. Following drug treatments, synaptosomes were spun at 10,000 x g for 5 min before addition of lysis buffer to the pellet (0.5% Triton X-100, 150mM sodium chloride, 10mM HEPES, complete protease and phosphatase inhibitor tablets (Roche), pH 7.4) and sample boiling buffer (62.5mM Tris pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol and 0.0025% bromophenol blue) before boiling for 5 min. Denatured synaptosome samples were stored at -20°C until required for SDS-PAGE and Western blotting, as detailed above.
2.2.10 APP-Gal4 cleavage luciferase reporter assay

To study APP cleavage using a high-sensitivity molecular gene reporter assay, primary neurons (following 5 DIV) were transfected with 0.5μg APP<sub>695</sub>-Gal4 fusion construct, 0.5μg pC1-CMV-Fe65 construct, 0.5μg pFR-Luciferase construct (firefly luciferase gene from <i>Photinus pyralis</i>) and 0.5μg phRL-Renilla construct (luciferase gene from <i>Renilla reniformis</i>) using Lipofectamine 2000 (0.5μl/well; Invitrogen). Transfection mixes were made up in OptiMEM I medium (Invitrogen) 25 min in advance of application onto neurons. 10μM DAPT was added 30 min prior to transfection mix and left for 24 h in a 37°C incubator before application of drugs. Following 6 h 10μM PNU-120596 and 10μM PNU-282987 drug treatments neurons were lysed for 15 min with Glo Lysis Buffer (Promega) and Dual-Glo luciferase activity measured using a FluorBMG microplate luminometer, according to the manufacturer’s instructions. Firefly luciferase reporter activity was normalised to constitutive Renilla luciferase activity to control for transfection rate efficiency between repeat conditions and expressed as fold change of vehicle-treated control. Following APP<sub>695</sub>-Gal4 cleavage by β-secretase, APP-CTF-Gal4 is produced, which is further cleaved by γ-secretase, giving rise to AICD-Gal4. AICD-Gal4 binds to the upstream activating sequence (UAS) of Firefly/Renilla luciferase DNA and promotes its transcription within transfected primary cortical neurons. Subsequent translation of luminescent luciferase peptide is detected through the Dual-Glo luciferase assay (Promega). A schematic of the luciferase APP cleavage reporter assay can be found in figure 4.7.

2.2.11 Egr-1 transcription luciferase reporter assay

1x10<sup>5</sup> plaque forming units (pfu)/ml Ad5-Egr1-luciferase plasmid was transduced into primary cortical neurons at 6-7 DIV in 24 well plates. For transduction, conditioned media was removed from the neurons and fresh media containing viral particles was added to the cells and incubated at 37°C for 3 h. Media was then removed and original conditioned media replaced onto the neurons. Neurons were subsequently treated as detailed in figure legends. 6 h post-treatment, media was removed from the cells and cells lysed in Glo Lysis Buffer (Promega) and incubated at room temperature whilst rocking for 15 min. Lysed cells were transferred to a white 96-well plate and Dual Glo substrate was added, the plate was incubated in the dark for 10 min followed by
measurement using a FluorBMG microplate luminometer. Luciferase activity was expressed as fold change of vehicle-treated control.

2.2.12 Microglial bead uptake assay

To observe microglial phagocytic activity, purified primary microglia were cultured on 20\(\mu\)g/ml poly-D-lysine coated 13mm round coverslips. Latex (amino-modified polystyrene) 1.0\(\mu\)m beads with fluorescent green-yellow tag (excitation/emission: 470/540nm) were used as quantifiable phagocytosis targets. Drugs were added, as indicated in figure legends, to a 0.5\(\mu\)l/ml bead stock solution of PBS supplemented with 0.1% bovine serum albumin (BSA), and were incubated on the microglia for 2 h at 37\(^\circ\)C. Following a 2 h bead ± drug incubation, cells were washed 3 times with ice cold PBS (Mg\(^{2+}\) and Ca\(^{2+}\)-free, pH 7.4) and fixed with warm 4% paraformaldehyde in PBS for 20 min at room temperature. Following fixation, cells were washed a further three times with PBS, nuclei counter-stained with 600nM DAPI and coverslips mounted onto glass slides using Mowiol for fluorescence microscopy. Cells were examined under a Zeiss 510 META confocal laser-scanning microscope at 20x magnification. Z-stack images indicated beads were engulfed by cells and not merely surface-bound. Numbers of ingested beads were counted manually and used to determine mean bead uptake across randomly selected fields of view containing 40+ cells.

2.2.13 Statistical analyses

Mean data ± SEM/SD were graphed and analysed using GraphPad Prism 6 software. Data were analysed using one-way ANOVA with Bonferroni post-test and considered statistically significant when p<0.05. Levels of significance between indicated conditions were: * = p<0.05, ** = p<0.01, *** = p<0.005, **** = p<0.001.
Chapter 3

3. Characterisation of $\alpha_7$nAChR at the glutamatergic synapse
3.1 Introduction

Glutamatergic synapse development is an essential and fundamental part of brain development, requiring communication between major excitatory and inhibitory receptor types, namely, N-methyl-D-aspartic acid (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and gamma-aminobutyric acid (GABA_A) receptors (Wang and Kriegstein, 2008). Synaptic activity is required for synapse formation, and in the developing synapse initial activity is mediated by NMDA receptors (NMDAR) (Durand et al., 1996; Wu et al., 1996). Immature neurons initially lack surface-expressed AMPA receptors (AMPAR), and the NMDAR pore is blocked by Mg^{2+} ions, rendering synapses silent until maturation occurs. During postnatal development, ACh signalling from the basal forebrain activates cortical presynaptic α7nAChR, which regulate glutamate release. Glutamate release subsequently activates postsynaptic NR2B-containing NMDAR, the activation of which contributes to enhanced insertion of AMPAR into the postsynaptic membrane (Metherate, 2004).

The importance of cholinergic input into the cortex has been reinforced by selective cholinergic input depletion in primates, through immunotoxin exposure. Cholinergic pathway-depleted monkeys retained episodic memory and decision-making capability, but displayed severely impaired working memory (Croxson et al., 2011), consistent with the cholinergic hypothesis of AD (Bartus et al., 1982; Perry, 1986; Francis et al., 1999) and the key role of ACh signalling to the cortex. The role of presynaptic α7nAChR in modulating cortical postsynaptic receptor function has largely focussed on neurotransmitter release, with α7nAChR playing a homeostatic role in modulating the subtleties of glutamate release at the glutamatergic synapse (Huang et al., 2010; Gomez-Varela and Berg, 2013; Cheng and Yakel, 2014), postsynaptic glutamate receptor expression (Wang et al., 2013), cell survival, neuronal plasticity, LTP and learning and memory (Zolles et al., 2009).

Much of what we currently understand about α7nAChR function comes from electrophysiology studies of overexpressing cell lines and exogenous receptor expression in Xenopus oocytes. Such data have paved the way for our in-depth understanding of the molecular and structural functionality of nAChR, but lack the physiological relevance and insight into downstream cellular signalling, following α7nAChR activation. Thus, the results described in this chapter are from experiments
utilising primary mouse cortical neurons as a model system for studying α7nAChR activity at glutamatergic synapses.

This chapter aims to thoroughly characterise this model system, first with respect to the expression and function of ionotropic glutamate receptors (GluR) before probing the expression and concomitant functionality of α7nAChR in vitro.
3.2 Results

3.2.1 Primary cortical cultures display a neuronal phenotype and express neuron-specific proteins

Initial characterisation of primary mouse cortical neuron cultures from e15-16 CD1 mice following 5 days in vitro (DIV) appeared neuronal under phase contrast microscopy, with extensive dendrites and axonal projections from the cell body (figure 3.1A). To further validate these cells were neuronal, the distribution of neuron-specific proteins Tau and MAP-2 was examined by fluorescence immunocytochemistry. Tau is known to be most abundant in axons, but can also be localised to somatodendritic compartments (Morris et al., 2011). MAP-2 is mainly expressed in neurons, where it is found specifically localised to dendrites; but is also expressed in oligodendrocytes (Dehmelt and Halpain, 2004). Double immunofluorescence showed distinct (non-colocalised) subcellular localisation of these proteins, revealing axonal Tau and dendritic MAP-2 (figure 3.1B) consistent with the expected neuronal phenotype of these cultures. Further immunocytochemistry with an anti-GFAP antibody showed minimal glial contamination suggesting cultures were 95-99% neuronal (data not shown).

3.2.2 Primary cortical neurons express postsynaptic AMPAR that couple to calcium influx

To initially determine whether the primary cortical neurons possessed the cellular components expected within glutamatergic synapses, 7 DIV neurons were used to assess expression and distribution of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor (AMPAR) subunits, GluA1 and GluA2. Immunofluorescence labelling of the cortical neurons revealed widespread expression of GluA1 (figure 3.2Ai) and GluA2 (figure 3.2Bi) throughout both the cell body and projections of neurons, consistent with the glutamatergic nature of the model system. Double immunofluorescence labelling of the AMPAR subunits with the nerve terminal marker synaptophysin revealed little colocalisation of either GluA1 or GluA2 with synaptophysin (figure 3.2Aii and 3.2Bii, respectively). However, GluA1 and GluA2 expression extensively colocalised with the postsynaptic marker PSD-95 (figure 3.2Aiii and 3.2Biii, respectively), indicating AMPAR are predominantly postsynaptic in primary cortical neurons, in accordance
Figure 3.1: Cortical neurons display a classical neuronal phenotype and express neuron-specific proteins. A: Phase contrast imaging of primary cortical neurons at 5 DIV and 40x magnification. Classical morphological features of neurons are observed, with networks of axons and dendrites extending from cell bodies. B: Neuron-specific immunofluorescence labelling of primary cortical neurons at 5 DIV at 40x magnification. Double immunostaining for the axonal marker Tau (red) and dendritic marker MAP-2 (green) reveals distinct subcellular localisation of the proteins. Nuclei are counterstained with DAPI (blue). Scale bars indicate 20μm.
Figure 3.2: Cortical neurons express postsynaptic and functional AMPAR. A: AMPAR GluA1 subunit-specific immunofluorescence of 7 DIV primary cortical neurons shows GluA1 (Ai, green) is expressed throughout the cell body and neuronal projections. Double staining with nerve terminal synaptophysin (Aii, red) reveals little overlap but a strong postsynaptic colocalisation of AMPAR with PSD-95 (iii, red). B: Similarly, GluA2 immunofluorescence (Bi, green) reveals widespread (~90%) neuronal expression, minimal nerve terminal expression (Bii) with no overlap with synaptophysin (red) and strong postsynaptic expression (Biii, colocalisation with PSD-95, red). GluA staining reveals 80-90% of the neuronal population express AMPAR. A-B scale bars indicate 20μm. C: Fura-2 AM microfluorimetry ratiometric trace reveals an AMPA-induced increase in intracellular calcium, across all n=11 cells, mean F340:380nm ±SD. Neurons were microperfused with assay buffer before a 20 sec pulse of 50μM AMPA (indicated by black line). Cells were imaged every ~1 sec by dynamic video imaging to capture live pseudocoloured images. D: Representative pseudocoloured images of baseline intracellular calcium influx (top) and maximal AMPA-induced calcium influx at 50 sec (bottom) are shown. Microfluorimetry scale bars indicate 100μm.
with previous studies both *in vitro* (Lozada *et al.*, 2012) and *in vivo* (Ehrlich and Malinow, 2004). The subunit composition of AMPAR determines the level of calcium ion permeability, and so to establish the calcium permeability properties of the primary cortical neurons, AMPA-mediated changes in intracellular calcium were probed, using a chemical calcium indicator FURA-2 AM and single cells visualised live by dual-emission microfluorimetry. As AMPA-induced calcium fluxes in neurons can be indirect, as result of the opening of voltage-dependent calcium channels, all microfluorimetry recordings were undertaken or performed in the presence of 1µM tetrodotoxin (TTX). Initial baseline recordings (0 to 20 sec) indicated little, if any, spontaneous action potential firing in the primary cultures (figure 3.2C), with no visible fluorescence change observed across the field of view (figure 3.2D, top). 50µM AMPA application for 20 sec induced a rapid increase in intracellular calcium, with the F340:380nm ratio recorded adopting a classical trace, as observed across many previous studies (Rainey-Smith *et al.*, 2010; Hoey *et al.*, 2013). The observation of rapid and strong intracellular calcium influx was reinforced by dynamic video imaging-captured images showing increased fluorescence intensity (blue/green to orange/white) within pseudocoloured images (figure 3.2D, bottom). These data suggest that widespread AMPAR expression in cultured cortical neurons enables calcium influx through calcium-permeable postsynaptic AMPAR.

3.2.3 Neuronal AMPAR are functional and couple to ERK phosphorylation

Having demonstrated glutamatergic components of the primary cortical neurons, through probing the expression and calcium-permeability of GluA1/2-composed AMPAR, AMPA-mediated neuronal activity was further assessed by examining modulation of a known downstream effector of AMPAR activation, ERK phosphorylation. 5-10 DIV neurons were treated with 50µM AMPA for up to 1 h, and lysates immunoblotted for dual-phosphorylated (Thr202 and Tyr204) active pERK2 and total ERK2. AMPAR activation caused a robust and significant ~2-fold increase in ERK2 phosphorylation, as rapidly as 3 min and was sustained over 15 min of AMPA treatment (figure 3.3). Over a longer AMPA treatment time course (30-60 min), the variation in AMPA-mediated ERK phosphorylation increased, likely due to AMPAR desensitisation, activity of ERK phosphatases and natural biological variation of the neurons between cultures. The AMPA-mediated change in pERK2 density was not due to varied levels of protein loaded into gels, as no change was
Figure 3.3: AMPA-induced ERK phosphorylation is time-dependent. 50µM AMPA treatment of 5-10 DIV primary cortical neurons induces rapid ERK phosphorylation. Neurons were treated with vehicle (control) or 50µM AMPA for 3, 10, 15, 30 or 60 min, followed by immunoblotting lysates with antibodies to dual phosphorylated ERK (ppERK) and total ERK2. Protein band densitometry quantification was expressed as the ratio of pERK2 to total ERK2 and indicates a significant time-dependent elevation in MAP kinase (ERK) activation. Data expressed as mean fold change of control pERK2:ERK2 ratio ± SEM, n=3 independent experiments, with representative ppERK1/2 and ERK2 blots shown. ** indicates p<0.01, control (white bar) vs AMPA (grey bars) subjected to one-way ANOVA with Bonferroni post-test.
total ERK2 levels was observed (figure 3.3). In order to establish the selectivity of AMPAR-dependent ERK phosphorylation, primary cortical neurons were pre-treated for 10 min with the MEK inhibitor U0126 (5μM), before application of 50μM AMPA for 3 min, observed to induce significant ERK phosphorylation (figure 3.3). Application of U0126 abolished baseline ERK phosphorylation levels (figure 3.4), indicating a tonic level of cellular activity in the primary neuronal cultures. U0126 also significantly abolished AMPA-induced ERK phosphorylation, indicating AMPAR signal to ERK in a classical MEK-dependent manner.

3.2.4 Neuronal NMDAR couple to cellular activation and ERK phosphorylation

To further establish the functional nature of the synapses present in the primary cortical neuron model system, assessment of the functionality of NMDA receptors (NMDAR) was carried out. As glutamatergic synapse development, maturation and plasticity is controlled by NMDAR, displaying the functionality of these receptors in vitro was essential. 5-10 DIV neurons were subjected to 50μM NMDA treatment for up to 1 h, and lysates immunoblotted for dual-phosphorylated (Thr202 and Tyr204) active pERK2 and total ERK2. NMDAR activation caused a rapid and significant ~9-fold increase in ERK2 phosphorylation, over vehicle treated control samples (figure 3.5). Over a time course of 1 h, ERK phosphorylation was significantly elevated following acute (3-10 min) periods of stimulation, with phosphorylation status returning to baseline levels over longer periods of treatment (15-60 min), in agreement with previously published findings from NMDAR-mediated ERK activation time course analyses in primary hippocampal neurons (Sala et al., 2000). Again, the NMDA-mediated change in pERK2 density was not due to varied levels of protein loaded into gels, as no change was observed in total ERK2 levels (figure 3.5).

To establish the selectivity of the NMDAR activation-dependent ERK phosphorylation, neurons were pre-treated for 10 min with either the NMDAR-selective antagonist MK801 (2.5μM) or the MEK inhibitor U0126 (5μM), before application of 50μM NMDA for the maximal ERK activation time of 3 min (figure 3.6). Application of MK801 alone had no effect on basal levels of ERK phosphorylation, indicating the tonic signalling activity in the cultures was mediated by another receptor population, most likely being AMPAR. MK801-mediated inhibition of NMDAR currents significantly abolished NMDAR-mediated ERK phosphorylation,
Figure 3.4: AMPAR-induced ERK phosphorylation is MEK-dependent. The selective MEK inhibitor U0126 blocks AMPA-mediated ERK phosphorylation. 5-10 DIV primary cortical neurons were treated with vehicle (control), U0126 (5μM, 10 min pre-treatment) or AMPA (50μM) alone or in the presence of U0126 for 3 min, followed by immunoblotting lysates with antibodies to dual phosphorylated ERK1/2 (ppERK) and total ERK2. Protein band densitometry quantification was expressed as the ratio of pERK2 to total ERK2 and indicates a significant AMPA-dependent elevation in MAP kinase (ERK) activation, selectively blocked by U0126. Data expressed as mean fold change of control pERK2:ERK2 ratio ± SEM, n=3 independent experiments, with representative ppERK1/2 and ERK2 blots shown. ** indicates p<0.01, **** indicates p<0.001, control (white bar) vs AMPA ± U0126 (grey bars) subjected to one-way ANOVA with Bonferroni post-test.
Figure 3.5: NMDA-induced cellular activation is time-dependent. 50μM NMDA treatment of 5-10 DIV primary cortical neurons induces rapid ERK phosphorylation. Neurons were treated with vehicle (control) or 50μM NMDA for 3, 10, 15, 30 or 60 min, followed by immunoblotting lysates with antibodies to dual phosphorylated ERK (ppERK) and total ERK2. Protein band densitometry quantification was expressed as the ratio of pERK2 to total ERK2 and indicates a significant time-dependent elevation in MAP kinase (ERK) activation. Data expressed as mean fold change of control pERK2:ERK2 ratio ± SEM, n=3 independent experiments, with representative ppERK1/2 and ERK2 blots shown. ** indicates p<0.01, control (white bar) vs NMDA (grey bars) subjected to one-way ANOVA with Bonferroni post-test.
Figure 3.6: NMDA-induced ERK phosphorylation is NMDAR- and MEK-dependent. The selective NMDAR antagonist MK801 and the MEK inhibitor U0126 blocks NMDA-mediated ERK phosphorylation. 5-10 DIV primary cortical neurons were treated with vehicle (control), MK801 (2.5µM, 10 min pre-treatment), U0126 (5µM, 10 min pre-treatment) or NMDA (50µM) alone or in the presence of MK801 or U0126 for 3 min, followed by immunoblotting lysates with antibodies to dual phosphorylated ERK1/2 and total ERK2. Protein band densitometry quantification was expressed as the ratio of pERK2 to total ERK2 and indicates a significant NMDA-dependent elevation in MAP kinase (ERK) activation, selectively blocked by MK801 and U0126. Data expressed as mean fold change of control pERK2:ERK2 ratio ± SEM, n=3 independent experiments, with representative ppERK1/2 and ERK2 blots shown. *** indicates p<0.005, **** indicates p<0.001, control (white bar) vs NMDA ± MK801/U0126 (grey bars) subjected to one-way ANOVA with Bonferroni post-test.
returning pERK to baseline level, reinforcing the selectivity of NMDAR-mediated cellular activation. U0126 abolished both baseline ERK phosphorylation (figure 3.6) and 50μM NMDA-induced ERK phosphorylation, indicating NMDAR signal to ERK in a classical MEK-dependent manner.

3.2.5 Primary cortical neurons express calcium-permeable α7 nicotinic acetylcholine receptors

In order to assess α7nAChR expression, primary cortical neurons were incubated with the α7nAChR-selective antagonist α-bungarotoxin (αBTX), labelled with a fluorescent AlexaFluor-488 tag (αBTX-488) to enable direct visualisation. The 74 amino acid 8kDa α-neurotoxin extracted from snake venom, αBTX, has been shown to bind to the agonist-binding pocket of nAChR α-subunits (Samson et al., 2002). The antagonist binds with high affinity to α7nAChRs (Chen and Patrick, 1997) and thus acts as a useful tool to study α7nAChR expression and pharmacology. Staining intact live primary cortical neurons with αBTX-488 yielded a subpopulation of fluorescently labelled cells, possessing the classical morphological phenotype of neurons (figure 3.7A). Parallel visualisation of all cell nuclei counterstained with DAPI revealed ~10-15% were fluorescently labelled with αBTX-488. The observed staining appeared selective for α7nAChRs as the fluorescence signal was blocked by pre-incubation with an excess of nicotine (1mM) before application of αBTX-488 (figure 3.7B), in accordance with other studies (Kawai et al., 2002; Chang and Fischbach, 2006; Shelukhina et al., 2009).

Upon establishing primary cortical neurons expressed α7nAChR, investigation into the functionality of these receptors was subsequently undertaken. As nAChR-mediated influx of calcium ions is known to influence a variety of cellular processes, from neurotransmitter release to postulated mechanisms of learning and memory, characterisation of the in vitro nAChR functionality was essential. α7nAChRs are distinguished from other nAChRs by their high relative permeability to calcium (Dajas-Bailador and Wonnacott, 2004), so in order to probe α7nAChR calcium permeability, the calcium-sensitive chemical indicator FURA-2 AM was used in dual emission microfluorimetry live imaging of primary cortical neurons.

As calcium fluxes in neurons can be indirect, such as through other voltage-gated calcium channels, all microfluorimetry recordings were done in the presence of 1μM tetrodotoxin (TTX). Prior to agonist treatment, the neurons were microperfused for 3
min with the positive allosteric modulator (PAM) PNU-120596 (10μM). Initial baseline recordings (0 to 40 sec) indicated little, if any, spontaneous action potential firing in the primary cultures (figure 3.7C), with no visible fluorescence change observed across the field of view (figure 3.7D, top), confirming PNU-120596 (10μM) application does not directly activate α7nAChRs. Subsequent PNU-282987 (3μM) agonist application for 20 sec induced a rapid increase in intracellular calcium, as observed from the recorded F340:380nm ratio trace (figure 3.7C). The observation of rapid intracellular calcium influx was reinforced by dynamic video imaging-captured images showing increased fluorescence intensity, as a surrogate marker of calcium ion influx (blue to light blue), within a number of cells within pseudocoloured images (figure 3.7D, bottom).

### 3.2.6 Neuronal nAChR couple to ERK phosphorylation

To further establish the nature of the nicotinic acetylcholine receptors (nAChR) present in the primary cortical neuron model system, assessment of their functionality was carried out. 5-10 DIV neurons were treated with the non-selective nAChR agonist nicotine (10μM) for up to 30 min, in the presence of 10μM PNU-120596, and lysates immunoblotted for dual-phosphorylated (Thr202 and Tyr204) active pERK2 and total ERK2. Nicotine-induced nAChR activation caused a rapid and significant ~2.5-fold increase in ERK2 phosphorylation, over vehicle treated control samples (figure 3.8A). Over the time course of 30 min, ERK phosphorylation was significantly elevated across all periods of stimulation, in agreement with previously published findings from nicotine-treatment of primary cortical neurons (Steiner et al., 2007). The nicotine-mediated change in pERK2 density was not due to varied levels of protein loaded into gels, as no change was observed in total ERK2 levels (figure 3.8A). To establish the relative α7- and non-α7nAChR component of nicotine-induced ERK phosphorylation, nicotine was applied to the cortical neurons for the maximal ERK activation time of 3 min, in the absence of the α7nAChR-selective PAM PNU-120596. 3 min nicotine treatment did not significantly increase ERK phosphorylation above vehicle treated (control) samples (figure 3.8B), but a slight increase was observed, and can be attributed to the expression of rapidly desensitising α7- and α3β4 nAChR subtypes (Fenster et al., 1997) predominantly expressed in cortical neurons (Alkondon et al., 2007). Incubation with10μM PNU-120596 alone had no effect on cellular activation; with no observed
Figure 3.7: Primary cortical neurons express functional calcium-permeable α7nAChR. A: Imaging of α7nAChR using 100nM AlexaFluor-488 labelled α-bungarotoxin (green) of 5 DIV neurons reveals ~10-15% of neurons express α7nAChR. B: To assess specificity of α7nAChR:α-bungarotoxin labelling, neurons were pre-incubated with an excess of the broad nAChR agonist nicotine (1mM) to probe non-specific α-bungarotoxin labelling. Nicotine pre-incubation blocked all fluorescent labelling of α7nAChR, confirming specificity of α-bungarotoxin AlexaFluor-488 labelling. Fluorescence images scale bars indicate 20μm. C: Fura-2 AM microfluorimetry ratiometric F340:380nm trace reveals an α7nAChR activation-induced increase in intracellular calcium, n=3 cells, mean F340:380nm ± SEM. Neurons were microperfused with assay buffer before a 3 min incubation with 10μM PNU-120596 and subsequent 20 sec pulse of 10μM PNU-282987 (indicated by black lines). Cells were imaged every ~1 sec by live dynamic video imaging to capture pseudocoloured images. D: Representative pseudocoloured images of baseline intracellular calcium influx (top) and maximal α7nAChR activation-induced calcium influx at 60 sec (bottom) are shown. Microfluorimetry scale bars indicate 100μm.
change in ERK phosphorylation indicating the PAM requires the presence of agonist to activate \( \alpha 7nAChRs \). The negligible PNU-120596 effect on ERK activation suggested that there was little if any tonic acetylcholine release in the cultures, which in the presence of a PAM could activate nAChRs. When pre-treatment (10min, 10\( \mu \)M) with PNU-120596 was combined with a 3 min nicotine (10\( \mu \)M) application, a significant increase in ERK phosphorylation was again observed (figure 3.8B), reinforcing the benefit of using PNU-120596, to enhance and unmask \( \alpha 7nAChR \)-activation-dependent signals \textit{in vitro}. To determine the specificity of the PNU-120596-potentiated nicotine-induced increase in ERK phosphorylation, primary cortical neurons were incubated with the \( \alpha 7nAChR \)-selective antagonist \( \alpha \)BTX (100nM). \( \alpha \)BTX had no effect on basal levels of ERK phosphorylation (figure 3.8B); indicating no acetylcholine-mediated tonic signalling was present within these cultures. Cells were pre-treated for 10 min with \( \alpha \)BTX (100nM), before application of 10\( \mu \)M PNU-120596 for a further 10 min, prior to 3 min nicotine treatment (figure 3.8B). \( \alpha \)BTX-mediated inhibition of \( \alpha 7nAChR \) significantly inhibited \( \alpha 7nAChR \)-induced ERK phosphorylation, returning phospho-ERK to baseline level, reinforcing the specificity of PNU-120596-mediated potentiation of \( \alpha 7nAChR \) in nicotine-induced ERK phosphorylation.

Nicotine is a weak and non-selective agonist of nAChR, typically binding to the \( \alpha 4\beta 2 \) nAChR subtype with significantly higher affinity (40-1000x) than at \( \alpha 7nAChR \) (Jensen \textit{et al.}, 2003) and significantly (10-100x) lower functional potency than other nAChR isoforms (Gopalakrishnan \textit{et al.}, 1995; Eaton \textit{et al.}, 2003). Thus to selectively investigate the effects of \( \alpha 7nAChR \), without other nAChR isoforms confounding analyses, the \( \alpha 7nAChR \)-selective agonist PNU-282987 was used (Bodnar \textit{et al.}, 2005; Hajos \textit{et al.}, 2005; del Barrio \textit{et al.}, 2011), in combination with PNU-120596. 5-7 DIV neurons were treated with PNU-120596 (10\( \mu \)M, 10 min pre-incubation) and PNU-282987 (10\( \mu \)M) for up to 1 h, and lysates immunoblotted for dual-phosphorylated (Thr202 and Tyr204) active pERK2 and total ERK2. \( \alpha 7nAChR \) activation caused a rapid and significant \( \sim 3 \)-fold increase in ERK2 phosphorylation, over vehicle treated control samples (figure 3.8C). Over a time course of 1 h, ERK phosphorylation was significantly elevated following acute (3 min) stimulation, with phosphorylation status returning to baseline levels over longer periods of treatment (10-60 min). The \( \alpha 7nAChR \)-mediated change in pERK2 was not due to varied levels of protein loaded into gels, as no change was observed in total ERK2 levels (figure 3.8C). No clear
effect was observed with 10μM PNU-282987 beyond an acute (3 min) treatment time. This cannot be attributed to α7nAChR desensitisation, due the presence of the PAM PNU-120596, which is known to reduce receptor desensitisation and to greatly prolong agonist-evoked cellular responses (Hurst et al., 2005), but instead can be likely ascribed to phosphatase-mediated deactivation of ERK. The agonist activity of PNU-282987 has previously been shown to more than double the frequency of synaptic activity, when compared to nicotine (Hajos et al., 2005), however, when comparing the relative effect of nicotine and PNU-282987 in the presence of PNU-120596, on ERK phosphorylation, no significant difference in peak ERK phosphorylation level was observed (figure 3.8A and B versus figure 3.8C and D). To determine the specificity of the PNU-282987-induced increase in ERK phosphorylation, via α7nAChR activation, primary cortical neurons were incubated with either the α7nAChR-selective antagonist αBTX (100nM), the MEK inhibitor U0126 (5μM) or the free calcium chelator EGTA (2.5mM), alone or before application of (PNU-120596 and) PNU-282987 for the maximal ERK activation time of 3 min. αBTX pre-treatment had no effect on basal levels of ERK phosphorylation (figure 3.8D). Application of αBTX (100nM), before PNU-120596 (10μM), prior to 3 min PNU-282987 agonist treatment (figure 3.8D) significantly attenuated PNU-282987-induced ERK phosphorylation, returning pERK to baseline level. U0126-mediated MEK inhibition abolished baseline ERK phosphorylation (figure 3.8D) and also PNU-282987-induced ERK phosphorylation. Finally, to investigate the extracellular calcium-dependence of the α7nAChR-mediated ERK activation, EGTA was applied in excess (2.5mM) to the cortical neurons. EGTA alone had no effect on baseline ERK phosphorylation, indicating extracellular calcium does not maintain basal ERK levels. Chelation of extracellular calcium with EGTA prevented an increase in α7nAChR-mediated pERK, following stimulation with PNU-282987 (figure 3.8D). When taken together, these data suggest that α7nAChR-mediated calcium influx stimulates robust MEK-dependent ERK phosphorylation in cultured cortical neurons.
Figure 3.8: nAChR couple to cellular activation and ERK phosphorylation. A: Nicotine treatment (in the presence of PNU-120596) induces rapid time-dependent sustained ERK phosphorylation. B: Nicotine-induced ERK phosphorylation requires the presence of the α7nAChR-selective PAM PNU-120596 and is selectively blocked by the α7nAChR antagonist αBTX. C: PNU-282987 treatment (in the presence of PNU-120596) induces rapid but non-sustained ERK phosphorylation. D: Agonist-mediated ERK phosphorylation is blocked by αBTX, the MEK-inhibitor U0126 and the extracellular calcium chelator EGTA. 5-10 DIV primary cortical neurons were treated with vehicle (control) or agonist (10μM nicotine/PNU-282987) for 3, 10, 15, 30 or 60 min, following 10 min pre-treatment with 10μM PNU-120596 and/or 20 min pre-treatment with antagonist or signalling inhibitors (100nM αBTX, 5μM U0126 or 2.5mM EGTA) followed by immunoblotting lysates with antibodies to dual phosphorylated ppERK1/2 and total ERK2. Protein band densitometry quantification was expressed as the ratio of pERK2 to total ERK2. Data expressed as mean fold change of control pERK2:ERK2 ratio ± SEM, n=3 independent experiments, with representative ppERK1/2 and ERK2 blots shown. * indicates p<0.05, ** p<0.01, *** p<0.005, control (white bar) vs agonist/PAM treatment (grey bars) or antagonist/inhibitor (black bars) subjected to one-way ANOVA with Bonferroni post-test.
3.2.7 α7nAChR-activation has no effect on Egr-1 promoter-driven luciferase expression

Assessment of the levels of pERK protein as a marker of ERK activity is a commonly used measure of cellular activation. However, analyses of α7nAChR activation-induced changes in pERK1/2 protein levels do not give an indication as to whether α7nAChR stimulation can recruit ERK-driven gene transcription, a known mediator of long-term cellular processes, such as cell survival, learning and memory and memory consolidation. Given the proposed distinct spatial distribution of α7nAChR populations, being presynaptic and/or postsynaptic, the ability of α7nAChR to drive effective transcriptional changes within the nucleus of primary neurons is unknown. Given the relatively insensitive technique of immunoblotting, coupled with the low expression level of α7nAChR observed in primary cortical neurons, a highly sensitive viral transduction method was used to further probe α7nAChR activation-mediated network effects in vitro. Primary neurons (at 6-7 DIV) were transduced with an Ad5-Egr-1 reporter plasmid, to measure ERK-dependent transcription of early growth response gene-1 (Egr-1), as measured by luciferase readout. Following transduction, neurons were treated with BDNF (50ng/ml), U0126 (5μM), PNU-120596 (10μM), PNU-282987 (10μM) or αBTX (100nM) for 6 h. A 6 h treatment time was required to allow sufficient detectable transcription of the Egr-1 gene product (Dr Carla Cox, personal communication and unpublished data). BDNF treatment induced a significant 2-fold increase in Egr-1-mediated luciferase expression (figure 3.9), which was blocked by pre-treatment with the selective MEK inhibitor U0126. Neither the α7nAChR-selective PAM PNU-120596 nor the agonist PNU-282987 had a significant effect on Egr-1 transcription of the entire neuronal population, either alone or in combination (figure 3.9). Inhibition of α7nAChR with αBTX had no effect on basal levels of Egr-1 transcription. This suggests that despite stimulating ERK phosphorylation chronic α7nAChR activation does not modulate transcription of the ERK target gene Egr-1.
Figure 3.9: Activation of α7nAChR does not stimulate ERK-dependent transcription of Egr-1 in primary cortical neurons. 6 DIV primary cortical neurons were transduced with an Ad5-Egr1-luciferase plasmid. Neurons were treated with vehicle (control), BDNF (50ng/ml), U0126 (5μM), PNU-120596 (10μM), PNU-282987 (10μM) or αBTX (100nM) for 6 h. Luciferase activity was measured post drug treatments and is expressed as mean fold change of control ± SEM (n=8-12 individually transduced wells across 3 independent experiments, ns indicates not statistically significant, ** p<0.01, **** p<0.001, control (white bar) vs BDNF/U0126 (black bars) or PNU (grey bars), subjected to one-way ANOVA with Bonferroni post-test.
3.3 Discussion

The aim of this chapter was to characterise primary cortical neurons to determine their suitability as a model system for studying α7nAChR signalling at the glutamatergic synapse. Accordingly, this chapter has shown primary cortical neurons express functional glutamate receptors (NMDAR and calcium-permeable AMPAR) that couple to cellular activation (ERK phosphorylation). Furthermore, detailed characterisation was undertaken to demonstrate the presence of functional calcium-permeable α7nAChR, which couple to ERK activation, but play no role in modulating ERK-mediated gene transcription.

3.3.1 Primary cortical neurons express functional glutamate receptors

Initial results, using phase contrast imaging and immunofluorescence with neuron-specific markers, showed that the primary cortical neuron model system possessed a neuronal phenotype. Furthermore, GluA-subunit immunofluorescence coupled with dual-emission microfluorimetry highlighted postsynaptic expression and functionality of calcium-permeable AMPAR, in accordance with previous literature (Rainey-Smith et al., 2010; Hoey et al., 2013). The widespread expression of AMPAR in primary cortical neurons was estimated as ~90%, in accordance with AMPAR expression in primary motor neurons (Damme, 2002) and primary cortical neurons (Hoey et al., 2013). Furthermore, following 5-10 DIV, AMPAR and NMDAR were coupled to ERK phosphorylation as previously demonstrated (Sala et al., 2000; Ivanov et al., 2006; Domercq et al., 2011). AMPAR- and NMDAR-mediated ERK phosphorylation was time-dependent and MEK-dependent, with rapid kinetics of activation, peaking at 2-5 and 5-10 min following treatment with NMDA (Sala et al., 2000) and AMPA (Domercq et al., 2011), respectively. Within the CNS, glutamate activates NMDAR, AMPAR and kainate receptors, which results in increases in intracellular calcium: a process that is a critical regulator of gene expression and long-term cell survival responses. Results described here show functionality of glutamate receptors in primary cortical neurons, reinforcing the use of these cells as an appropriate model system for the study of the glutamatergic synapse.
3.3.2 Primary cortical neurons express functional calcium-permeable α7nAChR

Using the α7nAChR-selective PAM PNU-120596, a clear α7nAChR activation effect was observed, through blocking receptor desensitisation (Hurst et al., 2005). Treatment of primary cortical neurons with the PAM and α7nAChR-selective agonist PNU-282987 enabled detection and measurement of a clear α7nAChR-mediated influx of calcium into a small population of αBTX-488-positive (10-15%) primary cortical neurons, as measured by dual-emission microfluorimetry calcium imaging (in accordance with Hu et al., 2009; Brown and Wonnacott, 2014). Previous literature has shown α7nAChR radiolabelling and immunoreactivity within primary neurons increases over time in culture, correlating with synapse formation and maturation (Samuel et al., 1997). When α7nAChR expression is compared to AMPAR expression and functionality, these data suggest a much lower expression level of α7nAChR than AMPAR in cultured primary cortical neurons. Immunofluorescence imaging of GluA1/2-containing AMPAR and FURA-2 AM microfluorimetry indicated widespread (~90%) AMPAR expression. Conversely, fluorescent αBTX-488 labelling of α7nAChR and FURA-2 AM dual-emission microfluorimetry indicated a modest (10-15%) cortical α7nAChR expression, in accordance with previously published findings (Liu et al., 2001; Poorthuis et al., 2013; Brown and Wonnacott, 2014; Genzen et al., 2014). As such, these results indicate a lower expression level of α7nAChR in a more representative and physiological model system than cell lines, which are currently favoured by many research groups. α7nAChR expression level may play a role in the differences and discrepancies observed between nAChR studies undertaken in cell lines, overexpressing transgenic mouse models and primary CNS tissues.

3.3.3 Primary cortical neuronal α7nAChR couple to ERK phosphorylation without effecting ERK-dependent transcription

Few studies have examined α7nAChR-mediated downstream signalling cascades, specifically ERK phosphorylation. Historically, this has arisen due to a lack of sensitive detection methods, owing to the rapid kinetics of activation and desensitisation of α7nAChR and also the relatively new emergence of α7nAChR-subtype selective ligands. Recent studies have highlighted both nicotine- and α7nAChR-selective
agonist-mediated ERK phosphorylation in primary cortical neurons, SH-SY5Y cells and PC12 cells. Accordingly, a similar kinetic was observed between PAM-potentiated PNU-282987-mediated ERK phosphorylation in PC12 cells (El Kouhen et al., 2009), with ERK phosphorylation peaking at 3-7 min, and also in nicotine-treated SH-SY5Y cells and primary cortical neurons, with ERK phosphorylation peaking rapidly between 1-5 min (Dajas-Bailador et al., 2002; Steiner et al., 2007). Similarly, the data presented here highlight a rapid 3 min maximal kinetic of ERK phosphorylation, mediated by PNU-120596-potentiated nicotine- and PNU-282987-mediated α7nAChR activation, which were blocked by αBTX and was both MEK- and extracellular calcium-dependent. Thus, these data presented in this chapter reinforce the published literature and combine distinct observations between nicotine and α7nAChR-selective ligands in a physiological cellular model.

Furthermore, data presented here highlight for the first time, that α7nAChR activation only couples to transient ERK phosphorylation and not ERK-dependent gene transcription. A limited number of studies have reported nAChR activation leads to c-Fos gene expression (Greenberg et al., 1986) following secondary activation of L-type voltage-dependent calcium channels. Neuronal activity-dependent gene transcription has been well documented for NMDAR and AMPAR, with ionotropic glutamate receptor activation tightly coupled to gene expression (West and Greenberg, 2011). So, why is this not the case for α7nAChR, which are also highly calcium-permeable? This may be a result of both the spatial localisation of presynaptic α7nAChR, with only postsynaptic receptors (such as NMDAR and AMPAR) capable of modulating transcription (Mokin and Keifer, 2005; Mittelbronn et al., 2009), or the low α7nAChR expression level observed in primary cortical neurons. Previous reports conform to this hypothesis, with in vivo data showing gene expression changes require neuronal signalling above a threshold level, met by a balance between the number of excitatory and inhibitory input signals (Mann and Paulsen, 2007). Overexpression of α7nAChR in cell lines is capable of prolonged and sustained ERK phosphorylation (Utsugisawa et al., 2002) and gene transcription, including the Egr-1 gene (Dunckley and Lukas, 2003). Conversely, data presented here show natively expressed α7nAChR are not able to bring about effects on gene transcription, but instead play a modulatory role in transiently activating intracellular (MAPK) signalling cascades.
3.3.3 Summary

Using a combination of an $\alpha 7$nAChR-selective PAM and agonist, this chapter highlights the activation of native $\alpha 7$nAChR within well-characterised primary cortical glutamatergic synapses induced rapid and robust ERK phosphorylation, in accordance with the published literature, but showed no effect on ERK transcription.
Chapter 4

4. $\alpha 7nAChR$-dependent regulation of APP processing
There is a strong link between cholinergic signalling (at both muscarinic and nicotinic receptors) and APP metabolism (Hellström-Lindahl, 2000; Fisher, 2012) and section 1.8.2.2). A number of studies in cell lines have demonstrated that $\alpha_7nAChR$ activation, with nicotine enhances sAPP$\alpha$ release (Kim et al., 1997; Lahiri et al., 2002; Mousavi and Hellström-Lindahl, 2009; Nie et al., 2010), inhibits soluble A$\beta$ production (Hellström-Lindahl et al., 2004; Hedberg et al., 2008) and reduces A$\beta$ plaque levels in vivo (Nordberg et al., 2002; Nie et al., 2010). These effects, which might be due to an $\alpha_7nAChR$-mediated reduction in BACE-1 protein levels, prevent A$\beta$-induced synaptic transmission defects and neurotoxicity (Zamani et al., 1997; Shimohama and Kihara, 2001; Picciotto and Zoli, 2008; Yu et al., 2011). Despite this body of evidence, the ability of $\alpha_7nAChR$ to couple to APP processing in neurons has not been thoroughly investigated.

As reviewed in section 1.8.2.2, NMDAR activation can potentially exhibit contrasting effects on APP processing. Hyperactivation and stimulation of extrasynaptic NMDAR is implicated in excitotoxicity, enhanced pro-amyloidogenic APP processing and A$\beta$ production, resulting in neurodegeneration (Hardingham et al., 2002; Léveillé et al., 2008; Bordji et al., 2010, 2011; Talantova et al., 2013; Parsons and Raymond, 2014; Rush and Buisson, 2014). In contrast, physiological signalling through synaptic NMDAR enhances non-amyloidogenic APP processing and is neuroprotective, playing a role in synaptic plasticity and neurotrophic processes (Hardingham et al., 2002; Léveillé et al., 2008; Hoey et al., 2009; Bordji et al., 2010). Ionotropic glutamate receptor-mediated non-amyloidogenic APP processing has been strongly linked to ERK phosphorylation (Verges et al., 2011; Wan et al., 2012; Hoey et al., 2013), with AMPAR activation-induced ERK phosphorylation following the same kinetic as APP processing (Hoey et al., 2013). Generally, the MAPK pathway has been shown to regulate neuron activity-dependent APP processing (Mills et al., 1997; Desdouits-Magnen et al., 1998) and enhanced $\alpha$-secretase activity (Cisse et al., 2011), reinforcing the potential of $\alpha_7nAChR$ to directly mediate non-amyloidogenic APP processing, given the data presented in Chapter 3, showing $\alpha_7nAChR$-induced ERK activation.

Furthermore, given the well-characterised capacity for presynaptic $\alpha_7nAChR$-mediated glutamate release (section 1.4.2.3), activation of this receptor population
may indirectly enhance non-amyloidogenic APP processing, via activation of synaptic ionotropic glutamate receptors, as well as directly through α7nAChR-mediated calcium influx and ERK-1/2 phosphorylation. As such, reduced glutamate signalling (by tetanus toxin application to primary hippocampal neurons) has been shown to increase α7nAChR dwell time at the nerve terminal. Accordingly, cell-surface immobilised α7nAChR enhanced the likelihood of glutamate release by increasing the size of the readily releasable pool of glutamate-containing vesicles (Gomez-Varela and Berg, 2013), thus reinforcing the potential for nerve terminal α7nAChR to modulate APP processing indirectly, through α7nAChR-induced glutamate release and postsynaptic glutamate receptor activation.

Given the calcium-permeability properties and activation-induced ERK phosphorylation of both ionotropic glutamate receptors and α7nAChR, this indicates α7nAChR are endowed with equal properties, and potentially capable of directly mediating non-amyloidogenic APP processing, or also indirectly via α7nAChR-mediated glutamate release and subsequent NMDAR/AMPAR activation. Therefore, the results described in this chapter aim to probe the in vitro APP processing functionality of α7nAChR natively expressed by primary cortical neurons, and compared to a known non-amyloidogenic APP processing-modulator, NMDAR. Through investigating whether α7nAChR couple to APP processing in primary cortical neurons, via a direct or indirect mechanism, secondary to NMDAR activation and calcium influx, will provide a new mechanistic insight into the physiological control of APP processing at the glutamatergic synapse and reinforce our understanding of the beneficial effect of targeting α7nAChR with agonists and PAMs, with a view to regaining control of Aβ production in aging and neurodegeneration.
4.2 Results

4.2.1 APP is predominantly expressed at postsynaptic sites in primary cortical neurons

Under basal homeostatic conditions, APP has been shown to be equally distributed across axonal and somatodendritic compartments of neurons (Back et al., 2007), but is most extensively expressed postsynaptically (Hoe et al., 2009; Hoey et al., 2009, 2013). To establish the expression and distribution of APP within our own primary cortical cultures, neurons at 5-7 DIV were used to examine physiological expression of endogenous APP holoprotein. APP immunofluorescence, using a custom-made primary antibody raised against the C-terminus of human APP, revealed widespread intracellular expression (figure 4.1A), with APP found throughout the cell body and neuronal projections. Double immunofluorescence of APP with the nerve terminal marker synaptophysin revealed little colocalisation (figure 4.1B). However, APP extensively colocalised with the postsynaptic marker PSD-95 (figure 4.1C), indicating APP is predominantly postsynaptic in primary cortical neurons, in accordance with previous studies.

4.2.2 Primary cortical neurons express putative $\alpha$-secretase enzymes, ADAM-10 and ADAM-17

To assess the capability of this model system to undergo non-amyloidogenic cleavage of APP, the expression of the constitutive $\alpha$-secretase ADAM-10 and stimulated $\alpha$-secretase ADAM-17 was established. To probe whether the primary cortical neurons express the putative $\alpha$-secretase proteins, commercially available primary antibodies were used in fluorescence immunostaining to investigate the expression and trafficking of ADAM-10 and ADAM-17. Under non-stimulated conditions, both ADAM-10/17 were expressed (figure 4.2) throughout neurons. Double immunostaining of both ADAM-10 (figure 4.2A) and ADAM-17 (figure 4.2B) with the postsynaptic marker PSD-95 revealed notable, but not total overlap, indicating ADAM-10 and ADAM-17 are both trafficked postsynaptically. This data is in accordance with previous biochemical and immunolabelling studies, which highlights ADAM-10 is enriched postsynaptically and shows punctate expression on PSD-95-positive spine-like structures (Marcello et al., 2007).
Figure 4.1: APP is mainly trafficked to postsynaptic neuronal compartments. A: Single immunofluorescence staining of 5-10 DIV primary cortical neurons reveals APP (green) is expressed throughout the cell body and neuronal projections. B: Double labelling of APP (green) with the presynaptic marker synaptophysin (red) indicates little colocalisation. Higher magnification (inset) of the indicated (dashed box) region suggests very little overlap between APP and synaptophysin (arrow). C: Double labelling of APP (green) with the postsynaptic marker PSD-95 (red) revealed extensive colocalisation, indicating APP is mainly postsynaptically expressed. All nuclei were counter stained with DAPI (blue) and scale bars show 20μm.
Figure 4.2: Primary cortical neurons express putative α-secretase proteins ADAM-10 and ADAM-17. A: Double immunofluorescence staining of 7 DIV primary cortical neurons reveals ADAM-10 (red) shows punctate expression throughout the neurons and is partly colocalised with the postsynaptic marker PSD-95 (green). B: Double immunofluorescence staining of 7 DIV primary cortical neurons reveals ADAM-17 (red) punctate expression throughout the neurons and is partly colocalised with the postsynaptic marker PSD-95 (green). Nuclei were counter stained with DAPI and scale bars represent 20μm.
4.2.3 NMDAR activation reduces levels of full-length APP

Having demonstrated expression of APP and two of secretase enzymes within primary cortical neurons, the kinetics of APP processing was investigated, first using a known APP processing enhancer, NMDA (Hoey et al., 2009; Hu et al., 2009b; Bordji et al., 2010; Verges et al., 2011). Neurons were treated with 50μM NMDA for up to 2 h and lysates immunoblotted using a custom-made primary antibody raised against the C-terminus of human APP and a loading control house keeping protein β-tubulin. Over the 2 h time course, NMDAR activation induced a time-dependent reduction in full-length APP holoprotein, reaching significance at 1 h and a maximal ~60% reduction in APP level by 2 h (figure 4.3), in accordance with reports (Hoey et al., 2009, 2013). A reduction in full-length APP is indicative of secretase-mediated cleavage of the holoprotein. The NMDA-mediated change in APP density was not due to varied levels of protein loaded into gels, as no change was observed in β-tubulin levels (figure 4.3) and was not due to cellular toxicity, as measured by MTT and LDH assays (data not shown).

4.2.4 α7nAChR activation has no effect on full-length APP levels

Upon establishing that endogenous APP undergoes NMDAR-dependent cleavage, the potential for α7nAChR to similarly couple to APP cleavage was investigated. Activation of α7nAChR has been reported to induce non-amyloidogenic cleavage of APP, (Kim et al., 1997; Hellström-Lindahl, 2000; Lahiri et al., 2002; Xiu et al., 2005; Mousavi and Hellström-Lindahl, 2009; Nie et al., 2010) in immortalised cell lines but this has not been tested in differentiated neurons. Therefore, to establish whether this effect is also observed in primary cortical neurons, cells were treated with the α7nAChR-selective agonist PNU-282987 (10μM), following a 10 min pre-incubation with the α7-PAM 10μM PNU-120596 for up to 2 h and lysates immunoblotted for full-length APP and a loading control house keeping protein β-tubulin. Over the 2 h time course α7nAChR activation had no effect on the overall levels of APP695, relative to the β-tubulin loading control (figure 4.4). Further detailed analysis of the immunoblots revealed no change to the high molecular weight form of APP, known to be glycosylated mature APP, which is typically the first pool of APP to be cleaved by secretase enzymes acting at the plasma membrane (Hoey et al., 2009, 2013).
Figure 4.3: NMDAR activation induces cleavage of APP. 5-10 DIV primary cortical neurons were treated with vehicle (control) or 50µM NMDA for either 3, 10, 30, 60 or 120 min followed by immunoblotting for endogenous full-length APP and the loading control β-tubulin. Data expressed as relative mean fold change of control APP:β-tubulin ratio ± SEM, n=3 independent experiments. * indicates p<0.05 and ** p<0.01, control (white bar) vs NMDA treatment (grey bars) subjected to one-way ANOVA with Bonferroni post-test.
Figure 4.4: $\alpha$7nAChR activation does not affect APP levels. 5-10 DIV primary cortical neurons were treated with vehicle (control) or 10 min pre-treatment with PNU-120596 prior to 10$\mu$M PNU-282987 for either 3, 10, 30, 60 or 120 min followed by immunoblotting for endogenous full-length APP$_{695}$ and the loading control $\beta$-tubulin. Data expressed as relative mean fold change of control APP:$\beta$-tubulin ratio ± SEM, n=3 independent experiments. No significant difference over control (white bar) vs PNU-1/2 treatment (grey bars) was observed, as subjected to one-way ANOVA with Bonferroni post-test.
4.2.5 Isolation and activation of presynaptic $\alpha_7$nAChR has no effect on full-length APP levels

Given the distribution of $\alpha_7$nAChR at both presynaptic and postsynaptic sites, probing the functionality of these receptor populations individually requires separation of the distinct bodies of receptors. Given the relatively low number of $\alpha_7$nAChR within glutamatergic synapses (~10-15% cells, as stated in Section 3.2.5), combined with the low-sensitivity of whole cell lysate immunoblotting, a synaptosome approach was adopted to purify and concentrate mature cortical presynaptic $\alpha_7$nAChR and thereby assess APP densitometry, following receptor activation. Using Percoll density gradient centrifugation, whole adult mouse brain homogenates were separated into four distinct fractions (F1-F4, figure 4.5), where F3 is enriched with synaptosomes and membranes and F4 is enriched with pure synaptosomes (Dunkley et al., 2008). F3 and F4 were pooled to ensure sufficient viable synaptosomal material, which was subjected to vehicle, 50$\mu$M NMDA or 10$\mu$M PNU-282987 treatment (following a 10$\mu$M PNU-120596 10 min pre-treatment) for 30 min at 37°C. Following drug treatments, synaptosomes were lysed and denatured for immunoblotting. Through Western blotting, synaptosomes were assessed for expression of the nerve terminal/presynaptic marker synaptophysin, the postsynaptic marker PSD-95, dual-phosphorylated (Thr202 and Tyr204) active pERK2 and total ERK2, APP$_{695}$ and a loading control of $\beta$-tubulin. Analysis of the immunoblotting bands revealed the purity of the synaptosome preparation and hence its validity for use in presynaptic assays. Lysates were positive for the presynaptic marker synaptophysin and negative for the postsynaptic marker PSD-95, figure 4.5 top two panels, which were unchanged following either NMDA- or PNU-1/2-treatment. Furthermore, the level of protein loaded across gel lanes was identical, as judged by $\beta$-tubulin (figure 4.5 fifth panel), and further suggested no toxicity or viability issues as a result of drug treatment. Furthermore, following 30 min NMDAR activation, a very minor increase in phospho-ERK levels was observed over basal (figure 4.5 third panel), which can be attributed to either very minimal contamination of the synaptosomes with some postsynaptic density and thus native NMDAR, or the presence of functional presynaptic NMDAR, which remains a highly controversial topic (Berg et al., 2013). In contrast to NMDA-treatment, 30 min $\alpha_7$nAChR activation resulted in a large increase in ERK phosphorylation, reinforcing the well-documented presence of functional presynaptic $\alpha_7$nAChR, which when
Figure 4.5: Density gradient centrifugation produces viable synaptosomes with functional presynaptic $\alpha_7$nAChR. Homogenised brain supernatant was applied atop a discontinuous Percoll density gradient. Five subcellular fractions (F1-F5) were produced, with the photograph identifying typical (white) gradient bands post-centrifugation. Small membranous material in F1; myelin, membranes and vesicles in F2; synaptosomes and membrane vesicles in F3; purified synaptosomes in F4 and extrasynaptosomal mitochondria in F5. Experimental synaptosomes were obtained from pooling F3 and F4 (*) and resuspending in isotonic physiological buffer before drug treatments. Synaptosomes were equilibrated at 37°C for 10 min (the duration of PNU-12596 pre-treatment, where required) and subsequently treated with vehicle (control), 50$\mu$M NMDA or 10$\mu$M PNU-282987 for 30 min before denaturing and lysates prepared for Western blot analyses. Typical immunoblots show purified synaptosomes positive for the nerve terminal marker synaptophysin and negative for the postsynaptic marker PSD-95. Activation of $\alpha_7$nAChR significantly increased ERK phosphorylation, unlike NMDAR activation, with no effect on either full-length APP or the loading control $\beta$-tubulin.
activated couple to the downstream activation of ERK (Dineley et al., 2001; Bitner et al., 2007; Steiner et al., 2007; Dickinson et al., 2008; El Kouhen et al., 2009). Purified presynaptic nerve terminals yielded low APP levels, relative to whole cell lysates, further reinforcing the mainly postsynaptic expression of APP, in accordance with Marcello et al., 2007. As detailed above, NMDAR activation induces robust APP processing in primary cortical neuronal whole cell lysates; however, in synaptosomes, NMDA treatment had no effect on APP holoprotein levels (figure 4.5 fourth panel). Also despite the isolation and activation of functional presynaptic α7nAChR, no effect on presynaptic APP levels was observed (figure 4.5 fourth panel), further reinforcing the lack of a measurable α7nAChR-mediated effect on APP processing in mature rodent cortex, as well as primary cortical neurons.

4.2.6 α7nAChR activation has no effect on APP-CTF production

In neurons, the constitutive cleavage of APP under basal/homeostatic conditions is carried out by an α-secretase enzyme (Kuhn et al., 2010) likely to be ADAM-9 (Koike et al., 1999), ADAM-10 (Lammich et al., 1999) or ADAM-17 (Slack et al., 2001), and results in the production of a C-terminal fragment (CTF), termed C83, along with soluble APP-α (sAPPα). Alternatively, under pathological conditions or following APP endocytosis (Cirrito et al., 2008), APP is cleaved by a β-secretase enzyme (BACE-1), and produces the CTF, termed C99, and soluble APP-β (sAPPβ) (Buxbaum et al., 1998). CTFs (8-12kDa) can be phosphorylated at Thr668 and Tyr682 (Sano et al., 2006; Barbagallo et al., 2010; Matrone et al., 2011), which may regulate APP processing (Barbagallo et al., 2010) and APP interaction with adaptor proteins (Schettini et al., 2010), however the definitive physiological role of CTF phosphorylation is yet to be determined. Following CTF production from APP695, by α-/β-secretase, subsequent cleavage occurs by the transmembrane γ-secretase complex (Selkoe and Wolfe, 2007) to yield the APP intracellular cellular domain (AICD) and either Aβ (initial β-secretase cleavage) or p3 fragment (initial α-secretase cleavage). Thus, in order to further assess the potential for α7nAChR-mediated APP processing, APP-CTF profiles were analysed, to gain a more sensitive readout of APP cleavage by α-/β-secretase following α7nAChR activation. Using 16.5% Tris-Tricine SDS-PAGE, primary cortical neuron lysates were immunoblotted using a custom-made primary antibody raised against the C-terminus of human APP to probe the CTF profile. To characterise the profile of CTF bands, commercially available inhibitors
were used to target each secretase enzyme family individually (through TAPI-1-, BSI-, or DAPT-mediated inhibition of $\alpha$-$\beta$-$\gamma$-secretase, respectively) to modulate the relative levels of $\alpha$- and $\beta$-CTFs. Primary cortical neurons were subjected to vehicle, 50µM TAPI-1, 10µM BSI, or 10µM DAPT for 3 h, and the CTF profile compared to 1 h 10µM PNU-1/2 treatment and 20 min 50µM NMDA treatment, figure 4.6A. Under vehicle-treated (control) conditions, primary cortical neurons predominantly produced C83 $\alpha$-CTFs under basal conditions (* lower molecular weight bands), in accordance with previously investigated APP-CTF profiles and constitutive $\alpha$-secretase activity in primary neurons (Hoey et al., 2009, 2013; Kuhn et al., 2010). Inhibition of $\alpha$-secretase with 50µM TAPI-1 ($\alpha$) appeared to have little effect on C99 $\beta$-CTF production, likely due to the broad-spectrum profile of the peptide-based inhibitor and its relatively low efficacy at ADAMs. Conversely, inhibition of $\beta$-secretase with 10µM $\beta$-secretase inhibitor ($\beta$) shifted the CTF profile to reflect enhanced $\alpha$-secretase-mediated APP processing, with increased density of lower molecular weight $\alpha$-CTF bands, as expected. Inhibition of $\gamma$-secretase with 10µM DAPT induced accumulation of CTFs, as they could no longer subsequently be cleaved to yield AICD and A$\beta$/p3 peptides. Thus the initial characterisation of CTF profiles in primary neurons mirrored that of previously published literature (Hoey et al., 2009, 2013; Kuhn et al., 2010) and the effects of $\alpha$7nAChR activation could therefore be compared to NMDA treatment which enhances $\alpha$-CTF production (Hoey et al., 2009; Tampellini et al., 2009; Bordji et al., 2010; Verges et al., 2011; Wan et al., 2012). Neurons were treated with 10µM PNU-120596 and 10µM PNU-282987 for 1 h and lysates analysed for their CTF profile, alongside the secretase inhibitors (figure 4.6A). $\alpha$7nAChR activation for 1 h produced no change in CTF profile over control, indicating $\alpha$7nAChR has no effect on $\alpha$-secretase activity. Conversely, 20 min 50µM NMDA-treated samples mirrored the CTF profile of $\beta$-secretase inhibition, with increased $\alpha$-CTF bands as a result of enhanced $\alpha$-secretase inhibition (figure 4.6A). Previous studies have shown a time-dependent NMDAR-mediated enhancement of $\alpha$-secretase-mediated APP processing, thus a time course of 50µM NMDA treatment was performed to establish the optimal time for $\alpha$-CTF production (figure 4.6B). Neurons were treated with vehicle (control) or 50µM NMDA for up to 2 h, and lysates immunoblotted for APP-CTFs. NMDAR-stimulation produced a time-dependent increase in $\alpha$-CTF.
Figure 4.6: NMDAR-stimulation increases time-dependent APP processing, whilst α7nAChR-stimulation has no effect over basal CTF production. A: APP C-terminal fragment (CTF) profiles under secretase enzyme activity-modulating conditions. Vehicle-treated (control) samples predominantly produced α-CTFs under basal conditions (* bottom bands), whilst inhibition of α-secretase with 50μM TAPI-1 (α), appeared to modestly modulate β-CTF production and inhibition of β-secretase with 10μM β-secretase inhibitor (β) shifted the CTF profile to reflect enhanced α-secretase-mediated APP processing, with increased α-CTF. Conversely, inhibition of γ-secretase with 10μM DAPT induced accumulation of CTFs, as they can no longer subsequently be degraded. Samples with activated α7nAChR (following PNU-120596 and PNU-282987 treatment) showed no change in CTF profile from control and 50μM NMDA-treated samples mirrored the CTF profile of β-secretase inhibition, with increased α-CTF bands. B: NMDAR-stimulation increases time-dependent non-amyloidogenic APP processing. NMDAR activation with 50μM NMDA increased α-CTF bands (* bottom bands), peaking around 20 min and returning to baseline by 2 h.
bands (* lower molecular weight bands, figure 4.6B), peaking around 20 min and returning to baseline by 2 h. Thus confirming primary cortical neurons are capable of stimulated non-amyloidogenic APP processing following NMDAR activation, but not α7nAChR activation.

4.2.7 α7nAChR activation has no effect on β-/γ-secretase activity

An APP-Gal4 gene reporter assay that can be used to very sensitively measure regulated APP processing has been previously described (Hoey et al., 2009, 2013; Cox et al., 2014). The assay requires transfection of primary cortical neurons with four plasmids: pRC-APP-Gal4, encoding full-length human APP695 fused to the yeast transcription factor Gal4 (APP-Gal4) via a glycine linker; pC1-CMV-Fe65; pFR-luciferase, encoding the Firefly luciferase gene and pRL-TKRenilla, encoding the constitutively expressed Renilla luciferase gene. Upon chemical transfection of primary neurons, APP-Gal4 is trafficked to the plasma membrane as an endogenous type I glycoprotein. Following secretase-mediated cleavage of APP-Gal4, AICD-Gal4 is released into the cytoplasm where it is bound directly by Fe65 and promotes AICD stabilisation (Kimberly et al., 2001). Upon translocation to the nucleus, AICD-Gal4 can bind to the promoter of the Firefly luciferase gene promoter of the pFR-luciferase plasmid and induce transcription of the Firefly luciferase gene. Both constitutive Renilla and APP cleavage-mediated Firefly luciferase gene expression is detected utilising a commercial luminescence assay kit (Section 2.2.10) and quantified Firefly luciferase data expressed as a ratio of Renilla luciferase expression, to account for differences in transfection efficiency between primary neurons. This sensitive molecular tool has been extensively characterised in mouse primary cortical neurons (Hoey et al., 2009; Cox et al., 2014) and has been validated as a preferential readout of pro-amyloidogenic β-γ-secretase-mediated APP processing. This APP cleavage luciferase assay was utilised to further probe the potential of α7nAChR-mediated APP processing, in response to α7nAChR activation and compared to γ-secretase inhibition using a pharmacological inhibitor, DAPT. Following 24 h 10μM DAPT treatment, a ~70% reduction in APP-Gal4-dependent luciferase gene expression was found relative to (vehicle-treated) control, indicating the assay was indeed a readout of γ-secretase-mediated APP processing. No significant effect over basal luciferase expression was observed following 6 h α7nAChR activation, by 10μM PNU-120596 and PNU-
Figure 4.7: α7nAChR activation does not affect APP-Gal4 cleavage in a luciferase reporter assay measuring γ-secretase-mediated APP processing. Human APP$_{695}$ fused to the yeast transcription factor Gal4 (APP-Gal4) is cleaved by endogenous γ-secretase, following β-secretase cleavage, to yield AICD-Gal4. AICD-Gal4 binds to the UAS and TATA box of the promoter of the Firefly luciferase plasmid and drives transcription of the luciferase reporter gene. Firefly luciferase signals are normalised to independently transfected Renilla luciferase plasmid signals, to account for transfection efficiency. 5 DIV primary cortical neurons were transfected with pRC-APP-Gal4, pCI-CMV-Fe65, pFR-Luciferase and pRL-TK Renilla plasmids and treated with either vehicle, γ-secretase inhibitor DAPT (10μM) for 24 h or PNU-120596 and PNU-282987 (both 10μM) for 6 h, before Dual-Glo and Stop-and-Glo luciferase activity measurement. DAPT treatment blocked γ-secretase-mediated APP processing, whilst α7nAChR activation had no effect on APP processing. Data expressed as mean fold change of control Firefly:Renilla luciferase activity ratio ± SEM, n=3 independent experiments, with 6 internal repeats for each independent experiment. ** indicates p<0.01, control (white bar) vs DAPT (black bar) subjected to one-way ANOVA with Bonferroni post-test.
282987 treatment. Thus, $\alpha 7nAChR$ activation does not modulate $\alpha /\gamma$ or $\beta /\gamma$-secretase activity and therefore $\alpha 7nAChR$ do not modulate APP processing in cultured cortical neurons. In contrast, NMDAR and AMPAR activation-suppressed $\beta$-$\gamma$-secretase-mediated cleavage of APP, as measured by APP cleavage luciferase assay, has been previously reported by our lab (Hoey et al., 2009, 2013; Cox et al., 2014). This APP cleavage luciferase assay further reinforces the data observed in figures 4.4-4.6; indicating $\alpha 7nAChR$ activation has no effect on secretase-mediated APP cleavage, as detected by APP$_{695}$ and CTF cleavage product immunoblotting.

4.2.8 $\alpha 7AChR$ stimulation does not modulate full length Tau

Neuronal activity is known to regulate APP processing (section 1.8.2.2); similarly, very recent emerging evidence suggests neuronal activity may also control Tau release (Pooler et al., 2013; Yamada et al., 2014) before its subsequent conformation switch (Nakamura et al., 2012), aggregation, seeding and pathological spread (de Calignon et al., 2012; Jucker and Walker, 2013) from cell-to-cell as a prion-like entity (Nakamura et al., 2012; Sanders et al., 2014) before inducing neurodegeneration (Lewis et al., 2001; Lei et al., 2012). The microtubule-stabilising protein Tau is the major constituent of neurofibrillary tangle (NTF) deposits, the hallmark of tauopathies. A$\beta$ exacerbates tau NFT formation, and tau mediates A$\beta$ toxicity thus understanding the interplay between neuronal activity, activation of postsynaptic receptors and A$\beta$-induced Tau/NFT toxicity at synapses is crucial (Ittner et al., 2010). As the relationship between activity-dependent Tau and A$\beta$ production, aggregation and tangle/plaque formation is coming to the fore; we reasoned activation of $\alpha 7nAChR$ might play a role in the activity-dependent regulation of Tau phenotypes. Unpublished data from our lab strongly suggests NMDAR activation can induce re-localisation of Tau (data not shown) from the axon to dendrites (in accordance with Frandemiche et al., 2014). Furthermore, NMDAR activation-induced cleavage and/or dephosphorylation of Tau is evident, which may give rise to the distinct early-stage Tau strains involved in propagation of Tau pathology (Sanders et al., 2014). These effects are all strongly calcium dependent and given $\alpha 7nAChR$-mediate glutamate release to potentially act on NMDAR and AMPAR, it seemed reasonable to hypothesise that $\alpha 7nAChR$ activation might modulate Tau. To this end, the effect of $\alpha 7nAChR$ activation on Tau protein phenotype was examined, and compared with NMDAR activation. To prevent $\alpha 7nAChR$ desensitisation, neurons were treated with 10$\mu$M PNU-120596 for 10 min
prior to a 1 h agonist treatment of PNU-282987 across a range of concentrations (300nM-30μM) and compared to the dose-dependent effect of 1 h NMDA treatment (1-100μM). Lysates were immunoblotted for Tau (figure 4.8) and the resultant molecular weight profiles analysed. Activation of NMDAR for 1 h induced the formation of lower molecular weight bands with 10-100μM NMDA, as a result of cleavage and/or dephosphorylation of Tau isoforms. The NMDA treatment was not excitotoxic, and the same protein concentration was loaded across the gel, and no change in β-tubulin loading control band profile was observed (figure 4.8A). In contrast, activation of α7nAChR with doses as high as 30μM PNU-282987 showed no effect on Tau or β-tubulin (figure 4.8B). PNU-282987 was restricted to a maximal dose of 30μM as higher concentrations activate non-α7nAChR (del Barrio et al., 2011). Therefore, activation of α7nAChR has no effect on either of the two key AD hallmarks, APP and Tau, whereas NMDAR promote both non-amyloidogenic APP processing and activity-dependent modulation of Tau.
Figure 4.8: NMDAR-stimulation induces concentration-dependent Tau cleavage and/or dephosphorylation, whilst α7nAChR-stimulation has no effect on Tau. A: 5-10 DIV primary cortical neurons were treated with vehicle (control, 0μM) or 1, 3, 10, 30 or 100μM NMDA for either 1 h followed by immunoblotting for endogenous full length Tau and the loading control β-tubulin. Concentration-dependent (10-100μM) NMDA treatment revealed the appearance of lower molecular weight Tau bands. B: 5-10 DIV primary cortical neurons were treated with vehicle (control, 0μM) or 0.3, 1, 3, 10 or 30μM PNU-282987 for 1 h following 10 min 10μM PNU-120596 pre-treatment, followed by immunoblotting for endogenous full length Tau and the loading control β-tubulin. Sustained α7nAChR activation had no effect on Tau protein profile, over control.
4.3 Discussion

The aim of this results chapter was to assess the $\alpha_7$-nAChR-mediated contribution to APP processing, with the hypothesis that $\alpha_7$-nAChR activation in primary cortical neurons would directly enhance non-amyloidogenic APP processing in an ERK-dependent manner, or indirectly via $\alpha_7$-nAChR-mediated glutamate release and concomitant activation of postsynaptic glutamate receptors. Accordingly, this chapter has shown primary cortical neurons express predominantly postsynaptic APP, along with the putative $\alpha$-secretases ADAM-10 and ADAM-17; but that $\alpha_7$-nAChR-specific activation had no effect on whole cell APP levels, presynaptic APP levels, CTF production, $\beta-/\gamma$-secretase activity or full length Tau levels, when compared to NMDAR activation.

4.3.1 $\alpha_7$-nAChR activation does not modulate APP processing

$\alpha_7$-nAChR-mediated cellular activation with PNU-282987, in the presence of the PAM PNU-120596, is insufficient to promote non-amyloidogenic APP processing, as $\alpha_7$-nAChR activation had no effect on full-length APP protein levels or APP cleavage product CTF levels. Given the limitations of low sensitivity biochemical immunoblotting, the highly sensitive measurement of $\beta-/\gamma$-secretase-regulated APP processing by APP cleavage luciferase assay was used to validate the lack of $\alpha_7$-nAChR effect. Again, $\alpha_7$-nAChR activation showed no effect on $\beta-/\gamma$-secretase activity-dependent production of Gal4-AICD, reinforcing the negligible effect on APP processing. Conversely, the majority of studies have shown the non-selective nAChR agonist nicotine enhances non-amyloidogenic sAPP$\alpha$ release from neuron-like cell lines (Kim et al., 1997; Lahiri et al., 2002; Mousavi and Hellström-Lindahl, 2009; Nie et al., 2010). This discrepancy may have arisen due to the cell lines expressing high levels of $\alpha_7$- and non-$\alpha_7$ nAChR, which are capable of coupling to non-amyloidogenic APP processing via nAChR-mediated calcium-influx. In contrast, the low physiological expression level of $\alpha_7$-nAChR within the primary cortical neurons, coupled with the spatial separation of presynaptic $\alpha_7$-nAChR being segregated from the large pool of postsynaptic APP may explain the opposing findings. Nonetheless, using synaptosomes, this study shows $\alpha_7$-nAChR activation cannot couple directly to APP processing at the presynaptic nerve terminal. Furthermore, the lack of $\alpha_7$-nAChR-mediated non-amyloidogenic processing is in agreement with the in vivo use of the
α7-selective agonist A-582941, in the treatment of 3xTg-AD transgenic mice, which display robust AD pathology and cognitive deficits. A-582941-mediated α7nAChR activation had no effect on AD pathology (Medeiros et al., 2014), in accordance with native physiological α7nAChR having no effect on APP processing and thus plaque deposition.

Furthermore, published data from α7nAChR-expressing SH-SY5Y and PC12 cell lines (Hellström-Lindahl et al., 2000; Hu et al., 2008), in vivo in wildtype and AD transgenic Tg2576 mice and validated in α7nAChR-knock-out mice, showed α7nAChR-selective activation reduced Tau phosphorylation (Bitner et al., 2009), through reduced GSK-3β activation (Cavallini et al., 2013). Conversely, data presented in this chapter highlighted α7nAChR activation in primary neurons had no effect on Tau phosphorylation. This contrasting effect may again be the result of a difference in α7nAChR expression level between cell types, especially following chronic in vivo activation of α7nAChR following a 2-week infusion of α7nAChR-selective agonist (Bitner et al., 2009). Chronic nAChR agonist treatment dramatically up-regulates nAChR receptor expression (Peng et al., 1994; Molinari et al., 1998; Liu et al., 2001; Vallejo et al., 2005; Fu et al., 2009; St John, 2009; Goriounova and Mansvelder, 2012; Mazzo et al., 2013), and subsequently leads to up-regulation of ionotropic glutamate receptor expression, following enhanced nAChR-mediated glutamate release both in vitro and in vivo (Risso et al., 2004; Wang et al., 2007; Lozada et al., 2012). Increased ionotropic glutamate receptor expression and activation thus modulates and attenuates Tau phosphorylation, indirect of subsequent nAChR activation.

4.3.2 NMDAR activation promoted non-amyloidogenic APP processing

Numerous previous studies have reported an NMDA-induced effect on APP processing, although whether NMDAR activation mediates non-amyloidogenic or pro-amyloidogenic APP processing remains somewhat controversial. Using SDS-PAGE and Western blot analyses; NMDAR activation was shown to reduce the levels of full length APP_{695}, indicative of cleavage, whilst also enhancing the production of α-CTF, thus promoting non-amyloidogenic APP processing. The findings presented here are in agreement with previous findings from our lab (Hoey et al., 2009), that NMDAR activation promotes non-amyloidogenic APP processing, and also in agreement with
independent findings (Tampellini et al., 2009; Bordji et al., 2010; Verges et al., 2011; Rush and Buisson, 2014).

Conversely, previous studies have reported functional APP processing and Aβ release from synaptosomes (Kim et al., 2010b), mediated by activation of metabotropic glutamate receptors. Given this study showed nerve terminal activation of ionotropic NMDA-type glutamate receptors had no effect on APP processing, this suggests NMDAR-mediated APP processing requires intact postsynaptic NMDAR-associated components (for downstream signalling cascades and/or direct modulation of postsynaptic APP cleavage); and further reinforces the previous evidence of postsynaptic NMDAR-mediated non-amyloidogenic APP processing (Hoey et al., 2009; Tampellini et al., 2009; Bordji et al., 2010; Verges et al., 2011; Rush and Buisson, 2014).

Furthermore, synaptic AMPAR and NMDAR activation both in this study and others in primary neurons indicate activation of ionotropic glutamate receptors modulates Tau phosphorylation (Mattson, 1990; Pooler et al., 2013) and cleavage (Garg et al., 2011). As with APP processing, memantine-mediated blockade of extrasynaptic NMDAR attenuates Aβ-induced tau hyperphosphorylation and toxicity (Song et al., 2008). This reinforces the protective effect of synaptic NMDAR activation, over the toxic repercussions of extrasynaptic NMDAR activation.

4.3.3 Non-amyloidogenic APP processing is not guaranteed following activity-dependent ERK phosphorylation

Given the data described in chapter 3, treatment with PNU-282987 and PNU-120596 selectively activates α7nAChR in primary cortical neurons, resulting in increased ERK phosphorylation. Thus, α7nAChR-induced cellular activation and resultant ERK phosphorylation is insufficient to induce APP processing, in contrast to ERK-dependent non-amyloidogenic APP processing following activation of other ligand-gated ion channels, such as NMDAR (Mills et al., 1997; Desdouits-Magnen et al., 1998; Kamenetz et al., 2003), AMPAR (Hoey et al., 2013) and P2X7 receptors (Delarasse et al., 2011); whereas mAChR-mediated non-amyloidogenic APP processing has been shown to be ERK phosphorylation-independent (Cissé et al., 2011). Furthermore, in accordance with the opposing effects of non-amyloidogenic versus pro-amyloidogenic APP processing following synaptic versus extrasynaptic NMDAR activation, a similar effect on ERK phosphorylation is also well documented. Synaptic NMDAR activation enhances ERK activation, whilst extrasynaptic NMDAR
activation inactivates ERK (Ivanov et al., 2006; Hoey et al., 2009). This further reinforces and validates the experimental conditions used in this thesis to characterise and investigate \( \alpha \)7nAChR- and NMDAR-dependent ERK-mediated non-amyloidogenic APP processing.

### 4.3.4 Summary

When taken together, the findings of this chapter are relevant as contrary to published literature; activation of \( \alpha \)7nAChR cannot promote APP processing. Furthermore, functional nerve terminal \( \alpha \)7nAChR were spatially separated from the majority of neuronal APP, localised postsynaptically. Following activation of synaptosome-isolated nerve terminal \( \alpha \)7nAChR, ERK phosphorylation resulted but could not directly promote APP processing. In whole-cell primary cortical neurons, \( \alpha \)7nAChR activation was incapable of directly modulating APP processing, nor indirectly via a validated non-amyloidogenic APP processing mediator: activation of postsynaptic ionotropic glutamate receptors.
Chapter 5

5. α7nAChR modulation of microglial behaviour
5.1 Introduction

5.1.1 α7nAChR and modulation of microglial function

Microglia, derived from erythromyeloid precursors, are found uniformly distributed throughout the CNS and form the innate defence as the resident CNS immune cells (Ginhoux et al., 2010; Prinz and Priller, 2014). Microglia are highly versatile in assuming either a protective or neurotoxic state in response to environmental changes, through switching from their default ‘resting’ state of scanning the local environment, to a specialised ‘activated’ state in a diseased environment (Gordon, 2003; Mosser and Edwards, 2008; Kettenmann et al., 2013), where they proliferate to expand the population of immunoresponsive cells (Gómez-Nicola et al., 2013). Recent data suggests there are not merely two phenotypic states, as originally perceived, but a spectrum of microglial activation states (Xue et al., 2014). Activated microglia can immediately remove damaged cells and synapses by phagocytosis, termed ‘phagoptosis’ and ‘synaptic stripping’, respectively, along with foreign and infectious agents. A balance must be struck with immune cell phagocytic activity (Brown and Neher, 2014), with basal phagocytosis processes controlling debris and bacterial clearance, whilst overactive phagocytosis induces widespread neuron death (Neher et al., 2011; Emmrich et al., 2013). Neuron-secreted signalling molecules and downstream microglial cellular cascades result in neuron-microglia cellular contact and induction of phagocytosis, which can influence the pathological processes involved in disease onset and progression. Understanding the distinct microglial-neuronal communications involved in regulating CNS development during synaptogenesis (Parkhurst et al., 2013), synapse pruning (Kettenmann et al., 2013) and synapse maturation (Salter and Beggs, 2014) is crucial for targeting aberrant glia-neuron signalling observed in chronic disease (Zhan et al., 2014). A recent study highlighted early (24 h post-injury) microglia-neuron contact following CNS damage, whilst subsequent infiltrating macrophages were shown to persist (up to 42 d post-injury). This suggests microglia phagocyte initial damaged material, whilst infiltrating peripheral macrophages may contribute to the secondary CNS damage following injury (Greenhalgh and David, 2014). Using RNA sequencing, the microglial transcriptome was shown to change over the course of aging, with transcripts shifting from an initial endogenous ligand recognition phase to adopt a neuroprotective microbe recognition and host defence state (Hickman et al., 2013), thus indicating a heightened capacity for phagocytosis with age. Microglial phagocytosis controls CNS
homeostasis, through removal of cellular debris and neurotoxic foreign contaminants. Reduced *in vitro* and *in vivo* microglial phagocytosis results in enhanced inflammation and neurodegeneration, with impaired phagocytic capacity observed in AD patient brain samples (Lucin *et al.*, 2013). Excessive release of microglial pro-inflammatory cytokines reduced Aβ phagocytosis (Koenigsknecht-Talboo and Landreth, 2005), further emphasising the need to understand and subsequently control microglial hyperactivation in chronic neurodegenerative disease states.

 Activation of microglial α7nAChR has been shown to reduce cytotoxicity, mediated by various extracellular insults (Kawamata and Shimohama, 2011). Much of the initial literature to date has focussed on α7nAChR-mediated attenuation of Aβ toxicity, through enhanced microglial phagocytosis, to explain the anti-inflammatory properties of α7nAChR activation. Accordingly, excessive levels of Aβ result in microglial conversion to the ‘activated’ state. Microglial phenotype conversion results in production and release of neurotoxic cytokines, chemokines and reactive oxygen species, with deleterious effects on the CNS. Pro-inflammatory cytokine release triggers Tau hyperphosphorylation (Rojo *et al.*, 2008), with implications for the etiology of AD, as previously discussed. Interestingly, α7nAChR immunoreactivity was observed to increase in glial cells throughout AD, representative of a compensatory mechanism to lower Aβ (Teaktong *et al.*, 2003). Activation of α7nAChR prevented Aβ-induced reactive oxygen species secretion by microglia (Moon *et al.*, 2008). Furthermore, the AChE inhibitor donepezil reduced pro-inflammatory microglial activation, with attenuated TNFα and reactive oxygen species production and release (Hwang *et al.*, 2010). The α7nAChR-selective partial agonist GTS-21 restored the phagocytic activity of compromised macrophages; to enable enhanced bacterial clearance (Sitapara *et al.*, 2014), whilst the AChE inhibitor galantamine has also shown enhanced microglial phagocytic activity, with increased Aβ clearance (Takata *et al.*, 2010).

 The current favoured signalling mechanism behind microglial phagocytosis involves the ligand-activated nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ, Heneka and Landreth, 2007), which acts in a metabolic cycle to increase brain apolipoprotein E (ApoE) levels (Mandrekar-Colucci *et al.*, 2012), with ApoE promoting the clearance of unwanted cellular material, such as Aβ (Heneka *et al.*, 2005). Both *in vitro* and *in vivo* PPARγ activation enhanced microglial phagocytosis and resulted in reduced soluble and insoluble Aβ in the cortex and hippocampus of
AD transgenic mice (Yamanaka et al., 2012), inhibited excessive pro-inflammatory cytokine gene expression and reduced Aβ- and cytokine-mediated neurotoxicity (Heneka and Landreth, 2007) and improved cognition (Cramer et al., 2012). In vivo application of a PPARγ agonist improved hippocampal-dependent cognitive deficits in humans and ameliorated cognitive deficits in AD transgenic mice. The mechanism of cognitive enhancement was purported to be through convergence of PPAR signalling and the MAPK-ERK cascade, strongly implicated in memory consolidation (section 1.4.2.3). PPAR agonism induced a PPARγ-phospho ERK complex, with PPAR activation facilitating recruitment of activated ERK (Jahrling et al., 2014).

Based on these published data, this chapter aims to show α7nAChR activation modulates microglial phagocytic behaviour. The results described within this chapter involve the characterisation of primary cortical microglia, analyses of functional expression of α7nAChR with respect to ERK phosphorylation and determination of microglial α7nAChR activation-induced phagocytosis.
5.2 Results

5.2.1 Primary cortical glia mature in vitro, with microglia adopting a basal ‘resting’ phenotype

Many studies attempting to understand CNS inflammation and the molecular mechanisms underlying neurodegeneration, use cell lines or microglia derived from embryonic tissue. As such, these in vitro models are less suitable in the study of aging and neurodegeneration (Stansley et al., 2012). In this study, we used neonatal P1-P2 CD1 mouse pups, to isolate primary mixed glia (astrocytes and microglia) from the cortex, which were grown and matured in vitro for 4-6 weeks (Saura et al., 2003). Photographed phase contrast microscopy of the mixed glial population revealed cellular maturation and proliferation in vitro over time (figure 5.1). The time-lapse sequence of images revealed significant cellular proliferation between 1 and 6 DIV (figure 5.1A and B, respectively), with a confluent monolayer by 14 DIV (figure 5.1C) that became dense by 22 DIV (figure 5.1E). Analysis of the surface characteristics of the culture revealed distinct morphologies at different microscopic focal planes. The top layer of cells possessed a round, flat and cobblestone morphology, typical of resting astrocytes (figure 5.1C and E), whilst the bottom layer of cells possessed the irregular, spiked and ramified morphology of resting microglia, (figure 5.1E) (Glenn et al., 1992) clearly visible at higher magnification (figure 5.1F).

5.2.2 Microglia are purified from a mixed glial population through mild trypsin incubation

Upon microglial cells reaching confluency, following 4-6 weeks in vitro, the contaminating astrocytes were removed from on top of the microglia through mild trypsin incubation. 0.0625% trypsin application onto mixed glia (figure 5.2A) resulted in the detachment of an intact layer of cells, starting at the periphery of the well and spread across the entire monolayer with time (figure 5.2B). The detached monolayer contained all the astrocytes and lifted away from the underlying microglia in one sheet (figure 5.2B, arrow). The trypsin isolation procedure was minimally invasive and resulted in a highly enriched and dense layer of microglia on the bottom of plastic wells or on glass coverslips (figure 5.2C).
Figure 5.1: Morphological assessment of primary cortical mixed glia over time in vitro. A: Freshly isolated and plated glial cells following 1 DIV. B: Proliferation gives rise to a mixed glial monolayer by 6 DIV. C: Astrocyte confluency was reached by ~14 DIV, with a dense and uniform top layer of astrocytes visible. D: A bottom layer of microglia was clear by 14 DIV. E: With increasing time (22 DIV), the astrocyte layer became increasingly dense. F: High magnification of 22 DIV microglia, beginning to reach confluency. Scale bars represent 20µm.
Figure 5.2: Purification of microglia from a mixed glial population. A: Confluent mixed glial cells following 35 DIV. B: Trypsin-EDTA (0.0625%) solution in DMEM-F12 medium was incubated on mixed glia for 15-25 min at 37°C, and the top astrocyte cell layer detached as a sheet (arrow). C: The remaining microglia monolayer was left in mixed glia-conditioned medium for 24 h, before use in immunofluorescence, biochemical assays or Western blotting.
5.2.3 Purified microglia are free from astrocytic contaminants and display microglia-specific protein expression

Both mixed glia and purified microglia were subjected to immunofluorescence staining, to determine expression of cell type-specific markers. Astrocytes are the major glial cell present within the CNS and selectively express glial fibrillary acidic protein (GFAP) (Brahmachari et al., 2006), figure 5.3A. Following trypsinisation of the mixed glial population, resulting in microglial purification and isolation, GFAP expression was completely abolished (figure 5.3B), indicating no contaminating astrocytes were present in the remaining microglial population. Microglia selectively express the β-integrin variant cluster of differentiation molecule 11B (CD11b) (Roy et al., 2006), figure 5.3C. Primary cortical microglia were positive for CD11b expression, which was localised to the cytoplasm and expressed throughout population of cells, indicating 100% microglial purity.

5.2.4 Primary microglia adopt a reactive ‘activated’ phenotype following exposure to LPS

To determine the reactive nature of the primary microglia, the cells were exposed to the bacterial endotoxin lipopolysaccharide (LPS, 100ng/ml) for 20 min. LPS is a widely used and powerful activator of microglial cells both in vitro and in vivo (Sun et al., 2008; Schmid et al., 2009; Chen et al., 2012), with LPS application triggering pro-inflammatory gene expression, signalling cascades, pro-inflammatory cytokine release and cell death. To establish the functional responsiveness of the primary cortical microglia, LPS was used to examine the reactive phenotype of the cells through their potential to undergo well-characterised shape changes from the ‘resting’ to ‘activated’ state (Pocock and Kettenmann, 2007). Under basal conditions, microglia appear classically ramified through both phase contrast microscopy (figure 5.4A) and confocal immunofluorescence (figure 5.4C), with microglial processes constantly surveying their surroundings. Following microglial activation with LPS, the cells undergo the characteristic shape change transformation and subsequently appear ameboid (figure 5.4B and D), indicative of responsive and functional primary cortical microglia.
Figure 5.3: Purified primary microglia are free of astrocytic contaminants and express microglia-specific markers. A: 38 DIV mixed glial populations were subjected to single immunofluorescence staining, revealing GFAP (green) expression throughout the cytoplasm of approximately one third of the DAPI-positive total cell population. B: Purified microglia were negative for GFAP expression, indicating no astrocyte contamination post-purification. C: Immunofluorescence of 38 DIV purified microglia exhibited CD11b expression (green) throughout the cytoplasm of all DAPI-positive cells, indicating a pure microglial population. All glial cells were negative for the neuron-specific markers Tau and NeuN (data not shown). All nuclei were counter stained with DAPI (blue) and scale bars show 20μm.
Figure 5.4: LPS exposure of primary microglia induces a reactive phenotype. A: Following purification and under homeostatic in vitro conditions, microglia appeared highly ramified with spiked processes by phase contrast microscopy. B: Following 100ng/ml LPS treatment for 20 min, microglia appeared to adopt a round and amoeboid morphology. C: Single immunofluorescence staining of untreated microglia revealed APP expression (green) throughout the cytoplasm, with an additional strong peri-nuclear localisation. D: LPS-induced cellular activation revealed the microglial cell body increases in roundness, indicative of an activated microglial phenotype. Scale bars show 20µm.
5.2.5 Primary microglia are functional and express $\alpha_7n$AChR that couple to ERK phosphorylation

To test the hypotheses that $\alpha_7n$AChR activation is capable of modulating microglial behaviour, demonstrating functional $\alpha_7n$AChR in vitro was essential. Changes in ERK phosphorylation status have been documented following glial cell activation, but its role is yet to be well defined in terms of microglial inflammatory cell behaviour. The effect of glial $\alpha_7n$AChR activation has been shown to both enhance (Koyama et al., 2004; Wang et al., 2013) and reduce (Shytle et al., 2004; Cui and Li, 2010) ERK phosphorylation, and is thus yet to be defined thoroughly. To establish the functional nature of the $\alpha_7n$AChR expressed by the primary cortical microglial model system, assessment of the ERK-coupling capacity of these receptors was carried out. 28-50 DIV microglia were subjected to combinatorial treatment with 10$\mu$M PNU-282987 for up to 1 h, following a 10 min pre-incubation with PNU-120596, and lysates immunoblotted for dual-phosphorylated (Thr202 and Tyr204) active pERK2 and total ERK2. Treatment with either the PAM (PNU-1) or agonist (PNU-2) alone had no significant effect over vehicle-treated control (figure 5.5A). However, PNU-1 potentiated $\alpha_7n$AChR activation with PNU-2 caused a rapid and significant ~18-fold increase in ERK2 phosphorylation, over vehicle-treated control samples (figure 5.5A). Over a time course of 1 h, ERK phosphorylation was significantly elevated following acute (3 min) PAM-potentiated $\alpha_7n$AChR activation, with phosphorylation status returning to baseline levels over longer periods of treatment (10-30 min). Interestingly, following 60 min $\alpha_7n$AChR activation, a trend towards an increase in ERK phosphorylation was observed (~10-fold), which can be attributed to a non-$\alpha_7n$AChR-mediated effect, as it is also observed following $\alpha$BTX-mediated inhibition of $\alpha_7n$AChR (figure 5.5B). To establish the selectivity of the $\alpha_7n$AChR activation-dependent ERK phosphorylation, microglia were pre-treated for 20 min with $\alpha$BTX (100nM), before application of PNU-120596 and PNU-282987 for up to 1 h (figure 5.5B). Application of $\alpha$BTX alone had no effect on basal levels of ERK phosphorylation, indicating the functional population of $\alpha_7n$AChR were not modulating baseline microglial signalling and activation state. $\alpha$BTX-mediated inhibition of $\alpha_7n$AChR currents significantly abolished PNU-282987-mediated ERK phosphorylation, returning phospho-ERK to baseline level, reinforcing the selectivity of $\alpha_7n$AChR-mediated microglial activation. Again, following 60 min $\alpha_7n$AChR
Figure 5.5: Cellular activation and stimulation of α7nAChR couples to ERK phosphorylation in 28-50 DIV primary microglia.

A: PNU-282987 treatment in combination with PNU-120596 induces rapid ERK phosphorylation. B: PNU-mediated ERK phosphorylation is blocked by αBTX. C: Cellular activation with treatment with the bacterial endotoxin LPS induces rapid ERK phosphorylation. Protein band densitometry quantification expressed as the ratio of pERK2 to total ERK2 and indicates a significant time-dependent elevation in MAP kinase (ERK) activation. Data expressed as mean fold change of control pERK2:ERK2 ratio ± SEM, n=3 independent experiments. Representative ppERK1/2 and ERK2 blots for each experiment A-C are shown. ** indicates p<0.01, control (white bar) vs agonist/PAM treatment (grey bars) subjected to one-way ANOVA with Bonferroni post-test.
activation, even in the presence of αBTX, a trend towards a sight increase in ERK phosphorylation was observed, further reinforcing an α7nAChR-independent secondary effect of prolonged α7nAChR activation (figure 5.5B). To establish the selectivity of microglial activation and downstream ERK phosphorylation, 28-50 DIV microglia were subjected to treatment with 100ng/ml LPS for up to 1 h, and lysates immunoblotted for dual-phosphorylated (Thr202 and Tyr204) active pERK2 and total ERK2. LPS treatment is a well-characterised immune cell activator, but results in the release of pro-inflammatory cytokines. Acute LPS treatment for 3 min increased ERK phosphorylation ~20-fold over vehicle-treated control, whilst longer time points of 30-60 min displayed a trend towards increased ERK activation (figure 5.5C). Furthermore, 50μM NMDA treatment for up to 1 h had no effect (data not shown) on microglial ERK activation, consistent with a lack of functional NMDAR on microglia (Pocock and Kettenmann, 2007) and reinforcing the selectivity of the α7nAChR-mediated cellular activation.

5.2.6 α7nAChR activation promotes microglial phagocytosis

Phagocytosis is a specialised form of endocytosis by which large particles are ingested by specialised cell types (macrophages, neutrophils and microglia). Phagocytosis is a triggered process that requires activated receptors at the cell surface initiating a signalling cascade into the cell interior to start the process. The molecular mechanisms underlying phagocytosis are yet to be fully identified, but can occur by either a non-classical receptor-mediated mechanism via β1-integrins, or by classical phagocytosis mechanisms via Ig receptors or complement receptors (Koenigsknecht and Landreth, 2004). The phagocytic capacity of primary microglia was assessed by ingestion of fluorescently labelled beads (Hassan et al., 2014) upon LPS-mediated cellular activation or stimulation of α7nAChR. Under basal vehicle-treated control conditions microglia phagocytosed 3 beads per cell, (figure 5.6A and 5.6B) whilst LPS treatment increased phagocytosis ~2.5-fold, indicative of responsive and activated microglia (figure 5.6A). Treatment with PNU-120596 or PNU-282987 alone had no significant effect on phagocytosis, reinforcing the previous observation for the requirement for PAM-potentiated α7nAChR activation to induce cellular activation and ERK phosphorylation. Combinatorial treatment with both PNU-1 and PNU-2 enhanced bead phagocytosis by 4-fold (figure 5.6A and 5.6C), in agreement with analogous published literature. For example, galantamine-mediated α7nAChR
activation enhanced microglial phagocytosis of Aβ, and depletion of the α7nAChR-selective agonist choline reduced Aβ phagocytosis (Takata et al., 2010). Furthermore, α7nAChR activation has previously been shown to enhance macrophage phagocytosis (Lee and Vazquez, 2013; Sitapara et al., 2014). Application of αBTX had no effect on basal levels of phagocytosis, when applied alone, but completely abolished the α7nAChR-mediated phagocytosis with PNU-120596 and PNU-282987, highlighting the specificity of the α7nAChR effect (figure 5.6A). The contribution of phagocytosis versus endocytosis was determined through blocking endocytosis with dynasore. Dynasore is a cell-permeable inhibitor of dynamin GTPase activity (Macia et al., 2006), which blocks both dynamin-1 and dynamin-2, required for clathrin-mediated endocytosis. Dynasore-mediated inhibition of endocytosis is well characterised (Macia et al., 2006; Hua et al., 2013; Xu et al., 2013). Pre-treatment with 100μM dynasore prior to bead and drug application was not sufficient to attenuate α7nAChR-mediated phagocytosis, suggestive that the bead uptake into microglia is not via endocytosis. Dynasore has previously been shown to reduce macrophage phagocytosis of parasitic protozoa (Barrias et al., 2010) and inhibits the formation of phagocytic cups in testicular Sertoli cells (Otsuka et al., 2009), but has not been tested as an inhibitor of microglial phagocytosis.
Figure 5.6: LPS-activated and α7nAChR-stimulated microglia display increased phagocytic behaviour. A: 28-60 DIV primary microglia were treated with fluorescently labelled latex beads for 2 h in 0.1% BSA in PBS, supplemented with vehicle (control), 100ng/ml LPS, 10μM PNU-120596, 10μM PNU-282987, 100nM αBTX or 100μM dynasore, followed by fixation and DAPI counter-staining. Data expressed as number of beads ingested per cell ± SEM, validated by z-stack image analysis, n=3-5 independent experiments with 40+ cells per field of view. * indicates p<0.05, ** p<0.01, *** p<0.005, **** p<0.001, control (white bar) vs LPS treatment (black bar) or vs PNU-1/2 ± inhibitor (grey bars), subjected to one-way ANOVA with Bonferroni post-test. B: Representative fluorescence microscopy image of vehicle-treated (control) primary microglial bead uptake. C: Representative fluorescence microscopy image of PNU-1/2-treated bead uptake into microglia.
5.3 Discussion

The previous results chapters of this thesis have shown that despite expression of α7nAChR at the glutamatergic synapse, neuronal α7nAChR activation had no effect on APP processing. Given the extensive literature on α7nAChR-mediated neuroprotective effects in cognitive decline, learning and memory, aging, AD and inflammation, understanding the functional effects of α7nAChR activation in all CNS cell types is important. Accordingly, this chapter aimed to show α7nAChR activation could modulate microglial behaviour and as such, assessment of α7nAChR-mediated microglial phagocytosis was undertaken. Characterisation of the primary microglial model system highlighted the specificity of the microglial cell type and the validity of the purification protocol in eliminating astrocyte contamination. Further analysis showed the model system was able to switch from a ‘resting’ to ‘activated’ morphological phenotype, which when coupled with α7nAChR-mediated ERK phosphorylation highlighted the presence of functional cell surface receptors on primary microglia. α7nAChR stimulation resulted in enhanced microglial phagocytosis, although the precise mechanism underling α7nAChR-mediated modulation of microglial behaviour is still unclear.

5.3.1 Trypsinisation of a primary cortical mixed glial population gives rise to pure microglia

Using conditions to promote a glial cell fate, both astrocytes and microglia were isolated from postnatal mouse cortex and sustained in vitro for long-term use. Cells proliferated in a time-dependent manner and by ~1 week in vitro a confluent layer of astrocytes was observed, with microglia reaching confluency by ~4 weeks in vitro. The cells adopted the classic morphology of round, flat and cobblestone shaped astrocytes and smaller irregular microglia with ramified processes, consistent with published glial culture morphometric characteristics (Alliot et al., 1991; Kettenmann and Hanisch, 2011; Torres-Platas et al., 2014). The purification protocol used (optimised from Saura et al., 2003) isolated and enriched primary cortical microglia, by using mild trypsin to detach astrocytes in one sheet from on top of the microglia. Commonly used alternative isolation procedures for primary microglia include density gradient centrifugation of mixed glial populations (Moussaud and Draheim, 2010) and shaking off and collecting loosely adherent microglia from mixed glial cultures (Ni and
Aschner, 2010), but result in a significantly lower yield of microglial cells (Saura et al., 2003), making these methods less favourable. Furthermore, the trypsin purification produced negligible astrocyte contamination, as judged by GFAP immunofluorescence, with retained residing cells shown to be microglia through expression of microglia-specific CD11b immunoreactivity, reinforcing the benefit of this culture method in producing high yields of pure primary microglia.

5.3.2 Primary cortical microglia are responsive and express functional α7nAChR

Primary microglia displayed a ramified morphology under resting conditions, and following an inflammatory activation signal, such as LPS, the cells adopted a round, large and flat amoeboid morphology, in accordance with previously published data (abd-el-Basset and Fedoroff, 1995), indicative of functional and responsive microglia. Upon inflammatory activation by LPS, microglia retracted and withdrew process branches, this process enables a transition to a motile state wherein the amoeboid shape aids locomotory actions required for CNS surveillance and tracking of pathogens (Stence et al., 2001). Transition from ramified to amoeboid morphology was not immediate, and an amoeboid state was not fully adopted following 20 min LPS treatment. Transition to a fully ‘activated’ state has been shown to require complete resorption of microglial cell processes before a fully motile amoeboid state can be adopted (Stence et al., 2001). Furthermore, LPS treatment induced acute ERK phosphorylation, further indicative of responsive microglia with functional cell surface receptors that are capable of transducing extracellular inflammatory signals to intracellular cell signalling cascades. Along with ERK activation, LPS treatment has also been shown to activate pro-inflammatory pathways, such as the p38 MAPK cascade (Pocock and Kettenmann, 2007; Bordjji et al., 2010) that induce microglial hyperactivation, cytokine release and subsequent neuronal cell death. As both in vitro and in vivo microglia can adopt either pro-inflammatory or protective behaviours, mediated via activation of distinct cell surface expressed receptor populations, this highlights the critical need for further understanding of the functionality of α7nAChR in primary microglia, as α7nAChR activation has been shown to reduce microglial activation, cytokine release and inflammation. Having displayed the expression of functional α7nAChR that selectively couple to ERK phosphorylation, this reinforces the use of primary microglia as a model system to study the mechanisms underlying...
heterogeneous cell population activation, inflammation and their roles in neurodegenerative disease onset and progression.

5.3.3 Primary cortical microglia are a good model system to study inflammatory cell phagocytic behaviour

Using a simple bead uptake assay, the phagocytic potential of primary microglial was defined and was significantly enhanced by 2 h exposure to LPS and activation of α7nAChR, blocked by the α7nAChR-selective antagonist αBTX. Preliminary data highlighted the phagocytosis was time-dependent (data not shown, as per Hassan et al., 2014) and an optimal 2 h time point was adopted to probe maximal microglial phagocytosis. Published literature has shown microglial phagocytosis required at least 30 min to form vacuoles before engulfment of foreign matter (Stence et al., 2001), in accordance with the 2 h timescale required for α7nAChR-mediated bead phagocytosis. The use of dynasore to block endocytosis is now a commonly used pharmacological tool in understanding cellular trafficking dynamics. The lack of a dynasore-mediated attenuating effect on phagocytosis highlights the distinct mechanisms underlying these cellular processes. Previous published data showed macrophage endocytosis required both clathrin and dynamin, whilst phagocytosis was unaffected by inhibition of dynamin or by reducing clathrin expression, conversely phagocytosis required actin assembly (Tse et al., 2003). This reinforces the relevance and selectivity of the observed α7nAChR-mediated bead uptake as a phagocytosis event.

5.3.4 Summary

When taken together, the findings of this chapter are relevant as selective activation of microglial α7nAChR enhanced both ERK phosphorylation and phagocytosis. Phagocytosis has previously been shown to be impaired in AD, through a loss of beclin-1 expression, which directly impaired phagocytic capacity (Lucin et al., 2013). Reduced phagocytosis results in increased cellular debris deposits, enhancing inflammation and resulting in neurodegeneration. Conversely, enhanced microglial phagocytosis, via PPARγ agonism, ERK activation and PPARγ-phospho ERK complex formation improved cognition in AD transgenic mice through enhanced Aβ phagocytic clearance (Cramer et al., 2012; Mandrekar-Colucci et al., 2012; Yamanaka et al., 2012; Jahrling et al., 2014). Therefore, having shown α7nAChR
activation can induce ERK phosphorylation and also enhance phagocytosis, this reinforces pharmacological activation of $\alpha 7nAChR$ is an excellent clinical target for cognitive enhancement, memory consolidation and A$\beta$ clearance in AD.
Chapter 6

6. General Discussion
6. Discussion

This thesis aimed to address the hypotheses that α7nAChR activation would both enhance non-amyloidogenic APP processing in primary cortical neurons and modulate inflammatory cellular behaviour of primary cortical microglia. Using a combination of immunofluorescence imaging, dual emission microfluorimetry and immunoblotting techniques, expression of APP and functional α7nAChR were demonstrated in primary cortical neurons. However, immunoblotting for full-length APP and APP C-terminal cleavage fragments, coupled with a highly sensitive APP cleavage luciferase reporter assay revealed that activation of α7nAChR with a subtype-selective agonist and PAM had no effect on APP processing, despite robust calcium influx and ERK phosphorylation. Stimulation of α7nAChR with a subtype-selective agonist and PAM also resulted in robust ERK phosphorylation in primary cortical microglia. Following α7nAChR activation and ERK phosphorylation, microglia displayed enhanced phagocytic behaviour, as determined through a bead-uptake assay, via a mechanism distinct from endocytosis. This suggests α7nAChR activation selectively regulates immunoresponsive behaviour in microglia. Together, these data provide no evidence to support the concept that targeting α7nAChR could be used to promote non-amyloidogenic APP processing in primary cortical neurons, but do support the ability of α7nAChR to promote neuroprotective phagocytic behaviour in microglial cells, figure 6.1.

6.1 α7nAChR-dependent regulation of APP processing

Over the last ~20 years, a number of research groups have shown activation of α7nAChR enhances non-amyloidogenic APP processing; resulting in increased sAPPα release (Kim et al., 1997; Lahiri et al., 2002; Mousavi and Hellström-Lindahl, 2009; Nie et al., 2010), reduced Aβ release (Hellström-Lindahl et al., 2004; Hedberg et al., 2008; Nie et al., 2010) and reduced plaque deposition (Nordberg et al., 2002). The results from primary cortical neurons presented here conflict with these findings; by showing α7nAChR activation has no clear effect either at increasing α-secretase activity or reducing β-/γ-secretase activity. Due to the nature of the model system, primary cortical neurons can be considered more physiologically relevant than the ‘neuron-like’ cell lines and overexpressing transgenic models used in previous studies. For example, chronic treatment of PC12 cells with the non-selective agonist
nicotine, increased sAPPα levels, derived from cleavage of the APP770 isoform (Kim et al., 1997), whilst SH-SY5Y cells chronically treated with nicotine also enhanced secretion of sAPPα, which was not blocked by the α7-selective antagonists MLA and αBTX (Mousavi and Hellström-Lindahl, 2009), suggestive of a contribution of other nAChR subtypes. Furthermore, transfected SH-EP1 cells stably overexpressing α7nAChR and human APP695 were treated with nicotine for 24 h, increasing sAPPα and αCTF production and reducing Aβ secretion, suggesting overexpression of α7nAChR is sufficient to promote APP processing, but without nicotine-mediated increases in α- and β-secretase activity (Nie et al., 2010). In vivo studies of α7nAChR-mediated effects on APP processing have assessed physiological sAPP release following high dose and chronic 14 d (Lahiri et al., 2002) or 16 week (Srivareerat et al., 2011) non-selective agonist infusion, reporting nicotine-mediated attenuation of Aβ-induced behavioural deficits.

There exists a wealth of research showing Aβ accumulation alongside altered nAChR expression is significant in the progression of AD, as per the amyloid cascade and cholinergic hypotheses of AD (Parri et al., 2011). Aβ-induced effects on α7nAChR may be mediated through direct Aβ-α7nAChR interactions (Wang et al., 2000a, 2000b; Dineley et al., 2001; Nagele et al., 2002) or secondary to activation of NMDAR (Snyder et al., 2005; Abbott et al., 2008). This interaction may play a physiological role, as low concentrations of Aβ peptide have been shown to enhance LTP via α7nAChR activation (Dineley et al., 2002a; Dougherty et al., 2003; Puzzo et al., 2008; Khan et al., 2010). However, increased soluble Aβ levels induce hyperexcitation of α7nAChR (Liu et al., 2013) and in cognitively impaired AD transgenic mouse models and AD patient brain, the extent and affinity of Aβ-α7nAChR interaction is enhanced, resulting in desensitisation and functional inactivation of α7nAChR (Ren et al., 2007; Wang et al., 2009; Söderman et al., 2010), reduced nicotine-evoked calcium influx (Wang et al., 2000b), disruption of synaptic signalling (Wang et al., 2000b; Lilja et al., 2011; Ni et al., 2013), and reduced ERK phosphorylation (Dineley et al., 2001).

Interestingly, chronic Aβ exposure (by exogenous Aβ application or in APP overexpressing AD model transgenic mice) up-regulates α3- and α7nAChR expression in both the cortex and hippocampus (Dineley et al., 2001, 2002a; Bednar et al., 2002; Jones et al., 2006; Mousavi and Nordberg, 2006), hypothesised to be due to an nAChR-Aβ interaction. Thus, AD-model transgenic mice are potentially endowed with the required nAChR expression level and thus the capability to mediate
nicotine-induced reductions in CSF Aβ level in vivo (Nordberg et al., 2002; Hellström-Lindahl et al., 2004; Unger et al., 2006). Given the on-going aim of both enhancing α7nAChR expression and reducing Aβ levels, agonist-mediated enhancement of α7nAChR expression and any resultant non-amyloidogenic APP processing would thus be highly beneficial, reinforcing targeting α7nAChR as an attractive and viable clinical strategy.

Given the low α7nAChR expression level coupled with the distinct spatial separation of presynaptic α7nAChR from the mainly postsynaptic APP, it is perhaps not unexpected that α7nAChR activation cannot couple directly to APP processing in these primary cortical neurons. Furthermore, the low level of natively expressed presynaptic α7nAChR appeared to be insufficient to promote indirect signalling through postsynaptic ionotropic glutamate receptors, to enhance ADAM-10 expression (Marcello et al., 2007) and non-amyloidogenic APP processing (Hoey et al., 2009, 2013). The neuroprotection (from NGF- and serum-deprivation) proffered by nicotine-mediated α7nAChR activation has already been shown to be proportional to the α7nAChR expression level in PC12 cells (Jonnala and Buccafusco, 2001).

Previous studies in primary neurons reported 95% of primary hippocampal neurons were positive for α7nAChR, as detected by rhodamine-αBTX labelling, versus only 36% of primary cortical neurons, which expressed half the number of hippocampal αBTX binding sites per cell (Barrantes et al., 1995b). Results presented here support this finding; by showing primary cortical neurons do not express a sufficiently high level of α7nAChR (estimated at ~10-15% of neurons); thus 85-90% of cells were incapable of modulating α7nAChR-mediated APP processing.

Further data presented in this thesis, supports previous findings that direct activation of neuronal synaptic NMDAR promotes non-amyloidogenic APP processing (Hardingham, 2006; Marcello et al., 2007; Léveillé et al., 2008; Hoey et al., 2009; Bordji et al., 2010), although this remains controversial (Cirrito et al., 2003, 2005, 2008; Bero et al., 2011). The hypothesis that presynaptic α7nAChR activation would promote glutamate release and activate postsynaptic NMDAR and AMPAR, thus indirectly enhancing non-amyloidogenic APP processing has not been explored previously. Initially data from this thesis, highlighting α7nAChR plays no role even in indirect APP processing, seem difficult to reconcile, with numerous studies showing α7nAChR activation promotes nerve terminal glutamate release (Cheng and Yakel, 2014) and even glutamate synapse formation (Lozada et al., 2012). However, given
the low expression of α7nAChR in this model system, and the fact that an overwhelming majority of the previous literature used cell lines expressing high levels of nAChR, activated by the non-selective agonist nicotine, the relative contribution to glutamate release of highly expressed non-α7 nAChR must be recognised. As such, increasing α7nAChR expression in primary cortical neurons might promote APP processing, through ionotrophic glutamate receptor activation following α7nAChR-mediated glutamate release.

Activation of primary cortical neuronal α7nAChR directly induced ERK phosphorylation (observed in total neuronal lysates and nerve terminal synaptosome lysates), but did not modulate ERK-dependent transcription of Egr-1. Given that the MAPK pathway and ERK phosphorylation have been strongly linked to neuron activity-dependent APP processing (Mills et al., 1997; Desdouits-Magnen et al., 1998; Verges et al., 2011; Wan et al., 2012; Hoey et al., 2013), it was unexpected to observe no α7nAChR-mediated ERK-dependent APP processing. Expression of Egr-1 has been linked to NMDAR (Worley et al., 1991), AMPAR (Wang et al., 1994) and L-type voltage-gated calcium channel activity (Murphy et al., 1991); resulting in the hypothesis that Egr-1 expression is maintained by synaptic activity in response to physiological stimuli (Veyrac et al., 2014). Egr-1 expression plays a role in learning and memory induction and consolidation (Knapska and Kaczmarek, 2004). As such, one would expect α7nAChR activation to promote ERK-dependent transcription of Egr-1 in neurons, but data presented in this thesis indicate no α7nAChR-mediated effect. This again is likely to be due to the low expression level and spatial distribution of presynaptic α7nAChR in this model system, with previous literature highlighting gene expression changes require signalling above a threshold (Mann and Paulsen, 2007), through receptor populations situated postsynaptically, and are thus optimally situated for induction of gene expression changes. Accordingly, overexpression of α7nAChR in cell lines induces sustained ERK phosphorylation (Utsugisawa et al., 2002) and Egr-1 gene transcription (Dunkley and Lukas, 2003), suggestive of an α7nAChR-induced effect on ERK-dependent transcription with higher α7nAChR expression.

6.2 α7nAChR-dependent modulation of microglial behaviour

The primary cortical microglia characterised here were observed as being highly responsive and capable of adopting classical morphological phenotypes, switching
between ‘resting’ and ‘activated’ states. This is in accordance with both primary microglia and microglial cell line studies (Kettenmann and Hanisch, 2011). Having shown the functional expression of α7nAChR on primary cortical microglia, this reinforces the extensive published literature on microglial neurotransmitter receptor expression, known to play diverse roles in the modulation of microglial behaviour. Microglial neurotransmitter receptors are akin to extrasynaptic receptors on neurons, which are not used for synaptic transmission, but instead play a regulatory role in modulating cell behaviour (Pocock and Kettenmann, 2007). For example, activation of α7nAChR (Giunta et al., 2004; Shytle et al., 2004) and GABA<sub>B</sub> receptor (Kuhn et al., 2004) populations are neuroprotective, reducing pro-inflammatory cytokine release; activation of AMPAR is pro-inflammatory (Hide et al., 2000; Hagino et al., 2004); metabotropic glutamate receptors induce mitochondrial depolarisation and microglial apoptosis (Taylor et al., 2002, 2005) and P2Y (Davalos et al., 2005; Haynes et al., 2006) and dopamine receptors (Färber et al., 2005) enhance microglial migratory behaviour. Furthermore, data presented here extends current knowledge reinforcing α7nAChR activation in microglia is protective (Wang et al., 2003; Cui and Li, 2010), through increased ERK phosphorylation and enhanced phagocytosis, in accordance with the α7nAChR-mediated ‘cholinergic anti-inflammation pathway’ (Giunta et al., 2004; Shytle et al., 2004; Moon et al., 2008; Hwang et al., 2010; Takata et al., 2010; Kawamata and Shimohama, 2011; Thomsen and Mikkelsen, 2012; Parada et al., 2013). Previous studies have shown α7nAChR-selective activation with PNU-282987 reduced TNFα release from an α7nAChR overexpressing immune cell line (Li et al., 2009) and enhanced anti-inflammatory gene expression in primary hippocampal microglia (Parada et al., 2013). The non-selective agonist nicotine also reduced TNFα release from primary microglia (Giunta et al., 2004; Shytle et al., 2004; Moon et al., 2008) and potentiation of α7nAChR on primary microglia and within AD transgenic mice with galantamine enhanced choline-mediated phagocytosis (Takata et al., 2010).

The Aβ phagocytosis capacity of microglia, has recently emerged as a topic of interest, with independent data showing Aβ phagocytosis is a tightly regulated process (Bamberger et al., 2003; Koenigsknecht-Talboo and Landreth, 2005; Lee and Landreth, 2010; Mandrekar-Colucci et al., 2012) that is impaired in AD patients and AD-model transgenic mice (Lucin et al., 2013; Orre et al., 2014). Enhanced phagocytic behaviour by microglia, through PPARγ activation has previously been shown to be neuroprotective and significantly lowers plaque burden in transgenic
Figure 6.1: Schematic of α7nAChR at the glutamatergic synapse. A: In primary cortical neurons α7nAChR are activated by the selective agonist PNU-282987, prevented from desensitising by the type II PAM PNU-120596 and antagonised by αBTX. Activation of α7nAChR induces calcium (Ca\(^{2+}\)) influx and MEK-dependent ERK phosphorylation (ERKP), which are inhibited by EGTA and U0126, respectively. Activation of α7nAChR does not drive ERK-dependent Egr-1 transcription or APP processing (red arrows, either directly or indirectly, via glutamate release and activation of postsynaptic NMDAR), but is sufficient for cognitive enhancement. NMDAR activation induces MEK-dependent ERK phosphorylation, enhanced α-secretase activity and promotes non-amyloidogenic APP processing (green arrows). Future experiments in primary neurons could probe the nicotine-mediated up-regulation of α7nAChR, with the aim of understanding whether nAChR expression level modulates APP processing (orange arrows). B: In primary cortical microglia α7nAChR activation with PNU-28987 and PNU-120596 is anti-inflammatory, enhancing ERK phosphorylation and phagocytosis of fluorescent latex beads. Phagocytosis is blocked by the α7nAChR-selective antagonist αBTX, but not blocked by the endocytosis inhibitor dynasore (red bar-headed line). Future experiments in primary microglia could establish the MEK- and PPARγ-dependence of phagocytosis (through U0126- and GW9662-mediated inhibition, respectively, orange bar-headed lines), whilst also characterising the physiologically relevant in vitro capacity of microglia to phagocytose Aβ peptide (orange arrow). Further behavioural paradigms could also be investigated, such as α7nAChR-mediated modulation of microglial migration (orange arrow).
mice (Cramer et al., 2012). PPARγ activation also reverses AD-like cognitive deficits (Yamanaka et al., 2012), but memory consolidation requires PPARγ-pERK complex formation (Jahrling et al., 2014). Furthermore, nicotine has been shown to up-regulate PPARγ expression in monocyte-derived human dendritic cells (Yanagita et al., 2012). Thus, data presented in this thesis corroborate with previous findings and extend our knowledge by showing α7nAChR-selective activation enhances ERK phosphorylation and promotes phagocytosis, which may be PPARγ-mediated.

Potential disadvantages and limitations of α7nAChR-mediated enhanced microglial phagocytosis exist. Aberrant and hyperactive phagocytosis can remove the synapses and processes of live neurons, termed ‘phagoptosis’ (Brown and Neher, 2014). Enhanced microglial phagoptosis has been implicated in the pathogenesis of Parkinson’s disease (Emmrich et al., 2013) and other neurological disorders, through release of microglial soluble pro-inflammatory mediators resulting in enhanced neuronal expression of cell-surface phagocytosis-promoting markers, such as phosphatidylserine (Neher et al., 2011). Previous studies have shown inhibition of cellular phagocytosis prevents inflammation-induced neuronal death, following a 3-day LPS incubation (Neher et al., 2011), however long-term damage through prolonged phagocytosis of CNS debris was recently shown to be induced by infiltrating macrophages and not resident microglia (Greenhalgh and David, 2014). Therefore in future investigations, characterising the neuroprotective potential of microglial phagocytosis would benefit from cell type-selective α7nAChR ligands or their local administration, to eliminate confounding results from other peripheral nervous system cell types.

Throughout this thesis, the α7nAChR-selective PAM PNU-120596 was used to reveal the effects of α7nAChR activity at the glutamatergic synapse. Given that the PAM alone had no effect on any cellular readout, such as ERK phosphorylation or microglial phagocytosis, this is found in contrast to in vivo examples of PAM use. For example, physiological concentrations of choline and PNU-120596 application activated α7nAChR-containing neurons within the hippocampus (Gusev and Uteshev, 2010; Kalappa et al., 2010) to facilitate action potentials and enhance cognition in rodents (Timmermann et al., 2007). In contrast, in these primary cortical neuronal and microglial model systems, under defined medium conditions, cells were plated into 20μM choline, a sub-maximal concentration for α7nAChR activation (Uteshev, 2014), given choline’s low potency (Papke and Porter Papke, 2002). Over time in vitro, the
concentration of choline will reduce, as it is taken into cells as an essential component of cell membranes and as an ACh precursor. Nonetheless, extracellular choline failed to activate native primary cortical \( \alpha 7nAChR \) in the presence of PNU-120596, and required application of the \( \alpha 7nAChR \)-selective agonist PNU-282987 to activate neurons and microglia to bring about \( \alpha 7nAChR \)-mediated cellular responses.

6.3 Future work

Given the wealth of literature on chronic nAChR stimulation up-regulating neuronal \( \alpha 7nAChR \) expression in both \textit{in vivo} and \textit{in vitro} models (Peng et al., 1994; Barrantes et al., 1995b; Molinari et al., 1998; Kawai and Berg, 2001; Vallejo et al., 2005; Fu et al., 2009; St John, 2009; Goriounova and Mansvelder, 2012; Mazzo et al., 2013), further experiments could be conducted to definitively establish whether up-regulation of \( \alpha 7nAChR \) expression in primary neurons, previously shown to be enhanced by 40% (Barrantes et al., 1995b; Jonnala and Buccafusco, 2001), through chronic nicotine treatment, enhances the potential for \( \alpha 7nAChR \) to directly and/or indirectly modulate non-amyloidogenic APP processing, figure 6.1. Looking further into the future, a greater understanding of the physiological role of APP is required; with particular focus on why APP processing and formation of neurotrophic (sAPP\( \alpha \)) and neurotoxic (A\( \beta \)) APP cleavage products are so closely related to neurotransmission. Furthermore, understanding the role of cortical layers in the nAChR-mediated onset of various pro-cognitive outcomes, such as improved attention and working memory, will require a deeper understanding and characterisation of \( \alpha 7nAChR \)-selective ligands at a molecular, cellular and neuronal network level.

Further minor experimental procedures, including characterising the ERK- and PPAR\( \gamma \)-dependence of microglial phagocytosis with U0126-mediated MEK inhibition and GW9662-mediated PPAR\( \gamma \) inhibition, respectively, would provide insight into the mechanism underlying microglial \( \alpha 7nAChR \)-induced phagocytosis. Of significant interest would be to establish whether A\( \beta \) phagocytosis is also affected by \( \alpha 7nAChR \) activation, through exogenous application of fluorescently-labelled A\( \beta \) into microglial culture medium, prior to \( \alpha 7nAChR \) stimulation. Such experiments could be coupled with characterisation of other microglial behavioural paradigms, such as \( \alpha 7nAChR \)-mediated modulation of microglial migration and pro-inflammatory cytokine release, figure 6.1. Looking further into the future, gaining a deeper understanding of the
cholinergic anti-inflammatory pathway is required. Until recently, glial cells were thought to be passive bystanders in the onset of neurodegenerative disorders, but the molecular mechanisms underlying chronic inflammation are yet to be discovered. Significant research efforts are required to characterise the anti-inflammatory signalling cascades in microglia with a view to targeting systemic inflammation in the treatment of neurodegenerative disorders.

6.4 Conclusion

Given the evidence supporting α7nAChR play a role in the pathophysiology of a number of neurological disorders, from AD to Parkinson’s disease and schizophrenia, the use of α7nAChR-selective ligands as therapeutic agents presents an on-going research interest. Targeting the cholinergic system in the treatment of AD has proved to be the most successful strategy to date. Given the prolific clinical use of AChE inhibitors, which activate α7nAChR though boosting ACh levels and also through acting as α7nAChR PAMs, this highlights selective targeting of α7nAChR remains a viable clinical option in the treatment of neurological disorders. AChE inhibitors reduce pro-inflammatory cytokine release, boost microglial phagocytosis, reduce pro-amyloidogenic APP processing and Aβ production and enhance attention and working memory, reinforcing the multi-faceted benefits of enhanced α7nAChR expression and activation at the glutamatergic synapse.

The major novel findings from this thesis highlight that activating natively expressed α7nAChR with an α7nAChR-selective PAM and agonist cannot modulate ERK-dependent transcription nor direct and indirect APP processing in a primary neuronal model system, unlike stimulation of NMDAR that have been validated as coupling to non-amyloidogenic APP processing. Furthermore, activation of microglial α7nAChR increases ERK phosphorylation and promotes neuroprotective behaviour through selectively enhancing phagocytosis.


Bitner RS et al. (2007) Broad-spectrum efficacy across cognitive domains by α7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. The Journal of Neuroscience 27:10578–10587.


Dajas-Bailador F, Soliakov L, Wonnacott S (2002) Nicotine activates the extracellular signal-regulated kinase 1/2 via the α7 nicotinic acetylcholine


Duffy AM, Fitzgerald ML, Chan J, Robinson DC, Milner T a, Mackie K, Pickel VM (2011) Acetylcholine α7 nicotinic and dopamine D2 receptors are targeted to many of the same postsynaptic dendrites and astrocytes in the rodent prefrontal cortex. Synapse 65:1350–1367.


Gusev A, Uteshev V (2010) Physiological concentrations of choline activate native α7-containing nicotinic acetylcholine receptors in the presence of PNU-120596 [1-(5-chloro-2, 4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)-urea]. The Journal of pharmacology and experimental therapeutics 332:588–598.


reduction in rat primary cortical neurons: neuroprotective effects of α7 neuronal nicotinic acetylcholine receptor ligands. Brain research 1151:227–235.


Kalappa BI, Gusev AG, Uteshev V (2010) Activation of functional α7-containing nAChRs in hippocampal CA1 pyramidal neurons by physiological levels of choline in the presence of PNU-120596. PloS one 5:e13964.


Kawai H, Berg DK (2001) Nicotinic acetylcholine receptors containing α7 subunits on rat cortical neurons do not undergo long-lasting inactivation even when up-


Lee RH, Vazquez G (2013) Evidence for a prosurvival role of alpha-7 nicotinic acetylcholine receptor in alternatively (M2)-activated macrophages. Physiological Reports 1:n/a–n/a.


(1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain research 924:133–140.


Williams DK, Peng C, Kimbrell MR, Papke RL (2012) Intrinsically low open probability of α7 nicotinic acetylcholine receptors can be overcome by positive allosteric modulation and serum factors leading to the generation of excitotoxic currents at physiological temperatures. Molecular pharmacology 82:746–759.


